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IV  Abstract 
Abstract 
Human respiratory syncytial virus (RSV) is the leading viral cause of severe bronchiolitis 
and pneumonia in infants and young children worldwide. It is estimated that RSV-associated acute 
lower respiratory tract infections cause up to 118,000 deaths of children under five years of age 
annually. It also causes substantial morbidity and mortality in the elderly and individuals with 
immunosuppression or cardiopulmonary disease. No vaccine or effective antiviral drug for general 
use is available. The mechanism of RSV entry into the host cell, and the host factors involved in 
this process, are not well understood. To gain insight into virus-host interactions, a genome-wide 
siRNA screen was performed. The expression of over 20,000 cellular genes was individually 
knocked down in human airway epithelial A549 cells, followed by infection with RSV expressing 
enhanced green fluorescent protein (GFP), which was used as a surrogate for infection. 
Knockdown of expression of the cellular ATP1A1 protein, the major subunit of the Na+, K+-ATPase, 
had the strongest inhibitory effect on GFP expression and viral titer, with minimal effects on cell 
viability. The inhibitory effect due to the ATP1A1 knockdown was not observed for vesicular 
stomatitis virus (VSV), indicating that it was RSV-specific rather than a general effect. This study 
identified and characterized the pro-viral role of ATP1A1 during RSV infection. It was found that 
RSV induced the formation of ATP1A1 clusters in the plasma membrane of the host cell very early 
during infection. This phenomenon was independent of viral replication, but dependent on the viral 
attachment glycoprotein G. RSV infection also triggered ATP1A1-mediated signaling, involving c-
Src activation that resulted in the transactivation of epidermal growth factor receptor (EGFR) by 
Tyrosine 845 phosphorylation. Further signaling events downstream of EGFR culminated in the 
formation of macropinosomes. There was extensive uptake of RSV virions into macropinosomes, 
suggesting that this is a major route of RSV uptake, with fusion presumably occurring at the 
membrane of the macropinosomes rather than at the plasma membrane. In addition, this study 
identified chemical compounds with anti-RSV activity: Ouabain, a cardiotonic steroid, and 
PST2238, a synthetic digitoxigenin derivative, that bind specifically to the extracellular domain of 
ATP1A1, inhibited RSV-induced signaling and resulted in the inhibition of RSV entry. Taken 
together, this study describes a novel ATP1A1-enabled mechanism used by RSV to enter the 
host cell, and identified candidate antiviral drugs that block this entry pathway. 
The second part of this dissertation thesis describes the development and preclinical 
evaluation of a live-attenuated human parainfluenza virus type 1 (HPIV1)-vectored intranasal 
vaccine against Ebola virus (EBOV). This project was prompted by the 2014 - 2016 EBOV 
outbreak in West Africa; the largest in history. Recombinant HPIV1 viruses expressing the 
membrane-anchored form of EBOV glycoprotein GP were developed and preclinically evaluated. 
GP is the major immunogen providing protective immunity against an EBOV infection. GP was 
codon-optimized and expressed either as a full-length protein or an engineered chimeric form in 
which its transmembrane and cytoplasmic tail (TMCT) domains were substituted with those of the 
HPIV1 F protein, in an effort to enhance packaging into the vector particle and improve 
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immunogenicity. GP was inserted either preceding the N gene (pre-N) or between the N and P 
genes (N-P) of the HPIV1 genome bearing a stabilized attenuating mutation in the P/C gene 
(C∆170). The viral constructs grew to high titers and efficiently and stably expressed GP in vitro. All 
viruses showed the expected attenuation in the respiratory tract of African green monkeys (AGMs), 
replicating at low titers over several days. Two doses of candidates expressing GP from the pre-
N position elicited higher GP neutralizing serum antibody titers than the N-P viruses, and 
expression of unmodified GP resulted in higher levels than its chimeric TMCT counterpart. 
Unmodified GP was packaged into the HPIV1 particle, and the TMCT modification did not increase 
packaging or immunogenicity but rather reduced the stability of GP expression during in vivo 
replication. In conclusion, this study developed an attenuated and immunogenic intranasal 
vaccine candidate expressing GP from the pre-N position of an attenuated HPIV1 vector. It is 
expected to be well-tolerated in humans and is available for clinical evaluation. 
 
VI  Zusammenfassung 
Zusammenfassung 
Das Respiratorische Synzytial-Virus (RSV) ist der bedeutendste virale Erreger von 
Bronchiolitiden und Pneumonien bei Säuglingen und Kleinkindern. Schwere RSV-Infektionen der 
unteren Atemwege verursachen jährlich weltweit bis zu 180.000 Todesfälle von Kleinkindern unter 
5 Jahren. Bisher ist kein Impfstoff oder eine effektive antivirale Therapie gegen RSV-Infektionen 
verfügbar. Die mechanistischen Details des Eintritts von RSV in die Zelle und die Wirtsfaktoren, 
die dabei notwendig sind, sind nur unzureichend charakterisiert. Um ein besseres Verständnis 
dieser Virus-Wirts-Interaktionen zu erlangen, wurde eine genomweite Untersuchung mittels 
siRNA-Knockdown durchgeführt. In der humanen Lungenepithelzelllinie A549 wurde die 
Expression von mehr als 20.000 zellulären Genen einzeln mittels siRNA-Transfektion 
herunterreguliert (knockdown), wonach eine Infektion der Zellen mit RSV, welches das grün 
fluoreszierende Protein (GFP) exprimierte, erfolgte. Die virale GFP-Expression wurde als 
Indikator für die Infektionseffizienz verwendet. Die Verringerung der zellulären Expression von 
ATP1A1 hatte den stärksten Effekt auf die virale GFP-Expression und den Virustiter, ohne die 
Zellviabilität signifikant zu beeinflussen. ATP1A1 ist die Hauptuntereinheit der in der 
Plasmamembran lokalisierten Na+, K+-ATPase.  Die inhibitorische Wirkung aufgrund des 
ATP1A1-Knockdowns wurde nicht für das vesikuläre Stomatitis-Virus (VSV) beobachtet, was 
darauf hinweist, dass es sich eher um einen RSV-spezifischen als einen allgemeinen Effekt 
handelte. In der vorliegenden Arbeit wurde damit ATP1A1 als pro-viraler Faktor identifiziert. Dabei 
kam es sehr früh während der Infektion zur Bildung von ATP1A1-Aggregaten in der 
Plasmamembran der Wirtszelle. Dieses Phänomen war unabhängig von der viralen Replikation, 
aber abhängig vom viralen Glykoprotein G. Mechanistisch induzierte RSV eine ATP1A1-
abhängige Signaltransduktion, welche zur Aktivierung der zellulären Src-Kinase und infolge 
dessen der Transaktivierung des epidermalen Wachstumsfaktorrezeptors (EGFR) durch die 
Phosphorylierung von Tyrosin 845 führte. Die Aktivierung der EGFR-abhängigen Signalkaskade 
induzierte die Bildung von Makropinosomen, die behüllte RSV-Virionen extensiv enthielten. Dies 
deutet darauf hin, dass dies ein Hauptmechanismus der RSV-Aufnahme in die Wirtszelle darstellt, 
wobei die Fusion von Virus- und Zellmembran vermutlich erst in Makropinosomen stattfindet, 
anstatt bereits an der Plasmamembran. Darüber hinaus identifizierte diese Studie zwei antiviral 
wirkende Verbindungen, Ouabain, ein Herzglykosid, und PST2238, ein synthetisches 
Digitoxigeninderivat, die spezifisch an die extrazelluläre Domäne von ATP1A1 binden. Dies führte 
zur Inhibierung der RSV-induzierten ATP1A1-Signalkaskade und folglich der Hemmung des RSV-
Eintritts in die Zelle. Zusammenfassend beschreibt diese Arbeit einen neuen ATP1A1-abhängigen 
Signalweg, der von RSV aktiviert wird, um in die Wirtszelle einzudringen. Zusätzlich wurden 
potentielle antivirale Medikamente, die diesen Eintrittsweg blockieren, identifiziert. 
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Der zweite Teil dieser Doktorarbeit beschreibt die Entwicklung und präklinische Evaluation 
eines attenuierten humanen Parainfluenzavirus Typ 1 (HPIV1) basierenden Lebendimpfstoff 
gegen das Ebolavirus (EBOV). Dieses Projekt wurde infolge des EBOV-Ausbruches (2014 - 2016) 
in Westafrika initiiert, welcher der größte EBOV-Ausbruch in der Geschichte darstellt. Die 
membranverankerte Form des EBOV-Glykoproteins GP, das das Hauptantigen für die Induktion 
einer schützenden Immunität gegen EBOV-Infektionen darstellt, wurde in einen rekombinanten 
HPIV1-Vektor eingefügt. Dabei wurde die Sequenz von GP codon-optimiert und entweder als 
vollständiges GP-Protein oder als chimäre Form, in der die Transmembran- und 
zytoplasmatische- (TMCT-) Domäne des EBOV-GP durch die des HPIV1 F-Proteins ersetzt war, 
exprimiert. Letztere, chimäre Variante sollte die Verpackung in das Viruspartikel erhöhen und 
dadurch die Immunogenität verbessern. Das GP-Gen wurde in zwei verschiedene Positionen, vor 
dem N-Gen (pre-N) oder zwischen dem N- und P-Gen, eines rekombinanten HPIV1-Genoms 
eingefügt, welches außerdem eine stabilisierte attenuierende Mutation im P/C-Gen (CΔ170) enthielt. 
In Zelllinien replizierten alle Vektoren effizient zu hohen Titern und wiesen eine effiziente und 
stabile Expression von GP auf. Die In-Vivo-Vermehrung aller Viren in den Atemwegen von Grünen 
Meerkatzen war, wie erwartet, attenuiert. Durch zweimalige Immunisierung mit den 
Impfstoffkandidaten, bei denen das GP-Gen proximal der N-Position eingefügt war, wurden 
höhere GP-neutralisierende Serumantikörpertiter induziert als durch die Viren mit dem GP-Gen 
in der N-P Position. Die Expression des vollständigen, unveränderten EBOV GP-Proteins, das 
effizient in HPIV1-Viruspartikel integriert wurde, induzierte höhere Antikörpertiter als die des 
chimären TMCT-Konstrukts. Dahingegen beeinflusste die TMCT-Modifikation weder die 
Verpackung noch die Immunogenität positiv, sondern reduzierte sogar eher die Stabilität der GP-
Expression während der Vermehrung in vivo. Zusammenfassend wurde in dieser Studie ein 
attenuierter und immunogener intranasaler Impfstoffkandidat identifiziert, von dem erwartet wird, 
dass dieser für Menschen gut verträglich ist. Dieser Impfstoffkandidat steht nach der hier 
vorgelegten präklinischen Evaluierung für weiterführende klinische Studien zur Verfügung. 
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1. Introduction 
1.1. Role of the alpha-1 subunit of the Na+, K+-ATPase (ATP1A1) in the macropinocytic 
entry of respiratory syncytial virus  
1.1.1. Respiratory syncytial virus (RSV) 
1.1.1.1. Phylogeny of Mononegavirales 
RSV belongs to the genus Orthopneumovirus of the family Pneumoviridae within the order 
Mononegavirales (Afonso et al. 2016). In addition to human RSV, the genus Orthopneumovirus 
contains two additional viruses: the bovine RSV (BRSV) and the murine pneumonia virus (MPV). 
The family Pneumoviridae is closely related to Paramyxoviridae. In fact, viruses of the family 
Pneumoviridae were previously included in the family Paramyxoviridae as the subfamily 
Pneumovirinae (International Committee on Taxonomy of Viruses. 2012). The re-classification of 
the subfamily Pneumovirinae as a new family took place in the 2016 Taxonomy update of the 
order Mononegavirales [International Committee on the Taxonomy of Viruses (ICTV) (Afonso et 
al. 2016)]. This change was made because of the recognition that the members of Pneumovirinae 
were as closely related to the family Filoviridae as they were to the members of the subfamily 
Paramyxovirinae of Paramyxoviridae (Afonso et al. 2016). Different conclusions on the 
phylogenetic relationships can be made depending on the viral proteins utilized for the 
phylogenetic comparison (Russell et al. 2018). For instance, the Pneumoviridae large (L) 
polymerase protein has a similar extent of relatedness to that of Filoviridae and Paramyxoviridae 
(Figure 1A). However, the Pneumoviridae fusion (F) glycoprotein is more closely related to the F 
protein of Paramyxoviridae than to single glycoprotein GP of Filoviridae, e.g. Ebola virus, which 
serves the same role as F (Figure 1B). 
 
 
Figure 1: Phylogenetic comparison of members of the family Paramyxoviridae, Pneumoviridae and 
Filoviridae of the order Mononegavirales. The amino acid sequences of the large (L) polymerase (A) or 
fusion (F) glycoprotein (B) were used for comparing phylogenetic relationships. Human respiratory syncytial 
virus (HRSV), human metapneumovirus (HMPV), Newcastle disease virus (NDV), Human parainfluenza 
virus type 1 (HPIV1), type 2 (HPIV2), and type 3 (HPIV3). Virus families are shown in accordance with the 
2016 Taxonomy update of the order Mononegavirales of the International Committee on the Taxonomy of 
Viruses (ICTV) (Afonso et al. 2016). Adapted from (Russell et al. 2018). 
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In addition, Pneumoviridae and Paramyxoviridae contain an attachment protein (G or HN) 
beside the F protein, whereas GP of Filoviridae mediates both attachment and fusion. Moreover, 
the genomes of the members of family Pneumoviridae contain an additional gene called M2, which 
encodes for two unique proteins (M2-1 and M2-2) by two overlapping open reading frames (ORFs), 
and which is absent in Paramyxoviridae and Filoviridae. 
The family Pneumoviridae also contains, in addition to the genus Orthopneumovirus, a 
second genus, Metapneumovirus, to which the avian and human metapneumoviruses (AMPV and 
HMPV) belong. The other families within the order Mononegavirales are Bornaviridae, Filoviridae, 
Mymonaviridae, Nyamiviridae, Paramyxoviridae, Rhabdoviridae and Sunviridae (Amarasinghe et 
al. 2018).  
The order Mononegavirales is defined primarily by the characteristics of the viral genome 
(Lamb 2013). All members are enveloped virus particles that contain a linear, single-stranded, 
non-segmented, negative-sense RNA genome that is tightly encapsidated by a viral nucleoprotein. 
Transcription initiation occurs at a single promoter situated at the 3’ leader sequence, which is the 
genomic 3’ untranslated region (UTR). Viral genes are separated by non-transcribed intergenic 
(IG) regions with variability in length and sequence among viruses and can be conserved or differ 
within a viral genome between different gene junctions. Each viral gene is flanked by a gene start 
(GS) and gene end (GE) sequence. 
The gene junctions, containing the GE, IG and GS sequences, guide the viral RNA-
dependent RNA polymerase (RdRp), of which the major protein, which bears the catalytic 
domains, is the L polymerase protein. At the GE and GS sequence, transcription of the upstream 
gene is terminated and that of the downstream gene is initiated, respectively. Due to the 
occasional failure of the RdRp to re-initiate transcription at the adjacent gene, the number of RdRp 
molecules that are available to transcribe mRNA continues to decrease towards the 5’ end of the 
viral genome. This results in a 3’ to 5’ polar transcription gradient of the viral genes, which is 
typical for the order Mononegavirales (Lamb 2013). The polar gradient is influenced by the 
efficiency of the GE and IG sequences to terminate transcription. Inefficient GE sequence causes 
read-through transcription and a bicistronic mRNA. Since the second ORF of a bicistronic mRNA 
is in general not efficiently translated in eukaryotes (Kozak 2005), the expression of the gene 
downstream of an inefficient GE would be reduced, as shown for example for the aberrant M GE 
in human parainfluenza virus type 3 (HPIV3) (Lingemann et al. 2015). Similar observations have 
been made for other members [reviewed in (Karron and Collins 2013)], for example the M GE of 
PIV5 has a single nucleotide substitution with effect similar to that of HPIV3 M GE (Rassa and 
Parks 1998); simian virus 41 lacks an M GE signal entirely (Kato et al. 1999); and clinical isolates 
of RSV showed variations in the G GE that resulted in a reduced F protein expression (Moudy et 
al. 2003). 
The families Filoviridae, Paramyxoviridae, Pneumoviridae, and Rhabdoviridae have 
genome arrangements that have a number of similar genes (Lamb 2013) and include, in 3’ to 5’ 
order, a 3’ leader region followed by the viral nucleocapsid protein (N or NP) gene, phosphoprotein 
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(P) gene, internal matrix or membrane (M) gene, one or more envelope protein genes (including 
HN, H, F, G, and SH, depending on the virus), and the L polymerase gene. The viral genome 
ends with the 5’ trailer (Lamb 2013). 
Depending on the virus family, the genome encodes a different number of envelope 
proteins. In Filoviridae and prototypical members of Rhabdoviridae, there is a single envelope 
glycoprotein GP or G, respectively, that mediates both attachment and fusion. Paramyxoviridae 
and Pneumoviridae have separate attachment (H, HN, or G) and fusion (F) proteins. Some 
members of Paramyxoviridae and all members of Pneumoviridae contain a third envelope protein 
called the small hydrophobic (SH) protein. Additional genes or open reading frames (ORFs) 
encoding other proteins may be present in certain viruses, such as an interferon antagonist C 
protein encoded by certain members of Paramyxoviridae and the RNA synthesis factor proteins 
M2-1 and M2-2 encoded by all members of Pneumoviridae (and described below). Thus, 
members of these families (and most members of Mononegavirales) have the general genome 
arrangement of leader-N-P-M-(glycoproteins)-L-trailer, with possible additional intervening genes 
present depending on the virus (Karron and Collins 2013, Lamb 2013). 
The encapsidated viral RNA with the nucleocapsid proteins N, P, and L is called the 
ribonucleoprotein (RNP) complex and, for most of these viruses, is considered infectious since it 
contains the viral proteins required for transcription/replication initiation and the de novo synthesis 
of viral proteins essential for viral replication. Members of Pneumoviridae may require in addition 
the M2-1 protein. Naked viral RNA is not infectious since it is negative-sense and thus does not 
directly encode protein, and is not associated with the viral RdRp and nucleocapsid that is 
necessary for direct transcription and thereby initiate viral replication. Filoviridae, Paramyxoviridae, 
Pneumoviridae, and Rhabdoviridae replicate in the cytoplasm of the host cell, with the exception 
of plant viruses in the genus Nucleorhabdovirus (Lamb 2013). Bornaviridae is different compared 
to the other families of Mononegavirales, since their replication and transcription occur in the 
nucleus (Lamb 2013). 
Maturation of the virions occurs by budding from a cellular membrane that provides the 
viral envelope with the incorporated viral surface glycoproteins. Most members of the order 
Mononegavirales bud from the host plasma membrane, with a few exceptions of some plant 
rhabdoviruses, which bud from the inner nuclear membrane (Lamb 2013).  
 
1.1.1.2. Genome organization and replication 
RSV has a single-stranded, non-segmented, negative-sense RNA genome that is 15.2 kilo 
base (kb) long and contains 10 genes that encode 11 proteins (Figure 2), namely (in 3’ to 5’ 
genomic order) two nonstructural proteins NS1 and NS2, nucleocapsid (N), phosphoprotein (P), 
matrix protein (M), the three envelope glycoproteins including the small hydrophobic (SH), 
attachment (G) and fusion (F) glycoproteins, followed by the M2-1 and M2-2 proteins, which are 
encoded by the two overlapping ORFs in the M2 gene, and the large polymerase L (Collins and 
Karron 2013).  
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Figure 2: Genome structure of RSV. Genes are color-coded for their general location in the virion. The 
nonstructural proteins (NS1, NS2) are yellow, proteins involved in the viral transcription and replication are 
blue, the matrix protein is magenta and the envelope glycoproteins are red. The M2 gene has two partially-
overlapping open reading frames (ORFs) that are depicted on the top of the M2 gene and encode two 
distinct proteins M2-1 and M2-2. le: leader; tr: trailer. Adapted from (Collins and Karron 2013). 
The RSV envelope glycoproteins G and F mediate viral attachment and fusion for entry 
into the host cell, while the role of SH in infection remains unclear. The glycoprotein G is a highly 
glycosylated type II transmembrane glycoprotein and is considered to be the attachment protein 
for RSV. The small hydrophobic protein SH is a small transmembrane protein that forms 
pentamers and may have properties of a viroporin (Collins and Karron 2013). SH and G are 
thought to be non-essential for virus replication as their deletion mutants can grow in cell culture 
(Bukreyev et al. 1997, Karron et al. 1997, Techaarpornkul et al. 2001). However, RSV lacking the 
G protein is impaired for HEp-2 cell entry and is highly attenuated in mice, indicating an important 
role of G in virus replication in vivo, presumably due to its role in cell attachment (Teng et al. 2001). 
The G protein contains a highly basic heparin binding domain and a CX3C motif [characteristic of 
a CX3C chemokine called fractalkine (Zlotnik and Yoshie 2000)] that mediate cell attachment by 
binding to the cell surface glycosaminoglycans (GAGs) (Hallak et al. 2000, Shields et al. 2003) 
and the CX3CR1 chemokine receptor (Tripp et al. 2001, Johnson et al. 2015), respectively. GAGs 
are commonly expressed on immortalized cell lines in vitro but do not appear to be significantly 
expressed on the apical surface of epithelial cells lining the respiratory tract, which is the site of 
RSV infection in vivo. Therefore, GAGs may be important for RSV attachment in immortalized cell 
lines but likely are not important for infection of differentiated primary humane airway epithelial 
cultures or in vivo, situations in which CX3CR1 appears to be the more important receptor for G 
(Tripp et al. 2001, Johnson et al. 2015). 
The RSV F protein mediates fusion of the viral envelope with the plasma membrane and 
is essential for virus infectivity. It is a type I transmembrane surface protein that assembles into a 
homotrimer. F is expressed as an inactive F0 precursor which is activated via cleavage at two 
sites by cellular furin endoprotease into a smaller, N-terminal F2 subunit and a larger, C-terminal 
F1 subunit that are linked by two disulfide bonds. The N-terminus of the F1 subunit, generated as 
a result of F0 cleavage, contains a hydrophobic domain that acts as a fusion peptide and is 
inserted into the host cell plasma membrane to mediate fusion (Collins and Karron 2013). RSV F 
is produced in a metastable pre-fusion F (pre-F) conformation. Upon contact with a host cell, pre-
F undergoes structural rearrangement that brings the viral envelope and plasma membrane in 
close proximity resulting in lipid bilayer fusion and the release of the viral nucleocapsid into the 
cytoplasm to initiate infection (Colman and Lawrence 2003). Limited evidence suggests that RSV 
may not fuse at the plasma membrane and is taken up in an enveloped form by macropinocytosis 
followed by fusion occurring in the macropinosomes (Krzyzaniak et al. 2013). 
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Beside the fusion activity, RSV F also has been described to interact with surface proteins 
of the host cell. For example, it has been reported that the F protein binds to a host cell protein 
called nucleolin, which may serve as an alternate attachment protein (Tayyari et al. 2011). A 
recent study also described a strain-specific (RSV A2-2-20F) interaction of the F protein with the 
epidermal growth factor receptor (EGFR) that results in EGFR activation and mucin expression 
(Currier et al. 2016). Knockdown of EGFR resulted in a strain-specific reduction of infectivity that 
was not observed with the prototypic RSV strain A2. The underlying mechanisms of these 
observed effects were not further elucidated. 
 Additional host proteins and pathways with suggested roles in RSV entry have been 
reported. For instance, it was shown that RSV utilizes lipid rafts in cholesterol-rich microdomains 
on the cell surface, known as caveolae, as a docking platform essential for entry (San-Juan-
Vergara et al. 2012). Similarly, EGFR signaling was postulated to play an important role in 
triggering macropinocytic uptake of RSV (Krzyzaniak et al. 2013). So far, it is not known how these 
previously described host factors for RSV entry might be linked to each other or function 
cooperatively to facilitate RSV entry. It remained unknown if EGFR alone is sufficient, or requires 
other factors, to initiate signaling or if EGFR and its associated signaling are somehow physically 
linked with caveolae. Limited evidence supports the existence of two incongruous RSV uptake 
mechanisms including the exclusive involvement of either the EGFR-triggered macropinocytosis 
(Krzyzaniak et al. 2013) or the clathrin-mediated endocytosis (Kolokoltsov et al. 2007) as the 
primary mode of uptake. It is unclear if one or both are involved. 
After viral entry, transcription of the viral genes is initiated by the viral RdRp complex, that 
is delivered by the virus particle and contains the L, N, P, and M2-1 proteins in association with  
the viral genome (Collins and Karron 2013). The large polymerase L contains the major catalytic 
domains for transcription. The phosphoprotein P is the major viral phosphoprotein and is an 
essential co-factor for the polymerase complex. M2-1 is an essential transcription processivity 
factor and its absence causes a premature and nonspecific termination of transcription (Fearns 
and Collins 1999). Viral mRNA contains a methylated 5’ cap structure and is polyadenylated by 
the viral polymerase copying reiteratively at the poly-U tract at the end of the GE signal. The viral 
mRNA is translated by the host translation machinery. 
The accumulation of the M2-2 protein in the RSV-infected cell switches the viral 
nucleocapsid/polymerase complex from mRNA transcription to RNA replication (Bermingham and 
Collins 1999) so that the polymerase ignores the gene junction signals and transcribes the entire 
viral genome into a continuous full-length anti-genome. The complementary sequence (anti-
genome) of the 5’ trailer contains a strong promoter that initiates RNA synthesis of the nascent 
negative-sense genome using the anti-genome as the template. As they are being synthesized, 
the nascent positive-sense (anti-genome) and negative-sense (genome) viral RNAs are 
encapsidated by the nucleoprotein N that protects the viral genome from degradation (Collins and 
Karron 2013). It has been shown that proteins involved in the transcription and replication process 
are concentrated in cytoplasmic inclusion bodies (Garcia et al. 1993) where viral transcription and 
6   Introduction 
RNA replication are thought to occur. This isolation might be a strategy to avoid innate immune 
recognition but the mechanism of how the inclusion bodies function is not well understood. 
The nonstructural proteins NS1 and NS2, encoded by the most 3’ proximal genes of the 
genome, are unique to the genus Orthopneumovirus. They are known to interfere with the induc-
tion and signaling of type I interferon and have anti-apoptotic activity (Collins and Karron 2013).  
The matrix protein M is a non-glycosylated internal virion component that organizes the 
virion components at the plasma membrane. The surface proteins F, G and SH are expressed 
and transported through the secretory pathway to, and inserted into, the plasma membrane. The 
budding of new pleomorphic viral particles occurs from the plasma membrane and is orchestrated 
by the M protein (Collins and Karron 2013). 
 
1.1.1.3. Epidemiology and pathogenesis 
RSV was discovered in the mid 1950s (Blount et al. 1956, Chanock et al. 1957) and is 
considered the leading viral cause of severe lower respiratory tract infection (LRI), primarily 
bronchiolitis and pneumonia, resulting in hospitalization of newborns and infants worldwide 
(Lozano et al. 2012). Infants are more susceptible to RSV earlier in life than to other common 
viruses such as HPIV1-3, influenza, HMPV, and measles virus (Figure 3). 
 
Figure 3: Susceptibility to the indicated viruses during early infancy (top) and host factors that 
influence the immune response to vaccines (bottom). Adapted from (Karron and Collins 2013). 
It was estimated that, in 2015, RSV infections of children younger than 5 years of age 
caused 33.1 million (uncertainty range [UR] 21.6 - 50.3 million) cases of RSV-associated acute 
lower respiratory infections (RSV-ALRI) that resulted in 3.2 million (UR 2.7 - 3.8 million) hospital 
admissions and 59,600 (UR 48,000 - 74,500) in-hospital deaths (Shi et al. 2017). Of these, 1.4 
million (UR 1.2 - 1.7 million) hospital admissions and 27,300 (UR 20,700 - 36,200) in-hospital 
deaths were estimated for children younger than 6 months (Shi et al. 2017). The estimated overall 
RSV-ALRI mortality for 2015 could be as high as 118,200 (UR 94,600 - 149,400) (Shi et al. 2017) 
and is slightly decreased compared to the estimations for 2005 (Nair et al. 2010). It also has been 
shown that infants two months of age or younger constitute 44% of all RSV-related 
hospitalizations. One-month old infants were at the greatest risk for RSV hospitalization and most 
(80%) of the hospitalized children had no prior conditions and were considered healthy (Hall et al. 
2013). 
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RSV infections also have a major impact on the health of elderly adults. It has been 
estimated that RSV causes 178,000 hospitalizations and 14,000 deaths (8% of those hospitalized) 
in the U.S. alone in people older than 65 years (Falsey et al. 2005). 
RSV occurs in yearly seasonal epidemics that typically occur in the winter or rainy season, 
but can vary depending on the climate and regional factors. For 2014 – 2017 the median onset in 
the U.S. occurred mid-October and lasted until early May, and the median national peak occurred 
in early February (Rose et al. 2018). 
The clinical manifestations of RSV infection vary and depend on age, general immune 
status, RSV serum antibody titer and other pre-existing conditions of the infected individuals 
[reviewed in (Collins and Karron 2013)]. Newborns mostly develop upper respiratory tract 
infections (URI) only, since they are protected by the maternal antibodies against LRI. With 
decreasing maternal antibody protection due to antibody decay (Figure 3), infants 6 weeks to 9 
months of age develop URI with up to 40% developing LRI with bronchiolitis and pneumonia that 
are the primary manifestations of RSV-associated LRI. Less frequently RSV also causes croup. 
In most instances, the URI are uneventful and recovery occurs after an illness of 7 to 12 days. A 
major problem that can cause additional complications is that infants infected with RSV often feed 
poorly, since the nasal obstruction prevents adequate respiration during feeding. The reasons for 
hospitalization due to RSV-associated LRI can range from bronchiolitis to severe pneumonia. LRI 
are associated with cough, sneezing, low-grade fever, wheezing, profuse rhinorrhea, and 
frequently otitis media. With increasing age and number of re-infections the disease severity 
usually decreases. Symptomatic infections in normal adults are common and usually are mild, but 
patients may develop rhinorrhea, pharyngitis, cough and bronchitis. The disease usually lasts 
about 5 days. Underlying pulmonary or cardiac diseases as well as immunocompromised 
individuals are at greater risk for RSV-ALRI. 
 
1.1.1.4. Vaccine and antiviral therapies 
Extensive research on various vaccine strategies and antiviral therapies has not thus far 
yielded a licensed vaccine or effective antiviral drug against RSV. The first attempt to create a 
vaccine against RSV infection was made in the 1960s. Formalin-inactivated RSV (FI-RSV) was 
evaluated as a vaccine in infants and children. The immune response to FI-RSV did not protect 
from infection but rather caused RSV disease enhancement upon infection in the following RSV 
season that resulted in the deaths of two vaccinees (Kapikian et al. 1969, Kim et al. 1969). FI-
RSV induced antibodies with poor neutralization activity and primed for a CD4+ T helper cell 
response more biased towards T helper type 2 (Th2) than type 1 (Th1), which is believed to be a 
major cause of vaccine-induced enhanced disease (Acosta et al. 2015, Knudson et al. 2015). FI-
RSV or subunit vaccines are associated with disease enhancement in RSV-naïve but not RSV-
experienced individuals. 
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Immunization of RSV-naïve individuals, such as infants, with live-attenuated vaccine 
candidates does not cause enhanced disease upon subsequent natural RSV infection (Wright et 
al. 2007). Hence, the pediatric vaccines (for RSV-naïve individuals) under development focus on 
live-attenuated RSV and live-attenuated vectored vaccines. In addition, subunit vaccines are 
being developed for RSV-experienced individuals, particularly for maternal vaccination and for the 
elderly. 
Various live-attenuated RSV vaccine approaches are being evaluated in Dr. Peter Collins’ 
laboratory at the Laboratory of Infectious Diseases (LID) of the National Institute of Allergy and 
Infectious Diseases (NIAID) within the National Institutes of Health (NIH). The two main strategies 
being pursued are (i) live-attenuated RSV vaccine candidates and (ii) live-attenuated vectored 
vaccines: 
For live-attenuated RSV vaccine candidates, various attenuating mutations are being 
evaluated, such as temperature-sensitive mutations and/or the deletion of genes [e.g. SH and 
M2-2 (Bermingham and Collins 1999)] that impart an attenuating phenotype but maintain its 
immunogenicity. The optimal balance between attenuation and sufficient immunogenicity has 
been difficult to achieve and various vaccine candidates have been evaluated in phase I clinical 
trials (Karron et al. 2015).  
Live-attenuated vectored vaccines that express RSV F protein from an added gene also 
are being developed as candidate pediatric RSV vaccines. Different vector backbones [human 
parainfluenza virus type 1 (HPIV1) (Mackow et al. 2015), bovine/human parainfluenza virus type 
3 (B/HPIV3) (Liang et al. 2014), and MPV (Brock et al. 2018)] have been evaluated, and the 
immunogenicity of RSV F could be improved by a variety of modifications. Recently it has been 
found that the F protein can be locked by structural modifications in the pre-F conformation to 
stabilize the highly neutralizing antigenic site Ø that is lost in the post-fusion conformation 
(McLellan et al. 2013, Krarup et al. 2015). Codon-optimization of the RSV F ORF and replacing 
the transmembrane and cytoplasmic tail (TMCT) domain of RSV F with the TMCT domain of the 
vector F protein, making it compatible to the vector proteins, increased expression and 
incorporation into vector particles, respectively (Liang et al. 2014, Liang et al. 2016). All current 
vaccine candidates were made by reverse genetics (Collins et al. 1995, Durbin et al. 1997) that 
provided the benefit of short passage history, rational vaccine design and the possibility of deletion 
and introduction of entire genes. 
In addition to the live-attenuated vaccine approach, different research groups and 
companies are also continuing to develop subunit vaccines for elderly and pregnant women 
[reviewed in (Mazur et al. 2018)]. The objective of these subunit vaccines are to boost the antibody 
titer to provide protection for the elderly and increase the maternally-derived antibody titer for 
newborn. Subunit vaccines should be a feasible approach for these groups as disease 
enhancement does not develop in individuals with previous RSV exposure. A live-attenuated 
vaccine approach might be difficult for this population due to the presence of serum antibodies 
against RSV and/or the viral vector. Pre-F-based and other RSV F- and G-based subunit vaccines 
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as well as various virus like particle- (VLP) and nanoparticle-based approaches are under 
development, and some of them are tested in clinical trials (Mazur et al. 2018). 
Ribavirin, a nucleoside analog inhibitor, is licensed as an antiviral treatment for RSV, but 
it is not recommended for routine use in pediatric patients (American Academy of Pediatrics 
Subcommittee on Diagnosis Management of Bronchiolitis 2006). The only licensed and effective 
prophylaxis for RSV infection is a monoclonal antibody-based passive immunoprophylaxis 
specific for RSV F protein. It was licensed under the name Synagis (palivizumab) by MedImmune 
in 1998 and is a humanized murine monoclonal antibody (MEDI-493) in which the 
complementarity-determining regions (CDRs) of the murine monoclonal antibody 1129 (Beeler 
and van Wyke Coelingh 1989) were recombinantly transferred onto a human immunoglobulin G 
(IgG) subclass 1 backbone (Johnson et al. 1997). Due to its high cost, its use is limited to infants 
at high risk for developing a severe RSV disease, such as premature infants, those with pulmonary 
abnormalities, or congenital heart disease (American Academy of Pediatrics Committee on 
Infectious Diseases Guidelines Committee 2014). Therefore, there is no prophylaxis or antiviral 
treatment available for general use in infants and the elderly that are at the highest risk of severe 
RSV infections. 
 
1.1.2. Genome-wide siRNA high-throughput screen 
Suppression of cellular protein expression using small interfering RNA (siRNA) emerged 
as a powerful tool to examine the functions of individual proteins. During virus infection, certain 
host proteins are utilized by the virus for efficient replication, while some host factors inhibit 
replication as part of the host antiviral defense. Knockdown of host protein expression offers a 
great tool to identify both types of proteins and can be performed on a large scale. Genome-wide 
siRNA libraries are readily available and allow the screen for potential pro- and anti-viral host-
factors in a high throughput manner. A number of siRNA screens have been performed for viruses 
such as human immunodeficiency virus, Influenza, Flaviviruses, and other pathogens (Hirsch 
2010). Novel host proteins involved in the viral replication cycle, as well as antiviral factors, have 
been identified that have contributed significantly to the understanding of host-virus interactions 
during infection. 
 
1.1.2.1. RNA interference (RNAi) 
RNAi is a process of post-transcriptional gene silencing resulting in reduced protein 
expression. RNAi is a naturally occurring phenomenon that is conserved in most eukaryotes to 
regulate gene expression and provide a rudimentary immune response (Hannon 2002, Ambros 
2004). RNAi can be divided into two different groups of effectors that mediate different silencing 
mechanisms [reviewed in (Meister and Tuschl 2004)]: siRNA and micro RNA (miRNA) (Figure 4). 
miRNAs, encoded by the cellular genome, naturally regulate messenger RNA (mRNA) translation 
and are transcribed by RNA polymerase II. The primary miRNA (pri-miRNA) transcripts are 5’ 
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capped, 3’ polyadenylated RNAs and contain a stem-loop structure. The pri-miRNA is cleaved by 
the Drosha enzyme complex in the nucleus and forms the pre-miRNA hairpin that is exported to 
the cytoplasm by Exportin 5. miRNAs possess partial complementarity to the target mRNA, which 
is their characteristic for inhibiting mRNA translation.  
 
 
Figure 4: Mechanism of RNA interference (RNAi) by siRNA (left) and miRNA (top and right). The 
schematics shows the differences between siRNA and miRNA processing and gene silencing. miRNA 
precursor is transcribed by RNA polymerase II (Pol II) and processed by Drosha prior to the export via 
Exportin 5 from the nucleus. Double stranded RNA (dsRNA) and pre-miRNA are processed by Dicer to 
siRNA or miRNA, respectively, and loaded into the RNA-induced silencing (RISC) complex. Synthetic 
siRNA also can be directly transfected into the cell. The passenger strand is cleaved (siRNA) or discarded 
(miRNA). The RISC is led by the guide strand to the target mRNA. siRNA requires full complementarity that 
results in the target mRNA cleavage. miRNA binds to partially complementary target sequences and causes 
translational inhibition and mRNA degradation. Schematic obtained from (Lam et al. 2015). 
On the other hand, siRNAs are derived from long double-stranded RNAs (dsRNAs) 
present in the cytoplasm and are processed similarly as the exported pre-miRNAs. Both are 
processed by the ribonuclease III-like enzyme (Dicer) into RNA duplexes of 21 to 23 nucleotides 
(nt) in length with a 3’ 2 nt overhang. These processed short dsRNAs are incorporated into the 
RNA-induced silencing complex (RISC) (Agrawal et al. 2003). The endonuclease argonaute 2 
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(AGO) of the RISC complex cleaves or discards the passenger strand of the siRNA and miRNA, 
respectively. The remaining siRNA guide strand (antisense) of the activated RISC binds to its 
complementary target sequence on mRNAs and initiates the cleavage by AGO. siRNAs only bind 
to fully complementary target sequences. Hence, it causes specific mRNA cleavage and 
expression silencing. In principal, siRNAs target one specific mRNA, however off-target effects 
can occur that cause siRNA-nonspecific effects and are discussed later. miRNAs, on the other 
hand, bind to the target mRNAs with partial complementarity and therefore, can bind to different 
mRNA sequences, resulting in the translation inhibition, mRNA degradation and/or mRNA 
cleavage of various mRNAs. miRNAs typically bind to the 3’UTR of the mRNA and cause the 
translational repression, whereas siRNAs always mediate cleavage of its target mRNA (Figure 4). 
 
1.1.2.2. Knockdown of gene expression in mammalian cells using siRNA  
RNAi induced by artificially introduced dsRNA was first described in Caenorhabditis 
elegans by the Nobel prize-awarded work of Andrew Fire and Craig C. Mello in 1998 (Fire et al. 
1998). C. elegans allowed the introduction of long dsRNA that was processed to siRNAs by Dicer 
and induced gene silencing. However, the transfection of long dsRNA into mammalian cells 
induces the innate immune response pathways, such as the activation of the dsRNA-dependent 
protein kinase (PKR) that results in the sequence-unspecific degradation of RNAs. To avoid the 
induction of the innate immune response, synthetic pre-processed siRNAs can be introduced into 
mammalian cells. The first siRNA knockdown in mammalian cells was successfully performed in 
2001 (Elbashir et al. 2001). Since then, many approaches to deliver siRNAs into mammalian cells 
have been developed. Target-specific synthetic siRNAs are commercially available and can be 
transfected into many different mammalian cells, without inducing the innate immune response. 
Another way of introducing siRNAs for the knockdown of a cellular protein is the introduction of 
short hairpin RNA (shRNA) -expressing DNA vectors, either by transient transfection or via 
retroviral vectors (Lam et al. 2015). shRNAs are processed by the cell in a miRNA-like manner 
(as described in section 1.1.2.1 and Figure 4) but its product has siRNA characteristics and only 
targets fully complementary mRNA sequences and therefore leads to specific mRNA degradation 
(Hannon 2002). 
With the rise of high-throughput siRNA screens and the vast availability of synthetic 
siRNAs, it was discovered that siRNAs also can target mRNAs nonspecifically. So-called “off-
target effects” can be induced by partial complementarity of the siRNA similar to miRNAs. The 
seed region of the siRNA sequence, nucleotide positions 2 to 8, has been shown to have the 
dominant effect in regards to off-target effects and might bias the siRNA screen results 
(Franceschini et al. 2014). 
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1.1.2.3. Identification of pro-viral host factors for RSV 
Previously, a genome-wide siRNA screen had been performed in collaboration with Dr. 
Scott E. Martin at the National Center for Advancing Translational Sciences (NCATS) to identify 
pro-viral host factors for RSV. Human lung epithelial A549 cells were used and individual host 
proteins were knocked down by transfection with individual siRNAs. The siRNA library “Ambion 
Silencer Select” contained three siRNAs per gene targeting over 22,000 genes. The effect on 
RSV replication was evaluated by viral GFP expression from a recombinant RSV-GFP virus that 
expressed enhanced GFP from an added gene inserted between the P and M genes in the viral 
genome (Munir et al. 2008). At 48 h post siRNA transfection, the cells were infected with RSV-
GFP and the GFP intensity, as a reporter for viral infection and replication, was quantified 48 h 
post infection. The results were compared with non-targeting negative siRNA and a common seed 
analysis was performed to identify off-target effects within the siRNA screen (Marine et al. 2012). 
The median seed-corrected Z-score was calculated for each gene target that factors out the 
influence of possible off-target effects. The corrected Z-score is calculated by subtracting the 
median Z-score for all siRNAs which have the same seed sequence as the siRNA. The calculated 
median corrected Z-score is used to rank genes in order of likelihood of confirmation. The 
strongest median seed adjusted Z-score of - 2.83 was obtained for the host gene ATP1A1 
(ATPase Na+/K+ transporting subunit alpha 1; GenBank1 Gene ID: 476), which was selected for 
further characterization in this study. 
Other hits of the same high-throughput screen have been independently characterized. It 
has been postulated that the actin-related protein 2 (ARP2), identified as another pro-viral factor 
in the same siRNA screen, plays a role in viral spread during RSV infection (Mehedi et al. 2016). 
 
1.1.3. Na+, K+-ATPase 
1.1.3.1. Physiological role 
The sodium, potassium ATPase (Na+, K+-ATPase) is a plasma membrane protein 
essential for all animal cells. In 1957 it was discovered by Jens Christian Skou, who received the 
Nobel prize for this work in 1997 (Skou 2004). Na+, K+-ATPase actively transports Na+ and K+ 
across the plasma membrane against their concentration gradient in an adenosine triphosphate 
(ATP)-dependent manner. The hydrolysis of the terminal phosphate of ATP provides the energy 
for the pump to transport three Na+ ions out of the cell in exchange for two K+ ions into the cell per 
ATP hydrolysis (Kaplan 2002). Na+, K+-ATPase maintains the electrochemical gradient and 
resting potential of the cell that is essential for many physiological processes. For example, the 
Na+, K+-electrochemical gradient is needed as a driving force for secondary active membrane 
protein transport of ions (e.g. H+, Ca2+, Cl-, PO43-, SO42-) and substrates (e.g. glucose and amino 
acids). It also provides the neuronal signaling potential and is involved in controlling the cell 
volume by maintaining the osmotic balance. Na+, K+-ATPase plays a primary role in the 
                                               
1 https://www.ncbi.nlm.nih.gov/genbank  
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reabsorption of sodium and water in the kidney and is essential in the maintenance of body fluid 
and electrolyte homeostasis (Blanco and Mercer 1998).  
Beside its pumping function of Na+ and K+ ions, it also has been described as signal 
transducer induced by the binding of cardiotonic steroids (CTS) at the ectodomain, which will be 
described in more detail in the following sections. 
 
1.1.3.2. Structure and function 
The Na+, K+-ATPase belongs to the family of the P-type ATPases, a family that contains 
more than 300 members. P-Type ATPases form an acyl phosphate intermediate during the ATP 
hydrolysis where the terminal (gamma-) phosphate of ATP is transferred to an aspartate residue 
within a conserved seven amino acid motif of the phosphorylation (P) domain of the Na+, K+-
ATPase. The most common amino acid motif of P-type ATPases, beginning with the aspartate, is 
DKTGTLT (Kaplan 2002).  
For the transport of Na+ and K+ ions across the plasma membrane the Na+, K+-ATPase 
cycles between the conformational E1 and E2 state [reviewed in (Jorgensen et al. 2003, Morth et 
al. 2011)]: Its conformational change is facilitated by ATP hydrolysis. Three Na+ ions bind 
intracellularly to the membrane transport domain in the E1-ATP state of the ATPase. ATP 
hydrolysis causes the transfer of the phosphate to the P-domain resulting in a conformational 
change of the actuator (A) domain to the E2P state, allowing the Na+ ions to be released to the 
extracellular side in exchange for two K+ ions. The E2P state closes that leads to the E2P 
dephosphorylation and the occluded E2 state. Upon binding of ATP to the nucleotide binding- (N) 
domain, the conformation changes to the initial E1-ATP state that results in the release of the 
bound K+ ions into the cell, binding of Na+ ions, and the restart of the cycle.  
The Na+, K+-ATPase complex contains an a-, ß-, and most often also a g- (FXYD protein) 
subunit (Figure 5) (Morth et al. 2011, Reinhard et al. 2013). The ß- and g-subunits are important 
for the transport properties of the Na+, K+-ATPase and also stabilize the complex (Geering 2008). 
The a-subunit is the major subunit of the Na+, K+-ATPase complex and contains ten 
transmembrane helices that embed the protein complex in the plasma membrane and forms the 
ion channel (Figure 5). It also provides its major cytoplasmic domains for the ATPase function 
(Figure 5): actuator- (A, yellow), nucleotide binding- (N, red) and phosphorylation- (P, blue) 
domain.  
Humans express four different a-subunit isoforms (a1 - a4) whose expression profile is 
cell type-specific (Blanco and Mercer 1998, Reinhard et al. 2013). The a1-isoform ATP1A1 is the 
most common isoform, is expressed ubiquitously on the plasma membrane of all cells, and is the 
predominant isoform in human airway epithelial A549 cells (Liu et al. 2016). Minor amounts of the 
a3-isoform (ATP1A3) have been found in A549 cells, but are 50-fold reduced compared to 
ATP1A1 (Liu et al. 2016). In the ciliated epithelial cells lining the nasopharynx and the bronchi of 
both mice and humans, Na+, K+-ATPase bearing ATP1A1 is present in greater abundance on the 
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basolateral surfaces and in lower abundance on the apical surface; it also is readily detected in 
human alveolar cells including on the luminal surface (Nieto-Torres et al. 2014, Uhlen et al. 2015, 
Human Protein Atlas 2018). 
 
Figure 5: Structure of the Na+, K+-ATPase. (A) Schematic presentation of the transmembrane orientation 
of the a- (gray), ß- (brown) and g- (orange) subunits of the Na+, K+-ATPase. The cytoplasmic ATPase 
domains are color-coded and show the actuator- (A, yellow) nucleotide binding- (N, red) and 
phosphorylation- (P, blue) domains. (B) Crystal structure of the Na+, K+-ATPase complex with bound 
ouabain (OBN, shown as orange molecule). Adapted from (Reinhard et al. 2013). 
A proportion of Na+, K+-ATPase is localized in caveolae due to the interaction of two 
caveolin-binding motifs of ATP1A1 with caveolin-1 (Xie and Cai 2003, Reinhard et al. 2013). 
Caveolae are membrane invaginations on the plasma membrane that are assembled by caveolin-
1 at microdomains that are rich in cholesterol and sphingolipid. In addition, caveolae are 
considered specialized “signaling organelles” since they contain many signal transduction 
molecules (e.g. Src, EGFR, Raf, MEK, ERK, PI3-kinase and others that also are involved in 
ATP1A1-mediated signaling, described in more detail in 1.1.3.4) and can facilitate the crosstalk 
of signaling pathways (Razani et al. 2002). Caveolae also are involved in the caveolin-mediated 
endocytosis [reviewed in (Conner and Schmid 2003)]. 
ATP1A1 also contains an extracellular binding site for CTS, such as ouabain (Figure 5B) 
which in effective doses (≥µM concentrations) inhibit the Na+, K+-ATPase ion pump activity. CTS 
bind selectively to the E2P state and lock it in this state, resulting in the inhibition of the ion pump 
function (Kaplan 2002). On the other hand, if CTS are present in sub-nanomolar concentrations, 
it does not inhibit the pumping activity, but has a hormone-like effect and induces ATP1A1-
mediated signaling (described in section 1.1.3.4. Na+, K+-ATPase signalosome). The sensitivity 
of ATP1A1 to CTS varies among isoforms and is different between species. For example, human 
ATP1A1 is relatively more sensitive to ouabain compared to the rodent ATP1A1 counterpart, 
which lacks the ouabain binding motif that results in a low affinity to ouabain and is therefore 
insensitive to it (Xie and Cai 2003). 
 
Introduction  15 
1.1.3.3. Cardiotonic steroids (CTS) 
The family of CTS are naturally derived compounds that can bind to the Na+, K+-ATPase 
and affect the performance of the heart. The compounds of this family are natural toxins and have 
been found as secondary metabolites in plants and several toad species (Melero et al. 2000). 
They all share common structural motifs [reviewed in (Prassas and Diamandis 2008)]: CTS 
contain a steroid core, which is considered to be responsible for the activity and binding of these 
compounds to ATP1A1. The steroid core contains a sugar moiety and an unsaturated lactone. 
The lactone moiety defines the subgroup of the CTS. Bufadienolides (derived from toads) possess 
a six-membered pyrone ring (Figure 6A), whereas cardenolides (derived from plants, e.g. digitalis 
from the foxglove plant) have a five-membered butyrolactone ring (Figure 6A). Bufalin and 
ouabain are examples of each of these subgroups, respectively (Figure 6). 
A  
 
 
B  
 
 
Figure 6: Chemical structure of the CTS Bufalin (A) and Ouabain (B), as example structures for the CTS 
subgroups of bufadienolides and cardenolides, respectively. 
These compounds show positive effects on the performance of the heart and have been 
used traditionally (over 200 years) to treat congestive heart failure and cardiac arrhythmia. The 
FDA approved drug for it is Digoxin (Drug Name Lanoxin, FDA Application Number: 40-282). Due 
to the inhibition of the Na+, K+ pump activity of the Na+, K+-ATPase, the cytoplasmic Na+ 
concentration is increased which inhibits the cellular Na+, Ca2+ exchange that leads to higher level 
of intracellular Ca2+ in cardiac myocytes. The increase of Ca2+ results in a positive inotropic effect 
which increases the cardiac contractile force (Prassas and Diamandis 2008). 
The best characterized CTS is ouabain (PubChem CID 2 : 439501), which could be 
considered the prototype of CTS. Ouabain is the most hydrophilic CTS and has been extensively 
studied in cardiovascular research. Ouabain has been found endogenously in humans and is 
associated with hormone-like effects (Schoner and Scheiner-Bobis 2007). It has been shown that 
continuous administration of ouabain causes hypertension in rats (Manunta et al. 1994) and 
elevated levels of endogenous ouabain also are associated with hypertension in humans 
(Schoner and Scheiner-Bobis 2007). It also had been reported that ouabain has antiviral effects 
for various viruses, such as coronavirus (Burkard et al. 2015), herpes simplex virus (Dodson et al. 
2007, Su et al. 2008), chikungunya virus (Ashbrook et al. 2016), human immunodeficiency virus 
(Wong et al. 2013), adenovirus (Grosso et al. 2017), and porcine reproductive and respiratory 
syndrome virus 1 (Karuppannan et al. 2012 ). However, in none of these studies was the antiviral 
mechanism further elucidated. 
                                               
2 Compound ID (CID) number of the PubChem database (https://pubchem.ncbi.nlm.nih.gov) 
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1.1.3.4. Na+, K+-ATPase signalosome 
Besides its ATPase and ion channel function, ATP1A1 of the Na+, K+-ATPase can form 
protein-protein complexes and can engage in signal transduction (Figure 7) [reviewed in 
(Reinhard et al. 2013)]. ATP1A1 does not possess a known cytoplasmic signaling domain, but it 
has been shown that ATP1A1 localized in the caveolae is associated with the cellular non-receptor 
tyrosine kinase c-Src and is thought to be involved in signal transduction via c-Src activation and 
most often EGFR transactivation (Liu et al. 2003, Wang et al. 2004). CTS can have hormone-like 
effects if present in nanomolar concentrations that are not inhibiting the ion channel function of 
ATP1A1 (Reinhard et al. 2013). ATP1A1 has been well-characterized as a sole receptor for CTS, 
such as ouabain. CTS-induced ATP1A1 signaling can regulate blood pressure and influences 
cellular processes (e.g. proliferation, differentiation and metabolism) (Schoner and Scheiner-
Bobis 2007). 
C-Src is part of the Src kinase family and consists of an SH3, SH2, and kinase domain 
(Boggon and Eck 2004). The SH2 and kinase domains of c-Src interact with the cytoplasmic 
domain 2 and 3 of ATP1A1 (Tian et al. 2006). Upon ouabain binding, the ATP1A1 cytoplasmic 
domain undergoes conformational changes and activates the c-Src kinase by releasing the 
catalytic core of the Src kinase domain and autophosphorylation of Src Tyr418 (Tian et al. 2006). 
c-Src is the only known signaling kinase associated with ATP1A1 and is the immediate effector of 
ouabain-induced ATP1A1 signaling. 
Multiple downstream signaling pathways can be triggered by ouabain-induced ATP1A1 
signaling [Figure 7, reviewed in (Xie and Cai 2003, Reinhard et al. 2013)] including the induction 
of the following:  
(i) Phospholipase C-gamma (PLC-g) pathway. Activation occurs by the phosphorylation of 
the PLC-g protein via c-Src kinase. PLC-g hydrolysis phosphatidylinositol 4,5-biphosphate (PIP2) 
that results in the increase of 1,2-diacylglyerol (DAG) and inositol 1,4,5 triphosphate (IP3). Latter 
is recognized by the IP3-receptor that can result in the release of calcium from the endoplasmic 
reticulum. 
(ii) Classical mitogen activated protein kinase (MAPK) pathway. The classical MAPK 
cascade includes Src-EGFR-Shc-Grb2 (growth factor receptor-bound protein 2) -SOS (Son of 
Sevenless) and involves Raf (MAP3K), MEK (mitogen-activated protein kinase kinase, MAP2K) 
and MAPK (ERK1/2). The MAPK signaling cascade can influence cellular processes, such as 
proliferation, differentiation, migration and metabolism. 
(iii) Phosphoinositide 3-kinase (PI3K) pathway. PI3K can be activated by c-Src (Wages et 
al. 1992, Pleiman et al. 1994) but the N-terminus of ATP1A1 also is able to interact directly with 
PI3K. This complex together with EGFR is able to attract AP2 (adaptor protein-2) and clathrin that 
result in the formation of clathrin-coated pits and endocytosis of Na+, K+-ATPase; a mechanism 
to downregulate the level of Na+, K+-ATPase on the plasma membrane (Liu et al. 2004).  
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Figure 7: Overview of ATP1A1-mediated signaling pathways that are induced by Ouabain (OBN).  
MAPK, mitogen activated protein kinase; EGFR, epidermal growth factor receptor; Shc, Src homology and 
collagen; Grb2, growth factor receptor-bound protein 2; SOS, son of sevenless; GDP, guanin triphosphate; 
GTP, guanin diphosphate; Raf, rapidly accelerated fibrosarcoma kinase; MEK, mitogen-activated protein 
kinase kinase; PLC-g, phospholipase C-gamma; IP3R, inositol 1,4,5-triphosphate receptor; PIP2, 
phosphatidylinositol 4,5-biphosphate; DAG, 1,2-diacylglycerol; IP3, inositol 1,4,5-triphosphate; PI3K, 
phosphoinositide 3-kinase; Akt, protein kinase B; eNOS, endothelial nitric oxide synthase (Ahmed and 
Prigent 2017). Obtained from (Reinhard et al. 2013) 
Most of the ATP1A1-mediated pathways involve c-Src as an immediate downstream 
signaling partner that transactivates EGFR or other effectors. Thus, c-Src and EGFR play a central 
role in ATP1A1-initiated signaling.  
EGFR is a receptor tyrosine kinase. Upon EGF binding at the EGFR ectodomain, the 
receptor dimerizes and the cytoplasmic domain is autophosphorylated, resulting in the induction 
of downstream signaling [reviewed in (Wee and Wang 2017)]. EGFR can also be phosphorylated 
by c-Src, in an EGF-independent manner, at otherwise atypical Tyrosine residues (i.e. Tyr845 or 
Tyr1101) (Biscardi et al. 1999, Donepudi and Resh 2008). The c-Src-mediated phosphorylation 
of EGFR triggers macropinocytosis (Donepudi and Resh 2008), similar to the well characterized 
EGF-induced macropinocytosis (Hewlett et al. 1994, Swanson and Watts 1995). 
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1.1.3.5. PST2238 (rostafuroxin) – an anti-hypertensive drug  
PST2238, also named rostafuroxin, (PubChem CID: 153976) is a synthetic digitoxigenin 
derivative with the chemical name 17b-(3-Furyl)-5b-androstane-3b,14b,17a-triol (Figure 8). 
PST2238 was identified in a chemical compound screen to selectively bind Na+, K+-ATPase and 
to possess anti-hypertensive activity (Quadri et al. 1997).  
 
Figure 8: Chemical structure of PST2238 (17b-(3-Furyl)-5b-androstane-3b,14b,17a-triol). 
PST2238 has been shown to bind to the ouabain-binding site of ATP1A1 and is able to 
competitively displace ouabain (Ferrari et al. 1998). Binding of PST2238 does not affect the ion 
pump activity of the Na+, K+-ATPase and antagonizes the ouabain-induced hypertension in rats, 
due to the competitive displacement of ouabain from its binding site at the ATP1A1 ectodomain 
(Ferrari et al. 1998, Ferrandi et al. 2002).  
PST2238 has also been tested in clinical trials as an anti-hypertensive drug for 
hypertension induced by elevated levels of endogenous ouabain. It lowered the blood pressure in 
hypertensive patients, but had no effect on the normal blood pressure of healthy individuals 
(Ferrari et al. 2006). 
 
1.1.3.6. Aim of this study 
The host-virus interactions are not well understood for RSV. A previously performed 
genome-wide siRNA screen was an attempt to gain a better understanding of the cellular factors 
playing a role in infection. This screen identified ATP1A1 as a potentially important pro-viral factor 
for RSV. The objective of this research project was to validate the screen results and characterize 
the role of ATP1A1, its pro-viral mechanism, and the associated pathways during RSV infection. 
Besides investigating the mechanistic role of ATP1A1 in facilitating RSV infection, chemical 
compounds that specifically act on ATP1A1 were evaluated for their antiviral activity to establish 
a foundation for developing an antiviral drug for RSV disease. 
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1.2. Development and pre-clinical evaluation of a human parainfluenza virus type 1 
(HPIV1)-vectored Ebola virus vaccine.  
The 2014 Ebola virus (EBOV) outbreak in West Africa and the resulting WHO declaration 
of an international health emergency prompted our laboratory to pursue the development of live-
attenuated HPIV-vectored EBOV vaccines. Peter Collins’ laboratory at the LID, NIAID, NIH had 
previously developed HPIV3-expressing EBOV envelope glycoprotein GP as an intranasal 
vaccine candidate that was evaluated in non-human primates (NHPs) (Bukreyev et al. 2006, 
Bukreyev et al. 2007, Bukreyev et al. 2009). In addition, HPIV1 and HPIV3 had been extensively 
characterized as live-attenuated vaccine vectors for RSV (Liang et al. 2014, Mackow et al. 2015, 
Liang et al. 2016, Liang et al. 2017, Liu et al. 2017) and provided a promising foundation for a 
rapid development of HPIV-vectored EBOV vaccine candidates. 
 
1.2.1. Ebola virus (EBOV) 
1.2.1.1. Phylogeny of Filoviridae 
EBOV is an enveloped, non-segmented, negative-sense RNA virus that belongs to the 
order Mononegavirales and family Filoviridae (Figure 1), which consists of three genera: 
Marburgvirus, Ebolavirus, and Cuevavirus (Misasi and Sullivan 2014). The genus Ebolavirus has 
five known species: Zaire, Sudan, Bundibugyo, Tai Forest, and Reston (Amarasinghe et al. 2018); 
and a recently characterized new proposed species, named Bombali (Goldstein et al. 2018). Zaire 
EBOV (ZEBOV) is the most pathogenic species and caused the 2014 - 2016 outbreak in West 
Africa. The ZEBOV variant Mayinga, the prototype strain, was isolated from the first outbreak in 
1976 (WHO 1978). The Makona variant of ZEBOV was responsible for the 2014 - 2016 outbreak 
in West Africa. 
 
1.2.1.2. Genome organization and replication 
The EBOV genome is a negative-sense single-stranded RNA of approximately 19 kb and 
encodes for seven viral proteins, namely (in 3’ to 5’ gene order) the nucleoprotein (NP), virion 
protein (VP) 35 (comparable to a P protein), VP40 (comparable to an M protein), glycoprotein GP, 
VP30 (a novel nucleocapsid protein), VP24 (a novel, minor matrix protein) and the viral 
polymerase L (Figure 9) (Feldmann et al. 2013). The genome structure is typical for the order 
Mononegavirales: the genome is flanked by 3’ leader and 5’ trailer sequences that contain the 
promoter sequences for transcription and replication initiation. Each gene is flanked by GS and 
GE sequences. Several genes overlap with each other (Figure 9). The adjacent genes that do not 
overlap are separated by an IG sequence that is variable between different junctions (Feldmann 
et al. 2013). 
The viral genome is encapsidated by NP and associated with the transcriptional activator 
VP30 that supports primary transcription and RNA editing (Baseler et al. 2017). The transcription 
and replication of the viral genome is performed by the viral polymerase L that is associated with 
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the cofactor VP35, which is the equivalent of the P protein of other mononegaviruses (Baseler et 
al. 2017). VP40 and VP24 are the major and minor matrix proteins, respectively, and have a role 
in the assembly and budding of the filamentous virions (Feldmann et al. 2013). 
 
Figure 9: Genome structure of EBOV. Genes are color-coded for their general location in the virion. The 
nucleoproteins are blue, membrane-associated proteins are red, the polymerase complex is light blue and 
the nonstructural soluble GP (sGP) is yellow. The gene non-coding regions are white and extragenic 
sequences are black. IG; intergenic region. Adapted from (Feldmann et al. 2013). 
All viral genes contain a single monocistronic ORF, except for GP that expresses, in 
addition to the transmembrane GP form, two soluble forms: soluble GP (sGP) and small soluble 
GP (ssGP) (Baseler et al. 2017). The sGP is a 50 - 70 kDa protein encoded by the unmodified 
GP mRNA. The full-length, transmembrane form of GP (which is sometimes called GP0) is a 110-
160 kDa glycoprotein [676 amino acids [aa], MW varies based on the glycosylation (Volchkov et 
al. 1998)] encoded by an edited form of the EBOV GP mRNA. A single non-template A residue 
(mRNA-sense) is added at a specific editing site by transcriptional editing of the viral RdRp that 
results in a frame shift and encodes for the full-length transmembrane form of GP. It is cleaved by 
a furin-like protease into two subunits, GP1 and GP2 [representing the N-terminal (469 aa) and C-
terminal (175 aa) ends of GP0, respectively; MW approximately 140 and 26 kDa, respectively 
(Volchkov et al. 1998)] that remain linked by a single disulfide bond (Feldmann et al. 2013). The 
EBOV GP is a highly glycosylated type I transmembrane protein (i.e., the membrane anchor is 
near the C-terminus). GP is the sole viral surface glycoprotein and mediates viral attachment and 
entry (Sanchez et al. 1996) and is the major EBOV neutralization antigen. Vectored vaccines 
expressing EBOV GP can elicit protective immunity against lethal EBOV challenge in NHPs 
(Bukreyev et al. 2007, Stanley et al. 2014, Meyer et al. 2015, Mire et al. 2015, Ewer et al. 2016). 
The vectored vaccine candidates developed in the present study (described in 1.2.4) involved 
expression of the transmembrane form of EBOV GP from a live-attenuated HPIV1 vector. 
 
1.2.1.3. Epidemiology and pathogenesis 
The first EBOV outbreak was documented in northern Zaire (now Democratic Republic of 
Congo) in 1976 (WHO 1978). The outbreak occurred at a mission hospital in Yambuku, close to 
the Ebola river that gave the virus its name. Almost simultaneously, another outbreak occurred 
near Maridi in Sudan. Retrospectively, it was recognized that these two outbreaks of EBOV were 
independent from each other and were caused by different EBOV species that were named after 
the countries of origin: Zaire and Sudan (Feldmann et al. 2013). 
EBOV is considered to be a zoonotic infection and is initiated by contact with body fluids 
of EBOV-infected animals. The animal reservoir is uncertain but substantial evidence suggests 
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that bat species might be the natural reservoir. It has not yet been possible to isolate infectious 
virus from bats, but indirect evidence, such as viral RNA and EBOV-specific serum antibodies in 
endemic regions, suggests that bats could be the natural reservoir for EBOV. In addition, 
experimental inoculation of bats showed viral replication without fatalities, which make them a 
suitable natural reservoir (Coltart et al. 2017). 
Since the discovery of EBOV and prior to the large 2014 outbreak in West Africa, many 
small outbreaks occurred, but were limited to remote and rural areas in Sudan, Democratic 
Republic of Congo, Republic of Congo, Gabon and Uganda (Coltart et al. 2017). Due to the 
geographical isolation, it was easy to contain the outbreaks and they lasted from several weeks 
to approximately 3 months (Bell et al. 2016). 
EBOV can be transmitted from human to human by puncture wounds or contact of a 
patient’s body fluids with skin or mucosal surfaces. Nosocomial transmissions, ceremonial 
washings, and touching of deceased EBOV-infected persons during burial practices are important 
routes of transmission. More recently, aerosol transmission via airborne droplets of body fluids 
has received increased recognition as an important mode of transmission (Osterholm et al. 2015). 
For example, aerosolized EBOV can cause lethal infection in NHPs and guinea pigs (Johnson et 
al. 1995) and can be transmitted from infected to naïve animals by aerosols (Jaax et al. 1995, 
Wong et al. 2015). Guinea pigs infected with aerosolized EBOV are more infectious for naïve 
animals than those infected intraperitoneally (Wong et al. 2015). This stresses the need to develop 
an EBOV vaccine capable of inducing both systemic and mucosal immunity, particularly in the 
respiratory tract.  
The incubation period of EBOV infections can last from several days to 21 days, but 
usually it takes between 7 and 14 days from exposure to the onset of first disease symptoms 
(Kaner and Schaack 2016). Infected individuals first develop general flu-like symptoms and rapidly 
progress to advanced disease. EBOV causes severe hemorrhagic fever in humans, multiple organ 
failure and a shock-like syndrome with case fatality rates ranging from 25 - 90% (Kuhn et al. 2011, 
Coltart et al. 2017). 
 
1.2.1.4. EBOV outbreak in West Africa (2014 - 2016) 
Zaire EBOV caused the 2014 - 2016 EBOV outbreak in West Africa that is the largest 
outbreak in history with over 28,000 cases and more than 11,000 deaths (Centers for Disease 
Control and Prevention (CDC) 2016). The affected area is one of the poorest in the world and was 
not equipped for dealing with an outbreak of this magnitude. The index case of this outbreak was 
retrospectively identified as a two-year old child in Meliandou in southeastern Guinea (Figure 10) 
who died in December 2013. It is assumed that family members and the midwife of the child 
transmitted the virus further. The high mobility of the people in the Kissi tribal area, which includes 
areas in Guinea, Sierra Leone and Liberia (Figure 10), accelerated the spread into larger, densely 
populated cities and neighboring countries that resulted in the largest EBOV outbreak in history 
(Coltart et al. 2017). 
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Figure 10: Map of the origin of the EBOV outbreak in West Africa (2014 - 2016). It shows the Kissi tribal 
area which spans across the border between Sierra Leone, Liberia and Guinea. The index case of the 
outbreak occurred in Meliandou, Guinea that is located within the Kissi tribal area in December 2013. 
Obtained from (Coltart et al. 2017) 
The first EBOV case in Liberia (Foya) and Sierra Leone (Kenema) were confirmed on 
March 30th and May 25th 2014, respectively. On August 8th 2014, the WHO declared the outbreak 
as an international public health emergency. Many factors made it challenging to contain the 
outbreak in a quick and effective manner. Major problems were lack of infrastructure in these 
resource-limited countries as well as cultural and behavioral factors. Traditional burial ceremonies, 
that include washing and touching of the deceased, were responsible for a large number of 
transmissions in Guinea during the outbreak (Coltart et al. 2017). In addition, the population did 
not trust the foreign support and also mistrusted their own government. With international support 
and public education, it was eventually possible to reduce the number of transmissions by classic 
epidemiological methods (quarantine and contact tracing). Besides Guinea, Sierra Leone and 
Liberia, which had the majority of EBOV cases, seven other countries, including the United States 
and European countries, had EBOV cases that were linked to the West African outbreak due to 
international travel or health care personnel that were infected during their work in the outbreak 
area [reviewed in (Coltart et al. 2017)]. It was eventually possible to contain and end the outbreak 
in 2016. After 42 days (twice the maximum incubation period for EBOV) past the last confirmed 
EBOV case, which is the WHO criteria to declare the end of an EBOV outbreak, the countries 
Sierra Leone (March 17th), Guinea (June 1st) and Liberia (June 9th) were finally declared EBOV-
free (Coltart et al. 2017). 
 
1.2.2. EBOV vaccine strategies 
No vaccine or post-exposure treatment is currently licensed, and the unprecedented scale 
of the recent outbreak raised concerns of larger outbreaks and spread. This outbreak prompted 
multiple initiatives with enhanced efforts to develop an EBOV vaccine, and multiple experimental 
vaccines moved forward into clinical trials during the outbreak. It has been shown that neutralizing 
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antibodies directed against GP, the viral attachment and fusion glycoprotein, can provide 
protection against an EBOV infection. Therefore, vaccination to induce an immune response 
against EBOV GP should be a promising strategy to protect against EBOV infection and to limit 
further spread. It also has been demonstrated that treatment of rhesus macaques post-EBOV-
exposure with a combination of monoclonal antibodies (ZMapp) directed against EBOV GP 
resulted in the rescue of infected animals from a lethal outcome (Qiu et al. 2014). ZMapp was also 
used as an experimental treatment during the outbreak (Group et al. 2016). 
Most efforts were made to develop vaccine strategies that induce a sufficient serum titer 
of neutralizing antibodies against the EBOV GP to provide protection. Currently the most 
advanced vaccine candidate is a recombinant vesicular stomatitis virus (VSV) that expresses 
Zaire EBOV GP (rVSV-ZEBOV) instead of the VSV glycoprotein G (Garbutt et al. 2004). It protects 
NHPs against EBOV infection and was administered in ring vaccinations in Guinea during the 
recent outbreak (Henao-Restrepo et al. 2015). This candidate showed promising immunogenicity 
in humans. Due to the replication competence of the VSV vector, adverse side effects, such as 
fatigue, myalgia, headache, fever (subjective), and frequent viremia were observed (Regules et 
al. 2017). 
Another vaccine strategy, which has advanced into clinical trials, is based on the 
recombinant replication-deficient chimpanzee adenovirus serotype 3 vector that encodes the 
Zaire EBOV GP and is called ChAd3 ZEBOV (De Santis et al. 2016). It has been previously shown 
to provide immune protection against EBOV infection in NHPs (Sullivan et al. 2006).  
HPIV3 vectors expressing EBOV GP also were developed prior to the outbreak in West 
Africa. HPIV3 (JS strain) expressing EBOV GP from an added gene (rHPIV3/EboGP) was 
evaluated as an intranasal mucosal vaccine candidate (Bukreyev et al. 2006, Bukreyev et al. 2007, 
Bukreyev et al. 2009). In NHPs, one intranasal dose was moderately immunogenic, with 88% 
protection, but two doses provided complete protection against an intra-peritoneal EBOV 
challenge. When delivered by aerosol, a single dose of this vaccine conferred 100% protection in 
NHPs, and was more immunogenic than an alphavirus replicon vaccine (Meyer et al. 2015). In 
addition, an HPIV3 vector with the deletion of its surface glycoproteins F and HN, and EBOV GP 
as the sole surface glycoprotein was evaluated. The goal of this construct (PIV3/ΔHNF/EbovZ GP) 
was to avoid the restriction of vector replication in human population due to pre-existing immunity 
to HPIV3 F and/or HN (Bukreyev et al. 2009). Initial clinical studies to evaluate safety and 
immunogenicity of these HPIV3-based vaccine candidates are in progress in the U.S 
(ClinicalTrials.gov identifiers for HPIV3-EbovZ GP: NCT02564575; and PIV3/ΔHNF/EbovZ GP: 
NCT03462004). 
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1.2.3. Human parainfluenza virus (HPIV) 
1.2.3.1. Phylogeny of Paramyxoviridae 
HPIV1 is an enveloped, non-segmented, single-stranded, negative-sense RNA virus that 
belongs to the genus Respirovirus of the family Paramyxoviridae within the order 
Mononegavirales (Figure 1). Four serotypes of HPIV are known: HPIV3 belongs to the same 
genus as HPIV1, whereas HPIV2 and HPIV4 belong to the genus Rubulavirus within the family 
Paramyxoviridae. HPIV3 has a bovine counterpart (BPIV3), and a recombinant chimeric form of 
bovine and human PIV3 (B/HPIV3) has been evaluated as a vaccine for seronegative children in 
a clinical trial (Karron et al. 2011). B/HPIV3 has the BPIV3 genome backbone with only the surface 
glycoproteins F and HN substituted with the HPIV3 counterparts (Haller et al. 2000, Schmidt et al. 
2000). The B/HPIV3 vector has been developed as an attenuated vaccine vector that induces a 
protective immune response against HPIV3 and can be used as a bivalent vaccine by expressing 
an additional foreign protein, such as RSV F (Liang et al. 2014) or the severe acute respiratory 
syndrome coronavirus (SARS-CoV) spike protein (Bukreyev et al. 2004). 
1.2.3.2. Genome organization and viral replication 
The HPIV1 genome consists of 6 genes (Figure 11) encoding (in 3’ to 5’ order) the 
nucleoprotein (N), phosphoprotein (P/C), matrix protein (M), fusion glycoprotein (F), 
hemagglutinin-neuraminidase glycoprotein (HN), and the large polymerase protein (L) (Karron et 
al. 2013). The P gene carries an additional overlapping ORF, with an alternative start codon, 
expressing the C protein that antagonizes the host interferon and apoptosis responses (Bartlett 
et al. 2008). HPIV3 shares considerable sequence relatedness and similarities in genome 
organization with HPIV1. In addition to the C ORF, HPIV3 P gene also carries one additional ORF 
coding for a D protein that is expressed by RNA editing (Galinski et al. 1992). 
 
Figure 11: Genome structure of HPIV1. Gray boxes indicate the gene start (GS, light gray) and gene end 
(GE, dark gray) sequences flanking each gene. Intergenic (IG) sequences are indicated by lines between 
the genes. 
As it is common for the order Mononegavirales, the genome of HPIVs contain a linear 
array of genes (Figure 11), that each are flanked by GS and GE transcription signals and are 
separated by IG sequences. HPIVs undergo cytoplasmic gene expression and replication typical 
for the members of the family Paramyxoviridae, as described in 1.1.1.1. 
The RNP complex of HPIVs is comprised of the viral RNA that is associated with the viral 
proteins N, P and L. The nucleoprotein N encapsidates the viral genomic (negative-sense) and 
anti-genomic (positive-sense) RNAs. It is predicted that each N protein molecule can bind to 
exactly 6 nt of RNA and this is thought to be the basis for the observation that the paramyxovirus 
genomes can replicate efficiently only when they are a multiple of 6 nt in length. This phenomenon 
is called “rule of six” (Calain and Roux 1993, Kolakofsky et al. 1998) and is important to be followed 
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for generating recombinant viruses and vaccine vector designs to ensure a stable genome that 
could efficiently replicate. 
HPIVs have two surface glycoproteins incorporated into the virion envelope (Karron and 
Collins 2013); namely, the fusion protein F and the hemagglutinin-neuraminidase glycoprotein HN. 
HN binds to sialic acid on the host cell and mediates attachment. It also binds to red blood cells 
and causes hemagglutination or hemadsorption, a property that can be used to detect and 
quantify virus. In the later phase of infection, the neuraminidase activity of the membrane-
incorporated HN protein cleaves nearby sialic acids to facilitate the release of progeny virions. 
The fusion protein F mediates fusion with the host cell plasma membrane to allow nucleocapsid 
entry into the cytoplasm. F is expressed as an F0 precursor that is cleaved by host proteases into 
the F1 (the larger, C-terminal fragment) and F2 (the smaller, N-terminal fragment) subunits that, 
for the HPIVs,  are connected by a single disulfide bond (Karron and Collins 2013). Cleavage is 
required to expose the fusion peptide at the N-terminus of F1 which makes PIVs infectious, since 
it mediates the insertion of the F protein into the plasma membrane for fusion to occur. Many PIVs 
(HPIV2, HPIV3, BPIV3) have a furin cleavage site (R-X-R/K-R) that allows the ubiquitously 
available cellular furin protease to cleave and “activate” F0 in cell culture. HPIV1 (and also Sendai 
virus and HPIV4) lacks the furin cleavage motif and depends on trypsin-like proteases for 
cleavage, which in vivo are present in mucosal secretions and in vitro can be added exogenously 
to the cell culture medium (Karron and Collins 2013). 
1.2.3.3. Epidemiology and pathogenesis 
HPIV3 is second only to RSV as a cause of hospitalization in children younger than 5 years 
of age. Infection with HPIV1 and HPIV2 occurs later in early childhood compared to HPIV3 and 
RSV (Figure 3), and typically 75% of children have been infected with HPIV1 by 5 years of age 
(Karron and Collins 2013). The later onset of HPIV1 infections in infants make it suitable for a live-
attenuated vector for use in slightly older infants that typically have not yet been exposed to HPIV1 
(Figure 3). Due to the possible later time point of vaccination, the maternally-derived antibodies 
and immature immune system (Figure 3) would interfere less with the efficacy of the vaccination 
as compared to the vaccination of younger infants. 
HPIV infection mostly causes mild URI but can develop clinical manifestations of croup, 
(most common for HPIV1) or bronchiolitis and pneumonia (typical for HPIV3). The seasonality of 
HPIVs vary between serotypes. HPIV1 outbreaks occur every other year in odd numbered years, 
whereas HPIV2 and HPIV3 circulate annually (Abedi et al. 2016). 
1.2.4. The development of an HPIV1-vectored EBOV GP vaccine 
In a recent study, our laboratory demonstrated that incorporation of RSV F protein in a 
PIV3 vector particle was substantially enhanced by substituting its TMCT domain with those of 
the vector F protein (Liang et al. 2016). The TMCT modification also resulted in a significant 
increase in both the quantity and quality of the RSV-neutralizing serum antibodies. This may 
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reflect increased immunogenicity of an antigen presented to the immune system in a particle, and 
also may reflect increased immunogenicity of antigen presented in a native, ordered array 
(Bachmann et al. 1993). Similar results have been observed for HPIV1 vectors expressing the 
RSV F protein (Liu et al. 2017). This indicates that, for HPIV3 and HPIV1 vectors, incorporation 
of a heterologous glycoprotein into the vector particle increases its immunogenicity. It is 
noteworthy that the incorporation of EBOV GP into the previously developed rHPIV3/EboGP virus 
particles (described in 1.2.2) was only 13% as efficient as the HPIV3 HN protein, suggestive of 
inefficient packaging of EBOV GP into an HPIV vector (Bukreyev et al. 2006). Moreover, the 
HPIV3 JS strain backbone used for developing the rHPIV3/EboGP had not been specifically 
attenuated and has a potential risk of vector-related respiratory illness (Kapikian et al. 1961), 
especially in children and the elderly, and thus an attenuated vector would be preferable. Also, 
the comparative properties of the different types of HPIVs as vectors have not been examined, 
and it is unclear which type would be the most effective as a human vaccine vector.  
Previously, a non-temperature-sensitive attenuating mutation consisting of a 6 nt deletion 
in the overlapping P and C ORFs called C∆170 was introduced in the HPIV1 genome (Bartlett et al. 
2007, Mackow et al. 2015). This mutation reduces the ability of the C protein to inhibit the host 
type I interferon response and apoptosis (Newman et al. 2004, Bartlett et al. 2006, Bartlett et al. 
2008), resulting in viral attenuation. Previous evaluation of HPIV1-C∆170 as a live-attenuated 
vaccine backbone for expressing the RSV F glycoprotein showed that it was suitably attenuated 
for vaccine development (Mackow et al. 2015). In the present study, efforts were made to enhance 
GP immunogenicity by increasing its packaging in the vector virions and an attenuated HPIV1- 
C∆170 backbone was evaluated to provide an attenuated vaccine expected to be safe for all age 
groups, including children and the elderly. 
1.2.5. Aim of this study 
The study was initiated in response to the 2014 EBOV outbreak in West Africa. The aim 
was to develop live-attenuated rHPIV1-C∆170 vectors expressing EBOV GP from two different 
positions (pre-N or between N-P) of the HPIV1 genome. Two different sites were chosen to 
determine the effect of GP insert position on HPIV1 attenuation, GP expression, and 
immunogenicity. To enhance immunogenicity, the EBOV GP ORF was codon-optimized for 
human expression and the TMCT domains were substituted with those of the HPIV1 F protein in 
an effort to obtain efficient incorporation into the vector particle. At each site, membrane-anchored 
EBOV GP was expressed either as a full-length unmodified GP protein, or as a derivative of GP 
with an HPIV1 F TMCT domain.  
The pre-clinical evaluation of these vaccine candidates was performed. All constructs were 
analyzed in vitro for replication and expression of EBOV GP and in NHPs for replication, stability 
of EBOV GP expression, and immunogenicity. The objective of this EBOV vaccine project was to 
identify a suitable vaccine candidate for further clinical development as a live-attenuated mucosal 
vaccine that could elicit protection against a lethal EBOV exposure. 
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2. Materials and Methods 
2.1. Materials 
In the following section, the materials are listed that were specifically used for the 
described studies. General laboratory supplies were purchased from various vendors, including 
NIH Supply Center (Bethesda, MD), Fisher Scientific (Hampton, NH), Thermo Fisher Scientific 
(Waltham, MA), Life Technologies (Carlsbad, CA) and Sigma-Aldrich (St. Louis, MO). 
 
2.1.1. Chemicals and Solutions 
The following table (Table 1) lists all chemicals and solutions used in this study along with 
their source companies. 
Table 1: List of chemicals and solutions 
Name Company 
4′,6-diamidino-2-phenylindole (DAPI) Life Technologies 
5-(N-Ethyl-N-isopropyl)amiloride (EIPA) Sigma-Aldrich 
Agarose gel, 1% (w/v), containing ethidium bromide BioRad 
Amphotericin, 250 µg/ml Quality Biological 
Ampicillin Sigma-Aldrich 
Big Dye Terminator v1.1 Applied Biosystems 
Bis-Tris SDS gels, 4-12% (w/v) Thermo Fisher Scientific 
Bovine serum albumin (BSA) Sigma-Aldrich 
Chlorpromazine Sigma-Aldrich 
Cleocin, 150 mg/ml Pfizer 
Dextran (MW 10,000), Alexa Fluor 568-conjugated Life Technologies 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Dipotassium phosphate (K2HPO4) Fluka 
Dithiobis(succinimidyl propionate) [DSP] Sigma-Aldrich 
DNA gel loading solution, 5x Quality Biological 
Ethanol, 200 proof Pharmco Products 
Ethylenediaminetetraacetic acid (EDTA) solution, 0.5 M Quality Biological 
F12-K medium ATCC 
Fetal bovine serum (FBS) Thermo Fisher Scientific 
Geneticin, 50 mg/ml Life Technologies 
Gentamycin, 50 mg/ml Life Technologies 
Glasgow’s MEM (GMEM) Life Technologies 
Guinea pig complement Lonza 
HEPES buffer, 1 M Sigma-Aldrich 
Hydrochloric acid (HCl), 1 M Sigma-Aldrich 
Isopropyl alcohol Avantor Performance Materials 
Kanamycin Sigma-Aldrich 
L-Glutamine, 200 mM (100x) Life Technologies 
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Name Company 
LB-Medium Mediatech 
Leibovitz's L15 medium Life Technologies 
MEM Amino Acids, 50x Life Technologies 
Methanol Fisher Scientific 
Methyl-beta-cyclodextrin (MBCD) Sigma-Aldrich 
Methylcellulose Sigma-Aldrich 
Mevinolin (Lovastatin) Sigma-Aldrich 
Monopotassium phosphate (KH2PO4) Fluka 
NP-40 (Igepal CA-630) Sigma-Aldrich 
NuPAGE Antioxidant, 10x Life Technologies 
NuPAGE Loading Dye Solution (LDS) sample buffer, 4x Life Technologies 
NuPAGE MOPS SDS running buffer, 20x Life Technologies 
NuPAGE Sample Reducing Reagent, 10x Life Technologies 
Opti-MEM I GlutaMax-I medium Life Technologies 
Ouabain Sigma-Aldrich 
Paraformaldehyde, 16% (w/v) Electron Microscopy Science 
PBS, 1x Life Technologies 
Penicillin/Streptomycin, 10x Quality Biological 
Phosphate buffered saline (PBS), 10x Life Technologies 
PP2 Sigma-Aldrich 
ProLong Diamond Antifade mountant Life Technologies 
PST2238 (Rostafuroxin) Sigma-Aldrich 
RPMI 1640 medium Life Technologies 
siLentFect transfection reagent Bio-Rad 
Sodium chloride (NaCl) Sigma-Aldrich 
Sodium deoxycholate  KD Medical 
Sodium dodecyl sulfate (SDS), 10% (w/v) Sigma-Aldrich 
Src-Inhibitor-I (SrcI-I) Sigma-Aldrich 
Sucrose Sigma-Aldrich 
TAE solution, 10x Quality Biological 
TaqMan reaction mastermix Life Technologies 
TBE solution, 10x Quality Biological 
Timentin Glaxo Smith Kline 
Tris-HCl solution, 1M KD Medical 
Triton X-100 Sigma-Aldrich 
TrypeLE Select (Trypsin) Life Technologies 
Tween 20 Sigma-Aldrich 
Ultra Complete Mini protease inhibitor Roche 
Ultrapure water (dH2O) Fisher Scientific 
Western blot blocking buffer Li-Cor 
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Table 2 shows the composition for each of the solutions that were prepared for these studies. 
Table 2: Composition of solutions 
Solution Composition 
30% (w/v) Sucrose solution 300 g Sucrose 
15 ml 5 M NaCl 
25 ml 1 M HEPES 
 add dH2O to 500 ml total 
60% (w/v) Sucrose solution 150 g Sucrose 
15 ml 5M NaCl 
25 ml 1M HEPES 
 add dH2O to 500 ml total 
Plaque assay overlay medium 500 ml Opti-MEM I GlutaMax-I 
0.8% (w/v) Methylcellulose 
2.0% (v/v) FBS 
1x L-Glutamine 
50 µg/ml Gentamicin 
 
For HPIV1 only: 4% (v/v) trypsin (no FBS) 
For animal derived samples: 
  200 µg/ml Ampicillin  
  30 µg /ml Cleocin  
  400 µg /ml Timentin  
  100 µg /ml Gentamycin 
  5 µg/ml Amphotericin 
RIPA lysis buffer 20 mM Tris-HCl, pH 8.0  
200 mM NaCl 
1.0 mM EDTA 
1.0% (v/v) NP-40 (Igepal CA-630) 
1.0% (w/v) Sodium deoxycholate 
0.1% (w/v) SDS 
1x Ultra Complete Mini protease inhibitor 
10x SP solution 2.18 M Sucrose, 
38.0 mM KH2PO4 
72.0 mM K2HPO4 
pH 7.1 
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2.1.2. Instruments 
The following instruments (Table 3) were used for performing the experiments described 
in this study. 
Table 3: Instruments 
Instrument Company 
-20 ˚C freezer VWR 
-80 ˚C freezer Thermo Fisher Scientific 
3730 DNA Analyzer Applied Biosystems 
4˚C fridge VWR 
7900HT Fast Real-Time PCR system Applied Biosystems 
Agarose gel electrophoresis chamber, Sub-Cell Model BioRad 
Analytical balance, Adventure Pro Ohaus 
Bacterial incubator, 10-140E Quincy Lab 
Bacterial shaker incubator, I-10002 Infors USA 
Benchtop centrifuge, Alegra 25R Beckman Coulter 
Biosafety cabinet, Class II Type A/B3 Nuaire 
Cell culture incubator, Forma Steri-Cult CO2 Incubator Thermo Fisher Scientific 
Confocal fluorescence microscope, SP5 and SP8 Leica 
ELISA reader Synergy 2 BioTek 
Epi fluorescence microscope Leica 
Flow cytometer Canto II BD 
Hemocytometer, Neubauer improved Fisher Scientific 
iBlot2 transfer system Life Technologies 
Infrared imaging system Odyssey Li-Cor 
Inverse bright field microscope, DMIL Leica 
Liquid nitrogen storage tank, MVE 1520HE-190 Chart Industries 
Magnetic stirrer Corning 
Microcentrifuge 5417R Eppendorf 
Mid speed centrifuge, Avanti J-20 XP Beckman Coulter 
Mini centrifuge, myFUGE Benchmark Scientific 
Nanodrop 1000 Thermo Fisher Scientific 
Orbital shaker VWR 
PCR thermal cycler, C1000 BioRad 
pH meter, SevenMulti Mettler Toledo 
Power supply, EC 300 XL Thermo Fisher Scientific  
QIAcube Qiagen 
Rocking platform VWR 
 SDS gel electrophoresis chamber, XCell4 SureLock Life Technologies 
Stratalinker UV Crosslinker 1800 Agilent 
Thermomixer, Modell R  Eppendorf 
Tissue homogenizer OMNI International 
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Instrument Company 
Typhoon imaging system GE Healthcare 
Ultracentrifuge, Optima L-100XP Beckman Coulter 
UV-Gel imaging system, Gel Logic 200 Kodak 
Vortexer Scientific Industries 
Water bath Thermo Fisher Scientific 
X-ray film developer, X-Omat 2000A processor Kodak 
 
2.1.3. Software programs 
The software programs listed in Table 4 were used for acquiring and analyzing the data. 
Table 4: Software programs 
Name Version Company 
Lasergene suite 14.0 DNASTAR 
Sequencher 5.4 Gene Codes Corporation 
ImageJ 1.46r NIH 
ImageStudio 5.2.5 Li-Cor 
Imaris 9.0.0 Bitplane AG 
UCSF Chimera 1.10.2 University of California 
FlowJo 10.1r1 FlowJo, LLC 
Image acquisition software LAS-X Leica 
FACSDiva 8.0.1 BD 
Prism 7.0 GraphPad Software 
ImageQuant TL Array Version 8.1. GE Healthcare 
 
2.1.4. Cells and cell culture media 
Cell lines used in this study (Table 5) were provided by Peter L. Collins or were purchased 
from American Type Culture Collection (ATCC; Manassas, VA).  
Cell lines were cultured in the cell line-specific medium listed in Table 5. Cells were 
maintained in T225 flasks and seeded in various multi-well plate formats (6-well, 12-well, 24-well, 
48-well and 96-well) as required for each experiment. All cell culture flasks and plates were 
obtained from Corning Inc. (Corning, NY). 
Table 5: Cells and cell culture media 
Cells (Passage Number) Reference Medium composition 
A549 (P87) ATCC CCL-185 F12-K medium  
10% (v/v) FBS, 1x L-Glutamine 
Vero (P149) ATCC CCL-81 Opti-MEM I GlutaMax-I  
5% (v/v) FBS 
LLC-MK2 (P27) ATCC CCL-7 Opti-MEM I GlutaMax-I  
5% (v/v) FBS 
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Cells (Passage Number) Reference Medium composition 
BHK BSR-T7 (P49) (Buchholz et al. 1999) Glasgow’s MEM (GMEM) 
10% (v/v) FBS, 1x MEM amino acid solution,  
Every other passage: 1x Geneticin 
Primary Small Airway 
Epithelial Cells (HSAEC); 
Normal, Human 
ATCC PCS-301-010 
Lot: 64079184 
Airway cell basal medium (ATCC PCS-300-
030), supplemented with bronchial epithelial 
cell growth kit (ATCC PCS-300-040) 
H1299-YFP-ATP1A1 (Sigal et al. 2006)  
Kindly provided by  
Uri Alon, Weizmann 
Institute of Science, 
Rehovot, Israel 
RPMI 1640  
10% (v/v) FBS 
 
 
2.1.5. Viruses 
Viruses used in this study (Table 6) were provided by Peter L. Collins. Virus working pools 
were grown and the viral consensus genome sequence was confirmed by Sanger sequencing as 
described in 2.2.9 of the Methods. 
Table 6: Viruses 
Virus  Reference 
wt RSV A2 (D53) (Collins et al. 1995); GenBank ID: KT992094 
rRSV-GFP (D46/6120) (Munir et al. 2008) 
rgRSV dSH (Techaarpornkul et al. 2001) 
rgRSV dSH/dG (Techaarpornkul et al. 2001) 
rVSV-GFP (Stojdl et al. 2003) 
wt HPIV1 HPIV1/Washington/20993/1964; GenBank ID: AF457102 
rHPIV1 CD170 (Bartlett et al. 2007) 
rHPIV3/EboGP (Bukreyev et al. 2006) 
rHPIV3/NotI ∆F-HN/EboGP Virus was recovered for this study. (see Appendix 6.4) 
 
2.1.6. Commercial Reagent Kits 
The kits listed in Table 7 were purchased from the indicated companies and were used as 
described in the manufacturer’s protocol, except otherwise mentioned. 
Table 7: Commercial Reagent Kits 
Name Company 
Advantage-HF PCR kit Clontech 
Antibody Labeling Kit Thermo Fisher Scientific 
BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit BD Biosciences 
Bicinchoninic acid (BCA) assay Thermo Fisher Scientific 
CellTiter-Glo Luminescent Cell Viability Assay Promega 
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Name Company 
DNA Gel extraction kit Fermentas 
DNeasy Blood and Tissue Kit Qiagen 
EGFR phosphorylation antibody array Ray Biotech, Norcross, GA 
EndoFree Plasmid Maxi Kit Qiagen  
LIVE/DEAD fixable dead cell staining kit Life Technologies 
Monkey anti-Zaire EBOV GP IgG ELISA kit Alpha Diagnostic International 
PCR purification kit Roche  
Plasmid Mini Kit Qiagen  
QIAamp Viral RNA Mini Kit Qiagen  
QIAshredder Qiagen 
QuikChange Lightning Site-Directed Mutagenesis Kit Agilent Technologies 
Rapid Ligation Kit Fermentas 
RNeasy Mini Kit Qiagen 
SuperScript TM First-Strand Synthesis System for RT-PCR  Life Technologies 
Universal Mycoplasma Detection Kit ATCC 
 
2.1.7. Oligonucleotide Primers 
 Sequencing primers used in this study were designed using the online program eprimer3 
(Helixweb, NIH). All primers were synthesized by Eurofins Genomics (Louisville, KY) and their 
sequences are listed in section 6.3 of the Appendix. 
 
2.1.8. Plasmids 
The plasmids used in this study are listed in Table 8. E.coli XL10-Gold ultracompetent 
cells (Stratagene, La Jolla, CA) were transformed with the indicated plasmids by the heat shock 
method, as described by the manufacturer’s protocol. Plasmid DNA was purified using the 
EndoFree Plasmid Maxi Kit (Qiagen, Germantown, MD). DNA concentrations were determined 
and plasmid stock solutions of 1.0 µg/ml were stored at -20˚C. 
Table 8: Plasmids  
Name Reference 
HPIV1 support plasmids for virus recovery: 
 pTM-HPIV1-N 
 pTM-HPIV1-P/C 
 pTM-HPIV1-L 
(Newman et al. 2002) 
T7-polymerase driven expression plasmids for the 
HPIV1 N, P and L protein, that are essential for virus 
recovery. 
HPIV3 support plasmids for virus recovery: 
 pTM-HPIV3-N 
 pTM-HPIV3-P/C 
 pTM-HPIV3-L 
(Durbin et al. 1997) 
T7-polymerase driven expression plasmids for the 
HPIV3 N, P and L protein, that are essential for virus 
recovery. 
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Name Reference 
pFlc HPIV1 CD170 MAN (Mackow et al. 2015) 
HPIV1 full-length anti-genome for virus recovery, 
containing the attenuating CD170 mutation and 
MluI (pre-N), AscI (N-P) and NotI (P-M) restriction sites. 
pFlc HPIV3 (JS) (Durbin et al. 1997) 
HPIV3 full-length anti-genome for virus recovery. 
EBOV GP inserts in pUC57 plasmid: 
 Ebola GP_GSopt_AscI 
 Ebola GP_TMCT_GSopt_AscI 
 Ebola GP_GSopt_MluI 
 Ebola GP_TMCT_GSopt_MluI 
Codon-optimized and synthesized by GenScript. 
Sequences of the GP and GP-TMCT ORF are shown in 
Appendix 6.2. 
 
2.1.9. Restriction enzymes 
All enzymes used in this study (Table 9) were purchased as Fast Digest enzymes from 
Thermo Fisher Scientific (Waltham, MA) and used as described in the manufacturer’s protocol. 
Table 9: Restriction enzymes 
Name Restriction site1) (5’-3’) 
AscI GG|CGCGCC 
MluI A|CGCGT 
BsiWI C|GTACG 
NotI GC|GGCCGC 
1) Vertical line indicates the cleavage site within the  
palindromic restriction site. 
2.1.10. siRNAs 
All siRNAs used in this study are listed in Table 10 and were purchased from Qiagen. 
Table 10: siRNAs 
Target Name Target sequence (5’-3’) 
ATP1A1 siRNA 1 CCC GGA AAG ACT GAA AGA ATA 
ATP1A1 siRNA 2 CTT GAT GAA CTT CAT CGT AAA 
ATP1A1 siRNA 3 ATC CAT GAA GCT GAT ACG ACA 
EGFR EGFR siRNA CAG AGG AAA TAT GTA CTA CGA 
Negative control siRNA Neg. siRNA 1 AllStars Neg. control siRNA [Qiagen 1027281], 
sequence proprietary 
Negative control siRNA Neg. siRNA 2 AAT TCT CCG AAC GTG TCA CGT 
Cell death positive control siRNA  AllStars Hs Cell Death siRNA control  
[Qiagen 1027299], sequence proprietary 
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2.1.11. Antibodies 
The antibodies used for various assays in this study are listed in Table 11, Table 12, and 
Table 13. Antibodies were either purchased from the indicated companies or were generated by 
previous members of the laboratory (see listed references) and were provided by Peter L. Collins 
for this study. 
Table 11: Primary antibodies 
Reactivity Host Clonality Reference 
alpha tubulin Mouse  monoclonal T6199, Sigma Aldrich 
ATP1A1 Mouse  monoclonal ab7671, Abcam 
ATP1A1 Rabbit  monoclonal ab76020, Abcam 
EBOV GP Human  monoclonal KZ52, IBT Bioservices 
EBOV GP Mouse  monoclonal 4F3, IBT Bioservices 
EGFR Rat  monoclonal ab231, Abcam 
EGFR Mouse  monoclonal ab181822, Abcam 
HPIV1 Goat  polyclonal ab20791, Abcam 
HPIV1 F peptide Rabbit  polyclonal  SKIA-15, (Bartlett et al. 2010) 
HPIV1 HN peptide Rabbit polyclonal  SKIA-13, (Mackow et al. 2015) 
HPIV1 N peptide Rabbit  polyclonal  HPIV1-N-485, (Bartlett et al. 2010) 
HPIV1 P peptide Rabbit  polyclonal  SKIA-1, (Bartlett et al. 2010) 
HPIV1 F Mouse  monoclonal MAb 7.1, (Komada et al. 1992) 
RSV F Mouse  monoclonal 1129, (Beeler and van Wyke Coelingh 1989) 
RSV F Mouse  monoclonal 1243, (Beeler and van Wyke Coelingh 1989) 
RSV F Mouse  monoclonal 1269, (Beeler and van Wyke Coelingh 1989) 
RSV G Mouse monoclonal ab94967, Abcam 
RSV N Mouse  monoclonal ab94806, Abcam 
RSV SH peptide Rabbit polyclonal Produced by Noble Life Sciences 
 
Table 12: Primary antibodies (conjugated)  
Reactivity Host Conjugate1) Source 
RSV N Mouse APC NB100-64752APC,  
Novus Biologicals (Littleton, CO) 
RSV F Mouse AF488 RSV F 1129, in-house conjugation 
1) APC: Allophycocyanin; AF: Alexa Fluor 
Table 13: Secondary antibodies (conjugated)  
Reactivity Host Conjugate1) Source 
Goat IgG Donkey IRDye 680LT Li-Cor 
Human IgG Goat AF488 Life Technologies 
Mouse IgG Donkey AF488 Life Technologies 
Mouse IgG Donkey AF568 Life Technologies 
Mouse IgG Donkey AF647 Life Technologies 
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Reactivity Host Conjugate1) Source 
Mouse IgG Donkey IRDye 680RD Li-Cor 
Mouse IgG Donkey IRDye 800CW Li-Cor 
Mouse IgG Goat AF647 Life Technologies 
Mouse IgG Goat IRDye 680RD Li-Cor 
Mouse IgG Goat IRDye 680RT  Li-Cor 
Mouse IgG Goat IRDye 800CW Li-Cor 
Rabbit IgG Donkey AF488 Life Technologies 
Rabbit IgG Donkey AF568 Life Technologies 
Rabbit IgG Goat AF700 Life Technologies 
Rabbit IgG Goat IRDye 680RD Li-Cor 
Rabbit IgG Goat IRDye 800CW Li-Cor 
Rat IgG Goat AF647 Life Technologies 
1) AF: Alexa Fluor; IRDye: infrared fluorescent dye 
2.2. Methods 
2.2.1. Cell culture  
All cell lines were maintained in T225 cell culture flasks (Corning Inc.) and were split 
biweekly for maintenance. To maintain cell growth in logarithmic phase, the split ratio for each cell 
line was adjusted to avoid complete confluency at each split. Cells were grown in the cell line-
specific cell culture media, listed in section 2.1.4, and kept at 37˚C and 5% (v/v) CO2. 
For splitting adherent cell cultures to maintain the cell line, cells were once washed with 
1x PBS, detached with trypsin, the reaction was stopped by adding cell culture medium and 1/5th 
to 1/20th of the total cell suspension volume, depending on the cell line, was transferred to a new 
T225 flask with fresh complete medium. The passage number was tracked and the cell line was 
discontinued after a certain number of passages: A549 cells were discontinued after 10 passages. 
All other cell lines used in this study (LLC-MK2, Vero and BHK BSR-T7) were discontinued after 
25 passages from the time of thawing. Initial passage number of each cell line used in this study, 
is listed in Table 5 of section 2.1.4. Primary HSAEC were only passaged for a total of two 
passages, to ensure the maintenance of the primary cell characteristics. HSAEC were passaged 
once for expansion and then seeded in the cell culture plates for performing the experiments. 
For seeding cells into various cell culture plates, trypsin was removed by centrifugation at 
400 x g for 5 min and the cell pellet was resuspended in fresh medium. The cell count was 
determined with a Neubauer improved hemocytometer and cells were seeded in the appropriate 
cell culture medium. 
For cryo-preservation of all cell lines, confluent cells were detached with trypsin, the 
reaction was stopped by adding cell culture medium and spun at 400 x g to remove the trypsin. 
The cell pellet was resuspended in fresh medium and 2x freezing medium (cell line specific 
medium, containing 20% (v/v) DMSO) was added 1:1 to the cell suspension to obtain a final 
DMSO concentration of 10% (v/v). Cells were frozen in a Nalgene freezing container (Sigma-
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Aldrich) submerged in isopropyl alcohol at -80˚C to obtain a slow cooling rate of 1˚C per min. After 
24 h at -80˚C, the frozen cells were transferred to a liquid nitrogen tank, where they were stored 
in the vapor phase at -190 ˚C until used.  
All cell lines were tested for mycoplasma contamination with the Universal Mycoplasma 
Detection Kit (ATCC) as described by the manufacturer’s protocol. 
 
2.2.2. Inoculation of cell cultures 
The virus titer of the inoculum for the infection of cell cultures was determined by the 
multiplicity of infection (MOI). The estimated cell numbers for fully confluent cells (listed in Table 
14) of the indicated cell culture vessels were used for the MOI calculation. Depending on the virus 
and the method of titration (plaque assay or hemadsorption), the MOI was described as plaque 
forming units (PFU)/cell (for RSV and VSV) or as 50% tissue culture infective dose (TCID50)/cell 
(for HPIV1 and HPIV3). 
Table 14: Estimated number1) of cells in different cell culture vessels for MOI calculations 
Cell culture vessel Growth area [cm2] Inoculum volume Number of cells 
T225 flask 225 10 ml 2 x 107 
6-well 9.5 1 ml 1 x 106 
12-well 4 200 µl 5 x 105 
24-well 2 200 µl 2.5 x 105 
1) Estimations are based on the manufacturer’s information. The estimated number of cells was used for all 
cell lines. 
The virus working pool was diluted based on the MOI calculation in the cell line-specific 
medium (see 2.1.4) for the indicated inoculum volume, based on the cell culture vessel (Table 14). 
For infections with HPIV1, 1.2% (v/v) trypsin was added to the cell culture medium, which is 
required for the production of infectious progeny virus (see introduction section 1.2.3.2). The cell 
culture medium was removed and the inoculum was added to the cells and incubated for 2-3 h on 
a rocking platform at 32˚C (for HPIV1 and HPIV3) or 37˚C (for RSV and VSV). For the inoculation 
of cells in multi-well plates for various experiments, the inoculum was removed, cells were washed 
three times with fresh cell culture medium and 3 ml (for 6-well), 600 µl (for 12-well) or 500 µl (for 
24-well) of fresh medium was added. For the inoculation of T225 flasks for preparing virus working 
pools, 25 ml cell culture medium was added, without removing the inoculum. The infected cells 
were incubated at 32˚C (for HPIV1 and HPIV3) or 37˚C (for RSV), with 5% (v/v) CO2 for the 
indicated time. 
 
2.2.3. Cell viability assay 
The ATP-based cell viability assay CellTiter-Glo (Promega, Madison, WI) was used for the 
evaluation of cell viability and performed as described by the manufacturer’s protocol. In brief, 
cells that were seeded in white 96-well plates, were lysed after the specified treatment at indicated 
time points and the ATP concentration was determined by luciferase activity. The light emission 
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of the luciferase was quantified using the Synergy 2 ELISA reader (BioTek, Winooski, VT). 
Viability was reported relative to mock-treated cells, based on the reduction of luciferase light 
emission and hence reduction of ATP, which was used as a parameter for cell viability. 
 
2.2.4. siRNA transfections to knock down the expression of cellular proteins 
Synthetic siRNAs (see Table 10 in section 2.1.10) targeting gene specific mRNAs were 
transfected into cells by a reverse transfection protocol, where the siRNAs were added 
simultaneously with cells in suspension. The transfection protocol was optimized with the negative 
control siRNAs (Neg. siRNA 1 and 2) and the cell death positive control siRNA. These control 
siRNAs were included in every experiment to control for a constant transfection efficiency. The 
best transfection results with maximal transfection efficiency and no increased cytotoxicity in a 12-
well plate format were obtained with 2.0 x 105 A549 cells in 500 µl regular F12-K complete cell 
culture medium (see Table 5 in section 2.1.4), a final siRNA concentration of 40 nM, transfected 
with 1.0 µl siLentFect transfection reagent (BioRad, Hercules, CA). The transfection mix was 
prepared in a total of 100 µl per well Opti-MEM I GlutaMax-I medium (without supplements) as 
described by the manufacturer’s protocol. In brief, the siRNA and siLentFect transfection reagent 
were separately pre-diluted in half of the total volume of Opti-MEM I GlutaMax-I (i.e. 50 µl per 
well), combined and incubated for 20 min before added to the well with freshly seeded cells. The 
cells were incubated for 48 h at 37˚C to allow the reduction of the targeted cellular protein, except 
otherwise stated. At 48 h post transfection (p.t.) the cells were used for further experiments. 
 
2.2.5. Quantitative reverse transcriptase (RT-) PCR TaqMan assay 
Cells were harvested and total RNA was isolated with RNeasy Mini Kit (Qiagen) as 
described by the manufacturer’s protocol, including an on-column DNase digestion to avoid any 
DNA contamination. 1 µg total RNA was used for reverse transcription of mRNA to cDNA with 
oligo(dT)12-18 primers and the SuperScript TM First-Strand Synthesis System for RT-PCR (Life 
Technologies, Carlsbad, CA). The synthesized cDNA was pre-diluted 1:10 and used for the 
TaqMan gene expression analysis of ATP1A1 (Life Technologies, Hs00167556_m1) and 18S 
rRNA (Life Technologies, Hs99999901_s1) as a normalization control. The TaqMan assay 
reactions were analyzed on the 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster 
City, CA). The threshold cycle (Ct) for each reaction was determined by the SDS RQ manager 
program (Applied Biosystems). The relative changes in transcript level of the targeted transcripts 
were calculated by the 2-ΔΔCt method (Livak and Schmittgen 2001) and reported relative to cells 
transfected with Neg. siRNA 1. 
 
Materials and Methods  39 
2.2.6. Cloning of the EBOV GP ORF into the HPIV1 full-length anti-genome at the first (pre-N) 
or the second (N-P) gene position 
The EBOV GP ORF nucleotide sequence used was that of the EBOV Mayinga strain 
isolated in 1976 (GenBank ID: AF086833.2) (Volchkov et al. 2001), which is identical to the other 
candidate vaccines under evaluation (Mire et al. 2015, Ewer et al. 2016). Unedited GP mRNA 
contains a stretch of 7 A’s at the editing site and is translated as secreted GP. Transcriptional 
editing results in the addition of a non-template A residue at this site causing frame shift and 
translation of the full-length membrane-anchored GP (Sanchez et al. 1996). For these constructs, 
an edited GP gene containing 8 U residues (negative sense) at the editing site (nt position 880-
887; transcribing to 8 A’s in the GP mRNA) was used to synthesize membrane-anchored GP.  
The editing site was previously shown to be unstable in HPIV3 and was stabilized by two 
silent changes to AAGAAGAA (Bukreyev et al. 2006). For the present study, the GP nucleotide 
sequence was codon-optimized for human expression (GenScript, Piscataway, NJ) with the 
exception of the editing site sequence (AAGAAGAA), which was left undisturbed. The GenScript-
optimized nucleotide sequence of the GP ORF is listed in the Appendix 0. In addition, a derivative 
of GP was made in which the GP TMCT region was replaced by that of the HPIV1 F protein 
(Figure 12C), which was presumptively identified based on a hydrophobicity analysis. 
The coding sequence for EBOV GP or EBOV GP-TMCT was inserted into the first (pre-N) 
or second (N-P) gene position of the rHPIV1-C∆170 genome (Figure 12). For insertion into the pre-
N position, the EBOV GP and GP-TMCT cDNAs were designed to be flanked upstream by an 
MluI site and Kozak sequence (Kozak 1987), and downstream by the GE signal of the N gene, 
followed by an IG trinucleotide CTT, the GS signal of the P gene, and an MluI site (Figure 12A). 
For insertion into the N-P gene position, the EBOV GP and GP-TMCT cDNAs were designed to 
be flanked upstream by an AscI site and Kozak sequence, and downstream by the N GE, IG, and 
P GS, followed by an AscI site (Figure 12B). All viruses were designed to keep the hexameric 
genome nucleotide length (rule of six) (Kolakofsky et al. 1998). Each vector gene maintained its 
wild-type hexamer phasing except the N gene in the pre-N constructs that had the P gene phasing. 
The GP and GP-TMCT inserts in pre-N and N-P sites had the hexamer phasing of the N and P 
genes, respectively. All inserts were synthetically derived (GenScript) and cloned into the rHPIV1-
C∆170 antigenomic plasmid (pFlc HPIV1 CD170 MAN) containing the unique restriction sites MluI 
and AscI in the pre-N and N-P positions, respectively, using published methods (Mackow et al. 
2015). This resulted in four constructs: the two with inserts in the pre-N position were called GP1 
and GP-TMCT1, and the two with inserts in the N-P position were called GP2 and GP-TMCT2. 
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Figure 12: Construction of the antigenomic cDNAs of rHPIV1-CΔ170 expressing full-length EBOV GP 
or chimeric EBOV GP with HPIV1 F transmembrane (TM) and cytoplasmic tail (CT) domains from the 
pre-N (A) or N-P (B) position. The EBOV GP ORF (strain Mayinga; GenBank ID: AF086833.2) was 
modified by the insertion of a single A residue at the editing site so as to encode full-length GP. The GP 
ORF was codon-optimized and inserted, as either the full-length GP or as a chimeric form in which the 
TMCT domain was replaced with that of HPIV1 F, at the pre-N (A) or N-P (B) position of rHPIV1-C∆170 
bearing an attenuating mutation in the P/C ORF (indicated by an asterisk) using the previously introduced 
(Mackow et al. 2015) unique MluI or AscI restriction sites, respectively. The GP insert was engineered with 
flanking HPIV1 gene transcription signals (GS: gene start; IG: intergenic; GE: gene end) to allow for its 
expression as a separate mRNA. (C) The amino acid alignment of EBOV GP, HPIV1 F, and the chimeric 
EBOV GP-TMCT containing the GP ectodomain and the TM and CT of HPIV1 F (bold). 
 
2.2.7. Recovery of the rHPIV1-C∆170 vectors expressing EBOV GP from cDNA 
The recombinant viruses were recovered by co-transfecting BHK BSR T7/5 cells with each 
of the full-length anti-genome plasmid (described in 2.2.6) and the HPIV1 support plasmids 
expressing the HPIV1 N, P, and L proteins as described (Newman et al. 2002, Bartlett et al. 2005). 
Transfected cells were incubated overnight at 37˚C, washed twice with Opti-MEM I GlutaMax-I 
medium and replaced with fresh Opti-MEM I GlutaMax-I medium containing 1 mM L-glutamine 
and 1.2 % (v/v) trypsin, followed by incubation at 32˚C. At 48 h post-transfection, cells were 
harvested by scraping into the medium and the cell suspension was added to 50% confluent 
monolayers of LLC-MK2 cells in Opti-MEM I GlutaMax-I medium, containing 1 mM L-glutamine, 
1.2% (v/v) trypsin. These cells were incubated at 32˚C until cytopathic effects, due to the virus 
replication, were visible. Recovered virus (seed pool) was amplified by one passage (working pool) 
in LLC-MK2 cells at 32°C. Virus titers were determined by hemadsorption (HAD) (2.2.11) and 
titers are reported as log10 TCID50/ml.  
All HPIV1 viruses were sequenced, as described in section 2.2.9, in their entirety except 
for the 26 nt at the 5’ end and 86, 79, 77, and 77 nt at the 3’ end of GP1, GP-TMCT1, GP2, and 
GP-TMCT2, respectively. All viruses were found to be free of adventitious mutations. 
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2.2.8. Virus sucrose gradient purification 
Partially-purified virus working stocks were generated by centrifugation on a discontinuous 
sucrose gradient. RSV and HPIV1 were grown in Vero and LLC-MK2 cells, respectively. Confluent 
cells in T225 cell culture flasks were inoculated, as described in section 2.2.2, with an MOI of 0.1 
PFU/cell for RSV and 0.01 TCID50/cell for HPIV1 and incubated at 32˚C until the cell monolayer 
showed high levels of cytopathic effects. For RSV, the cells were scraped into the supernatant 
and extensively (3 min total, in intervals of 30 sec) vortexed to release bound virus from the cell 
membrane. For HPIV1, the cell culture supernatant was collected without vortexing.  
The supernatant was clarified by centrifugation (478 x g) and loaded onto a discontinuous 
sucrose gradient containing 60% (w/v) and 30% (w/v) sucrose solution (see 2.1.1) followed by 
centrifugation for 100 min in a Beckman Coulter SW32 rotor at 26,000 rpm at 4˚C. The cloudy 
interface, containing the virus particles, was collected with the minimum amount of sucrose 
solution. The virus containing sucrose solution was diluted with Opti-MEM I GlutaMax-I medium 
and the virus was spun out of sucrose by centrifugation at 8,000 x g for 2 h at 4˚C. The supernatant 
was discarded and the virus pellet was resuspended in fresh Opti-MEM I GlutaMax-I medium, 
aliquoted, flash frozen on dry ice, and stored at -80˚C until further used. 
 
2.2.9. Virus genome sequencing 
The consensus genome sequences of all virus working pools used in these studies were 
confirmed by automated Sanger sequencing of uncloned RT-PCR products copied from RNA from 
virus preparations. This determined the complete genome sequence except for the 3´end and the 
5´end, as indicated, that were obscured by PCR primers. The viral RNA was isolated from 140 µl 
(for HPIV1 and HPIV3) or 280 µl (for RSV) virus working pool with QIAamp Viral RNA Mini Kit 
(Qiagen) as described in the manufacturer’s protocol, including on-column DNase digestion to 
eliminate any plasmid DNA used for virus recovery. The RNA was eluted in 50 μl dH2O and cDNA 
was generated by reverse transcription of 7 μl viral RNA by SuperScriptTM First-Strand Synthesis 
System for RT-PCR (Life Technologies) with 2 μl random hexamers (50 ng/μl) as described in the 
manufacturer’s protocol. Overlapping fragments of the viral genome were amplified by PCR 
(Advantage-HF PCR kit) using 2.5 µl of cDNA template and the following sequencing primer pairs, 
listed in Table 15 to Table 18. 
 
Table 15: Primer sets for the RSV genome fragment amplification for Sanger sequencing 
Reaction # (viral amplicon1)  Size Forward primer Reverse primer TA2) 
1 (13 – 2189 nt)  2.2 kb RSV_3UTR_FOR_13 RSV_N_REV_2164 51 ˚C 
2 (2051 – 3859 nt)  1.8 kb RSV_N_FOR_2051 RSV_M_REV_3834 51 ˚C 
3 (3254 – 7670 nt)  4.4 kb RSV_M_FOR_3254 RSV_M2_REV_7645 53 ˚C 
4 (7465 – 12406 nt)  4.9 kb RSV_F_FOR_7465 RSV_L_REV_12382 53 ˚C 
5 (12282 – 15216nt)  2.9 kb RSV_L_FOR_12282 RSV_5UTR_REV_15188 51 ˚C 
1) Referred to the nt position of the unmodified wt RSV A2 genome (GenBank ID: KT992094). 
2) Annealing temperature; optimized for each fragment. 
42   Materials and Methods 
Table 16: Primer sets for the HPIV1 genome fragment amplification for Sanger sequencing  
(HPIV1 with EBOV GP located in the pre-N position): 
Reaction # (viral amplicon1)  Size Forward primer Reverse primer 
1 (78 – 244 nt + EBOV GP) 2.2 kb PIV1_3UTR_FOR_78 PIV1_N_REV_223 
2 (153 – 2813 nt)  2.6 kb PIV1_N_FOR_153 PIV1_P_REV_2792 
3 (2353 – 5446 nt) 3.1 kb PIV1_P_FOR_2353 PIV1_F_REV_5425 
4 (4859 – 7858 nt) 3.0 kb PIV1_F_FOR_4859 PIV1_HN_REV_7837 
5 (7291 – 10102 nt) 2.8 kb PIV1_HN_FOR_7291 PIV1_L_REV_10081 
6 (9332 – 12134 nt) 2.8 kb PIV1_L_FOR_9332 PIV1_L_REV_12113 
7 (11396 – 14287 nt) 2.9 kb PIV1_L_FOR_11396 PIV1_L_REV_14267 
8 (13237 – 15600 nt) 2.4 kb PIV1_L_FOR_13237 PIV1_5UTR_REV_15575 
1) Referred to the nt position of the unmodified wt HPIV1 genome (GenBank ID: AF457102). 
Table 17: Primer sets for the HPIV1 genome fragment amplification for Sanger sequencing  
(HPIV1 with EBOV GP located in the N-P position): 
Reaction # (viral amplicon1)  Size Forward primer Reverse primer 
1 (78 – 1125 nt) 1.0 kb PIV1_3UTR_FOR_78 PIV1_N_REV_1103 
2 (910 – 1823 nt + EBOV GP) 3.0 kb PIV1_N_FOR_910 PIV1_P_REV_1802 
3 (GP 1724 nt – 2813 nt)  1.4 kb optEBOV-GP_For_10 PIV1_P_REV_2792 
4 (2353 – 5446 nt) 3.1 kb PIV1_P_FOR_2353 PIV1_F_REV_5425 
5 (4859 – 7858 nt) 3.0 kb PIV1_F_FOR_4859 PIV1_HN_REV_7837 
6 (7291 – 10102 nt) 2.8 kb PIV1_HN_FOR_7291 PIV1_L_REV_10081 
7 (9332 – 12134 nt) 2.8 kb PIV1_L_FOR_9332 PIV1_L_REV_12113 
8 (11396 – 14287 nt)  2.9 kb PIV1_L_FOR_11396 PIV1_L_REV_14267 
9 (13237 – 15600 nt) 2.4 kb PIV1_L_FOR_13237 PIV1_5UTR_REV_15575 
1) Referred to the nt position of the unmodified wt HPIV1 genome (GenBank ID: AF457102) or EBOV GP 
ORF. 
Table 18: Primer sets for the HPIV3 genome fragment amplification for Sanger sequencing: 
Reaction # (viral amplicon1)  Size Forward primer Reverse primer 
1 (1 – 3215 nt)   3.1 kb PIV3_3UTR_FOR_1 P_REV_3215 
2 (3136 – 5768 nt)  2.7 kb P_FOR_3136 F_REV_5768 
3 (5489 – 8649 nt)  3.2 kb F_FOR_5489 L_REV_8649 
4 (8293 – 11294 nt)  3.0 kb HN_FOR_8293 L_REV_11294 
5 (10615 – 14422 nt)  3.8 kb L_FOR_1061 L_REV_14422 
6 (13939 – 15462 nt)  1.5 kb L_FOR_13939 PIV3_5UTR_REV_15436 
1) Referred to the nt position of the unmodified wt HPIV3 genome (GenBank ID: Z11575.1). 
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The PCR program used for the amplification of the fragments is shown below. The 
annealing temperature (TA) was optimized for each viral genome amplification. For RSV the TA 
for each fragment is listed in Table 15. For HPIV1 and HPIV3 the TA was 52 ˚C for all fragments. 
 
Initial denaturation:  95˚C  1 min 
  33x Cycles:  95˚C  30 sec 
     TA  30 sec 
     68˚C  4 min 
 Final elongation step:  68˚C  4 min 
 
The PCR products were purified with the PCR purification kit (Roche, Indianapolis, IN), eluted in 
50 µl dH2O and the purified PCR product was used for the sequencing reaction: 
 0.5 µl (approx. 40 ng) purified PCR product 
 8.0 µl BigDye Terminator V1.1 
 7.5 µl dH2O 
 4.0 µl Sequencing primer (1 µM) (see Appendix 6.3 for primer sequence list) 
 
The sequencing reaction was performed on a PCR thermocycler with the following program: 
33x Cycles: 95˚C  10 sec 
    50˚C  5 sec 
    60˚C  4 min 
 
The sequencing reaction was diluted 1:2 by adding 20 µl dH2O und purified by applying it to a 
Performa DTR Ultra 96 well plate (EdgeBio, Gaithersburg, MD). The purified sequencing reaction 
was denatured for 3 min at 95 ˚C before it was loaded onto the 3730 DNA Analyzer to determine 
the nucleotide sequence. The resulting histograms were analyzed with Sequencher software 
program and a minimum of three reads were required for each nucleotide to be considered as a 
confirmed read. 
 
2.2.10. Multi-cycle replication of HPIV1 EBOV GP  
To determine the replication characteristics of the recovered HPIV1 vectors expressing 
EBOV GP, a multi-cycle replication assay was performed over 6 days. Confluent Vero cells in 6-
well plates were infected with the recombinant viruses at an MOI of 0.01 TCID50/cell in triplicate. 
At 24 h intervals, starting on day 1 through day 6, 500 µl (one-sixth of the volume) of culture 
medium supernatant was collected from each well and replaced by fresh medium. The samples 
were flash frozen on dry ice and stored at -80°C. The virus titer of each sample was determined 
in duplicate by hemadsorption assay on LLC-MK2 cells as described in section 2.2.11. 
44   Materials and Methods 
2.2.11. TCID50 titration of HPIV1 EBOV GP by hemadsorption (HAD) 
The hemagglutinin-neuraminidase (HN) is an envelope glycoprotein of human 
parainfluenza viruses. It is expressed on the surface of infected cells and binds to red blood cells 
(RBC), a process called hemadsorption that could be visualized with a microscope. 
Hemadsorption was used to detect infected cells and to determine TCID50 titer (Shelokov et al. 
1958). For titration, virus-containing samples were 10-fold serially diluted in quadruplicates onto 
confluent LLC-MK2 cells in 96-well plates. Before performing the serial dilution, the cells were 
washed twice with 1x PBS to remove any FBS and 180 µl fresh Opti-MEM I GlutaMax-I medium 
containing 1.2% (v/v) trypsin was added. The inoculated cells were incubated for 6 days at 32˚C. 
Hemadsorption was performed with 0.1 % (v/v) guinea pig RBC (Lonza, Allendale, NJ) in 1x PBS 
(1:1000 v/v dilution of packed RBC). The medium supernatant was removed and 100 µl of RBC 
suspension was added, incubated for 20 min at 4˚C and washed twice with 1x PBS to remove 
any unbound RBC. Each well was visually screened for bound RBC by bright field microscopy 
and wells were considered positive if RBC were detected bound to the cells. The TCID50 titer was 
determined by the dilution factor that caused 50% infection of the infected replicates of one sample 
and was reported as log10 TCID50 per ml. 
 
2.2.12. Plaque assay  
Plaque assay was performed by inoculating confluent Vero cells in 24-well tissue culture 
plates with a 10-fold serially diluted inoculum in duplicates and incubated for 6 days at 32˚C (for 
HPIV1 and HPIV3) or 37˚C (for RSV) under a methylcellulose overlay medium (see 2.1.1). 
Depending on the virus and the assay readout the plaques were visualized in different ways:  
For RSV-GFP, the viral GFP expression was used to visualize the plaques and images 
were acquired on the Typhoon imaging system (GE Healthcare, Boston, MA) without any further 
treatment. 
For all other plaque assays with viruses that did not express GFP, cells were fixed twice 
with ice-cold 80% (v/v) methanol and subjected to immunostaining for plaque detection. The fixed 
cells were blocked with Western blot blocking buffer (Li-Cor, Lincoln, NE) and depending on the 
virus following antibody dilutions were prepared in the same blocking buffer. Wt RSV plaques 
were stained with three RSV F-specific mouse monoclonal antibodies (MAbs) (1129, 1243 and 
1269, diluted 1:2,000 each). HPIV1 immunostaining was performed with an HPIV1-specific goat 
polyclonal antibody (ab20791, diluted 1:1600). A double-immunostaining fluorescent plaque 
assay detecting the co-expression of HPIV1 antigens and EBOV GP was performed to determine 
the stability of GP expression for all vector working pools and samples derived from AGMs. In 
addition to the HPIV1 immunostaining, described above, the plaques also were stained for EBOV 
GP with an EBOV GP-specific mouse MAb (4F3, diluted 1:2,000). The corresponding secondary 
antibodies were conjugated with infrared fluorescent dye (IRDye) 680LT or 800CW (Li-Cor, for 
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the list of used antibodies see Table 11 in 2.1.11), each used at a 1:800 dilution. Plaque images 
were acquired using an Odyssey infrared imaging system (Li-Cor). 
For plaque assay titrations, plaques were counted by ImageJ software and an appropriate 
dilution with counts between 10 - 60 singular plaques were chosen for the titer calculation.  
For the HPIV1, EBOV GP double staining, plaques were pseudo colored to appear red 
and green for HPIV1 and EBOV GP expression, respectively. HPIV1 plaques expressing EBOV 
GP appeared yellow (HPIV1 and GP staining merged). 
 
2.2.13. RSV infection evaluated by viral GFP expression 
Recombinantly generated RSV-GFP contains an additional gene encoding eGFP that is 
inserted between the P and M genes in the RSV genome (Munir et al. 2008). Viral GFP expression 
was used as a surrogate for quantifying RSV infection/replication in the infected cells. GFP 
expression was quantified either by an ELISA reader or flow cytometry. GFP intensity of infected 
cells in 12-well plates was quantified by an area-scan (excitation 485/20, emission 528/20) with 
the Synergy2 ELISA reader (BioTek). The area-scan function allowed to obtain 29 individual 
measurements that covered the entire well and the obtained intensities were averaged to a mean 
relative light unit (RLU) value for each well. This method allowed to take into account any 
variations of GFP expression within the infected cell monolayer. 
A flow cytometry approach was used for the quantification of viral GFP expression in 
individual cells. Infected cells were detached with 1 mM EDTA in 1x PBS, stained with a 
LIVE/DEAD fixable near-infrared amine-reactive dead cell discriminating dye (Life Technologies) 
and fixed with BD Cytofix/Cytoperm solution (BD, Franklin Lakes, NJ). Data were acquired on BD 
FACS Canto II flow cytometer and FACSDiva acquisition software. The software program FlowJo 
(FlowJo, LLC, Ashland, OR) was used for the quantification of the GFP intensity of single, live, 
GFP+-gated cells.  
 
2.2.14. Western blot analysis 
For the analysis of cellular protein levels of siRNA-transfected cells, A549 or HSAEC cells 
were seeded in 12-well plates and transfected with the indicated siRNAs, as described in section 
2.2.4. Cells were lysed with 75 µl 1x LDS sample buffer (Life Technologies) at indicated time 
points, homogenized by a QiaShredder (Qiagen) and 22.5 µL lysate of each sample was 
processed for Western blot analysis.  
For the quantification of viral protein expression in infected cells, confluent Vero cells in 6-
well plates were infected at an MOI of 3.0 TCID50/cell, as described in section 2.2.2, and incubated 
for 48 h at 32˚C, after which cells were washed with 1x PBS, lysed in 100 µl LDS sample buffer 
and homogenized by applying the lysate to a QiaShredder. 22.5 µL lysate of each sample was 
subjected to Western blot analysis. 
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All samples were reduced with 1x NuPage Sample Reducing Agent (Life Technologies), 
denatured at 70˚C for 10 min, and electrophoresed (constant 200V for 55 min) on a 4-12% Bis-
Tris SDS gel (Life Technologies) with 1x NuPage MOPS (3-(N-morpholino)propanesulfonic acid) 
SDS running buffer (Life Technologies), containing 1x NuPAGE Antioxidant (Life Technologies) 
in the upper chamber. Proteins were transferred onto a PVDF membrane using the iBlot2 transfer 
system (Life Technologies) and analyzed by Western blotting.  
ATP1A1 was detected by a ATP1A1-specific rabbit MAb (ab76020, 10,000). EGFR was 
detected by a EGFR-specific mouse MAb (ab151522, 1:1,000). Tubulin was used as a loading 
control for all quantifications and was detected by an alpha-tubulin-specific mouse MAb (T6199, 
1:10,000). For the detection of HPIV1 proteins, the rabbit polyclonal antibodies raised individually 
against peptides derived from F, HN, N, or P (see Table 11 in section 2.1.11) were used at a 
dilution of 1:200 each. EBOV GP was detected by the EBOV GP-specific mouse MAb (4F3, 
1:1,000). All primary antibodies were diluted in Western blot blocking buffer (Li-Cor) containing 
0.1% (v/v) Tween 20 and incubated on a rocking platform for at least 2 h at room temperature or 
overnight at 4˚C. The primary antibodies were removed by washing the membrane three times 
with 1x PBS, containing 0.1% (v/v) Tween 20. The corresponding secondary antibodies were 
IRDye 680RD- or 800CW-conjugated (for list of used antibodies see Table 13 in section 2.1.11), 
each diluted 1:10,000 in Western blot blocking buffer, containing 0.1% (v/v) Tween 20 and 0.01% 
(v/v) SDS. The secondary antibodies were incubated on a rocking platform for 1 h at room 
temperature. The membranes were washed two times with 1x PBS, containing 0.1% (v/v) Tween 
20, followed by a final wash with 1x PBS. Western blot images were acquired on the Odyssey 
infrared scanner (Li-Cor) and analyzed with Image Studio Software (Version 5.2.5, Li-Cor). 
 
2.2.15. Quantification of protein incorporation into the virus particles 
For the evaluation of proteins packaged into the virions, viruses were sucrose purified via 
a discontinuous sucrose gradient centrifugation (described above in section 2.2.8). 1.5 ml of the 
harvested virus was spun for at least 2 h at 20,000 x g and 4˚C, to pellet the virus particles. The 
virus pellet was lysed in 50 µl RIPA lysis buffer (see 2.1.1). The total protein concentration of the 
lysates was determined by BCA assay (Thermo Fisher Scientific), as described by the 
manufacturer’s protocol. Equal amounts (1 µg) of total protein were loaded onto a 4-12% Bis Tris 
gel and subjected to Western blot analysis, as described in section 2.2.14. 
 
2.2.16. Flow cytometry assays 
For assessing the stability of EBOV GP expression by the HPIV1 vectors, a flow cytometry-
based assay was used in addition to the double staining plaque assay described in section 2.2.12. 
Vero cells infected at an MOI of 5.0 TCID50 per cell were harvested at 24 h p.i. with 1 mM EDTA 
in 1x PBS. Cells were stained with LIVE/DEAD fixable near-infrared amine-reactive dead cell 
discriminating dye (Life Technologies) followed by HPIV1 F-specific mouse MAb (clone 7.1 at 
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1:1,000 dilution, pre-titrated to achieve specific F detection with no detectable background 
staining), and EBOV GP-specific human MAb (KZ52 at 1:300 dilution; IBT Bioservices, Rockville, 
MD). Cells were washed and stained with the Alexa Fluor (AF)-conjugated secondary antibodies 
goat anti-mouse AF647 and goat anti-human AF488 (Life Technologies). All antibody dilutions 
and washes were performed with FACS buffer (1x PBS containing 2.0% (v/v) FBS). Cells were 
fixed with BD Cytofix/Cytoperm solution. Data were acquired on BD FACS Canto II with FACSDiva 
acquisition software, followed by analysis using the software program FlowJo. Cells were 
sequentially gated on single cells, live cells, HPIV1 F+ cells, and finally GP+ cells. An average total 
of 15,000 collected HPIV1 F+ cells was evaluated to determine the percentage of GP+ cells. 
 
2.2.17. Immunofluorescence microscopy 
Cells were seeded on glass cover slips (Fisher Scientific, Hampton, NH) in 24-well plates 
and were treated, as indicated, when sub-confluent. For the immunofluorescence microscopy 
based assays, cells were fixed with 4% (w/v) paraformaldehyde (PFA, Electron Microscopy 
Science, PA) overnight at 4˚C, permeabilized with 0.1% (v/v) Triton X-100 (Sigma Aldrich) for 15 
min, and blocked with 5% (w/v) BSA (Sigma Aldrich) in 1x PBS for 1 h at room temperature. All 
antibody dilutions were prepared in 1x PBS, containing 5% (w/v) BSA and 0.1% (v/v) Triton X-
100. The primary antibody incubation was performed in a humidified chamber for 2 h with the 
following antibodies, depending on the target of interest for the specific assay: anti-ATP1A1 rabbit 
MAb (ab76020, 1:100), anti-EGFR rat MAb (ab231, 1:100), anti-RSV N mouse MAb (ab94806, 
1:1,500) and anti-RSV F mouse MAb (1129, 1:200). After washing with 1x PBS, the secondary 
antibody staining was performed with the corresponding AF-conjugated secondary antibodies, 
diluted 1:1,000: donkey anti-rabbit AF488, goat anti-rabbit AF700, donkey anti-mouse AF647 and 
goat anti-rat AF647. The primary conjugated mouse MAbs RSV-F (1129)-AF488 and RSV-N-APC 
were used for the simultaneous detection of RSV F and N. The nuclei were counterstained with 
DAPI (Life Technologies) at a concentration of 300 nM in 1x PBS for 5 min, mounted on glass-
slides (Fisher Scientific) with ProLong Diamond Antifade mountant (Life Technologies) and cured 
overnight at room temperature. 
Images were acquired with the Leica LAS-X software on a Leica TCS-SP8 or SP5 confocal 
microscope (Leica Microsystems, Mannheim, Germany) using a 63x oil immersion objective 
(numerical aperture [NA] 1.4) and a zoom between 1.0 to 3.5x. Fluorochromes were excited using 
an argon laser at 488 nm for AF488, 561 nm for AF568, 633 nm for AF647, and 690 nm for AF700. 
DAPI was excited using a 450 nm diode laser. Detector slits were configured to minimize any 
crosstalk between the channels and, if necessary, the channels were collected sequentially and 
merged afterwards. All images were acquired as z-stacks with 0.3 µm steps. Images were 
processed with the image processing software Imaris (Version 9.0.0, Bitplane AG, Zurich, 
Switzerland) and ImageJ. 
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2.2.18. EGFR phosphorylation antibody array 
To analyze the EGFR phosphorylation during RSV infection, an EGFR phosphorylation 
antibody array (Ray Biotech, Norcross, GA) was used that probed for the phosphorylation of 17 
different sites of the EGFR receptor family. Cells were treated as indicated, either transfected with 
siRNA 48 h prior to inoculation or pre-treated with the indicated chemical compounds for 16 h. 
Simultaneously to the indicated pre-treatments, all cells were serum-starved for 16 h in FBS-free 
medium before incubated with wt RSV (MOI = 5 PFU/cell) for 5 h at 37˚C, 5% (v/v) CO2. Cells 
were washed twice with cold 1x PBS and lysed in the provided lysis buffer containing the protease 
and phosphatase inhibitor cocktails (provided in the kit). The protein concentration of the lysate 
was quantified by BCA assay and lysate containing 150 µg total protein was used for each array. 
The array was processed as described by the manufacturer’s protocol. In brief, the array 
membrane was incubated with the diluted lysate for 16 h at 4˚C on a rocking platform, washed 
and incubated with a biotinylated anti-pan EGFR antibody, followed by horse reddish peroxidase-
conjugated streptavidin. The light emission from the array spots was detected by exposure to X-
ray films. The films were scanned and the intensity of each spot was quantified by ImageQuant 
TL (Array Version 8.1., GE Healthcare). The EGFR phosphorylation of three independent 
experiments with two technical replicates were normalized to the signal of the array internal 
positive controls and pan-EGFR. Signals are reported relative to the signal of mock-treated, RSV-
infected samples assigned the value of 1.0. 
 
2.2.19. Macropinosome quantification assay 
Macropinosomes have no unique cellular marker and can be best defined by their 
unspecific fluidic uptake and size. Therefore, a fluorescence confocal microscopy-based dextran 
assay was used for quantifying the macropinocytic uptake activity of cells (Wang et al. 2014). 
A549 cells were seeded on cover slips (Fisher Scientific) in 24-well plates two days prior to the 
assay so that they had reached a sub-confluent density. Cells were inoculated with wt RSV at an 
MOI of 5 PFU/cell in F12 medium containing 50 mg/ml AF568-conjugated dextran (MW 10,000, 
Life Technologies). Cells were incubated on a rocking platform at 37˚C, 5% (v/v) CO2 for 5 h, 
washed three times with 1x PBS, and fixed overnight with 4% (w/v) PFA at 4˚C. The cells were 
counterstained with DAPI (300 nM in 1x PBS for 5 min) and mounted on glass-slides with ProLong 
Diamond Antifade mountant. Multiple, random images, using the mark and find function of the 
Leica-AF image acquisition software, were acquired as z-stacks (0.15 µm steps) on a Leica TCS-
SP8 confocal microscope (Leica) with a 63x Objective (NA 1.4) and a zoom of 1.0x. 
For the quantification of dextran-AF568 uptake, the acquired images were analyzed by 
batch processing using the Imaris image processing software. The DAPI stained nuclei were 
detected as spots to count the number of cells per field. The uptake of dextran was quantified by 
creating surfaces that recognize distinct dextran-AF568-positive vesicles and disregards any 
background staining. The total intensity of dextran-AF568 within the created surfaces, which had 
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a volume larger than 1.0 µm3, of each field was normalized to the number of nuclei. The values 
were reported relative to Neg. siRNA 1-transfected or mock-treated cells that had been infected 
with RSV. For each experiment at total of at least 600 cells per condition were analyzed. 
 
2.2.20. Animal studies 
2.2.20.1. Ethic Statement 
All animal studies were approved by the NIH Institutional Animal Care and Use Committee 
(IACUC) and the mice and African green monkey studies were performed under the animal study 
protocols #LID 34E and #LID 22, respectively. 
The National Research Council’s Guide for the care and use of laboratory animals and the 
Public Health Service Policy on humane care and use of laboratory animals served as the 
guidelines for the care and use of the animals in this study. 
 
2.2.20.2. Evaluation of replication and immunogenicity of HPIV1 vectors expressing EBOV 
GP in African green monkeys (AGMs) 
2.2.20.2.1. Study design 
In vivo replication and immunogenicity of the HPIV1 vectors expressing EBOV GP was 
assessed in African green monkeys (AGMs, Cercopithecus aethiops). Animals were confirmed to 
be naïve for HPIV1 and HPIV3 by serum hemagglutination inhibition assay (HAI) (van Wyke 
Coelingh et al. 1988). Groups of four animals were infected with each of the HPIV1 EBOV GP 
viruses by the combined intranasal (IN) and intratracheal (IT) routes with 106 TCID50 per site. In 
parallel two animals were infected with wt HPIV1 for comparison. Two animals infected with the 
previously described candidate rHPIV3/EboGP (Bukreyev et al. 2006) also were included as a 
positive reference. Nasopharyngeal swabs (NP) were collected daily for 14 days whereas tracheal 
lavage (TL) with 3 ml 1x PBS was performed every other day p.i. for 14 days by the technicians 
of the animal facility. The NP swaps were resuspended in L15 medium containing 1x SP (see 
Table 2 in section 2.1.1). TL samples were 1:1 diluted in L15 medium containing 2x SP to obtain 
a final concentration of 1x SP. SP was added stabilize the virus during freezing. All samples were 
aliquoted, flash frozen on dry ice, and stored at -80˚C.  
After 28 days two animals of each group received a second inoculation (boost) with the 
same virus. Dose, routes, and NP/TL sample collection were the same as for the first dose. Virus 
titers of NP and TL samples were determined by serial dilution on LLC-MK2 cells and HAD assay 
(described in section 2.2.11). The viral titers were reported as log10TCID50 per ml. Serum was 
collected from all animals weekly by the technicians of the animal facility, starting on the day of 
inoculation, to determine GP-specific antibody response following the first and second dose. 
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2.2.20.2.2. Stability of EBOV GP expression during replication in AGMs 
After the titration of all samples to determine the viral shedding in the upper (NP samples) 
and lower (TL samples) respiratory tract of the inoculated AGMs, the day of peak shedding was 
defined. For each virus, NP and TL samples from all 4 animals at their peak titer day (P2) following 
the first inoculation, as well as a day before (P1) and after (P3) the peak day were subjected to 
double-immunostaining plaque assay, as described in section 2.2.12, to determine the stability of 
GP expression during in vivo replication.  
 
2.2.20.2.3. EBOV GP-specific ELISA 
A commercially available monkey anti-Zaire EBOV GP IgG ELISA kit (Alpha Diagnostic 
International, San Antonio, TX) was used to quantify the GP-specific serum antibody response of 
the immunized AGMs. The assay was performed as described in the manufacturer’s protocol and 
all incubation steps were performed on an orbital shaker. Briefly, 5-fold serially diluted serum was 
added to EBOV GP coated wells of a 96-well ELISA plate and incubated for 1 h to capture GP-
specific antibodies. The wells were washed and the bound GP-specific antibodies were detected 
with a secondary horseradish peroxidase conjugated anti-monkey IgG antibody that was 
incubated for 30 min. After washing the wells, a chromogenic substrate (3,3′,5,5′-
Tetramethylbenzidine, TMB) was added and incubated for 10 min. A color was developed by the 
HRP substrate, the intensity of which is directly proportional to the EBOV GP-specific antibody 
concentration present in the serum. The reaction was stopped by adding the stop solution (diluted 
sulfuric acid) and the absorbance at 450 nm (OD450) was measured on the Synergy2 ELISA reader 
(BioTek). The titer dilution of each sample yielding a value of OD450=1.0 was calculated by linear 
regression analysis. 
 
2.2.20.2.4. EBOV GP neutralization assay 
Serum titers of EBOV GP-specific neutralizing antibodies were determined by 60% plaque 
reduction neutralization titer (PRNT60) on Vero cells, using an HPIV3-based construct (called 
rHPIV3/NotI ∆F-HN/EboGP) that lacks the HPIV3 F and HN glycoprotein genes and expresses 
EBOV GP from an added gene as the sole viral surface protein. This virus is very similar to another 
version reported previously (Bukreyev et al. 2009) and was constructed as described in the 
Appendix 6.4. Sera from the immunized AGMs were heat inactivated at 56°C for 30 min, and 4-
fold serial dilutions in Opti-MEM I GlutaMax-I medium were made. As a positive control the human 
MAb KZ52 (IBT Bioservices) was included, which is a purified antibody preparation at 1.49 mg/ml. 
It is an EBOV GP-specific MAb derived from an EBOV survivor, and has been shown to neutralize 
EBOV to 50% at 0.3 µg/mL (Maruyama et al. 1999). These serum dilutions were combined with 
a set amount of rHPIV3/NotI ∆F-HN/EboGP and adjusted to contain 10% (v/v) of a commercial 
preparation of guinea pig complement (Lonza). The virus was incubated with the diluted serum 
samples for 30 min at 37°C and then transferred to Vero cell monolayers in 24-well plates. 
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Inoculated cells were rocked for 2 h at 32°C on a rocking platform, overlaid with methylcellulose 
overlay medium (see 2.1.1) and incubated for 6 days at 32°C. The cells were fixed twice with ice-
cold 80% (v/v) methanol, and plaques were detected with anti-GP mouse MAb (4F3, 1:2,000) and 
a secondary goat anti-mouse IRDye 680LT-conjugated antibody (Li-Cor), as described in section 
2.2.12. Images were acquired using an Odyssey infrared imaging system (Li-Cor) and the plaques 
of each well were counted with ImageJ software. Based on the plaque reduction due to the diluted 
serum, the PRNT60 titer for each serum was calculated by linear regression analysis. To confirm 
that the HPIV1- or HPIV3-specific antibodies present in the serum samples did not neutralize the 
rHPIV3/NotI ∆F-HN/EboGP virus, control HPIV1 and HPIV3 hyperimmune rabbit sera, with known 
high HPIV1- or HPIV3-neutralization titers, were included as controls which showed no detectable 
neutralizing activity, indicating that neutralization was due to anti-EBOV GP antibodies. 
 
2.2.20.3. ATP1A1 heterozygous knockout (ATP1A1+/-) mice  
Cryo-preserved embryos of the heterozygous mutant mouse strain B6;129S5-
Atp1a1Gt(neo)311Lex/Mmucd (RRID: MMRRC_011687-UCD, referred to as ATP1A1+/- here after) were 
obtained from the Mutant Mouse Resource & Research Centers (MMRRC) at the University of 
California, Davis. The ATP1A1 knockout was obtained by targeted retroviral insertion of a trapping 
cassette that abrogates the protein expression. Insertion of the trapping cassette in this ATP1A1 
mutant mouse strain occurred between exon 1 and 2 of the murine ATP1A1 gene on chromosome 
3 (Figure 13) (Lexicon Genetics Inc. 2005). The embryos were resuscitated by embryo transfer 
into 0.5 day pseudopregnant female recipient mice at the Mouse Genetics and Gene Modification 
Section (NIAID, NIH, Bethesda, MD). The litter was genotyped, as described below in section 
2.2.20.3.1, and used to establish breeding colonies. 
 
Figure 13: Insertion site of the trapping cassette in the murine ATP1A1 allele on chromosome 3 
(GenBank ID: 11928) by retroviral insertion. The arrangement of the exons (yellow horizontal bars) and 
introns (black horizontal lines) of the murine ATP1A1 gene are shown. Obtained from the Mouse Genome 
Informatics (MGI) (http://www.informatics.jax.org, ID: NIH-0128) 
It has been shown that the homozygous mutation causes preweaning lethality and only 
heterozygous (ATP1A1 +/-) knockout mice were viable. The information available on the Mouse 
Genome Informatics (MGI) website lists no major defects due to the heterozygous knockout, only 
behavioral changes of increased anxiety-related response and decreased exploration in new 
environment were noted (Lexicon Genetics Inc. 2005). 
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2.2.20.3.1. Genotyping 
The resuscitated animals as well as all offspring derived from the breeding colonies were 
genotyped for the ATP1A1 knockout allele. The genotyping strategy was provided by MMRRC. 
New litters were ear tagged and tail samples for genotyping were obtained post-weaning 
at 21 days of age. The tail tissue was lysed in 180 µl ATL buffer, containing 20 µl Proteinase K 
and incubated overnight at 56˚C. The genomic DNA (gDNA) was isolated from the lysate with the 
DNeasy Blood and Tissue Kit (Qiagen) as described in the manufacturer’s protocol. 
A diagnostic PCR was used to screen for the presence of the trapping cassette in the 
genome by using the below listed primer set (primer sequences are listed in the Appendix in 
section 6.3.1). ATP1A1 knockout was detected by an ATP1A1 gene-specific forward primer (128-
5’), located upstream of the insertion site of the trapping cassette, and a trapping cassette-specific 
reverse primer (LTR-rev). Two ATP1A1 gene-specific primers (128-5’ and 128-3’) were used as 
a control PCR for the wt genotype: 
Knockout ATP1A1 PCR: Primer 128-5' and Primer LTR-rev, Amplicon size: 132 bp  
wt ATP1A1 PCR: Primer 128-5' and Primer 128-3', Amplicon size: 131 bp 
The PCR reaction was set up with the Advantage-HF PCR kit as followed: 
5 µl/rxt 10xHF Buffer 
 5 µl/rxt dNTPs 
 1 µl/rxt forward primer, pre-diluted to 10 µM 
 1 µl/rxt reverse primer, pre-diluted to 10 µM 
 1 µl/rxt HF polymerase 
 36 µl/rxt dH2O 
  -> add 1 µl gDNA (include negative control: 1 µl dH2O) 
The PCR reaction was performed on a thermocycler with the following touch-down PCR program: 
 10 cycles:  94˚C   15 sec 
   65˚C (-1˚C/cycle) 30 sec 
   72˚C   40 sec 
 30 cycles:  94˚ C  15 sec 
   55˚C  30 sec 
   72˚C  40 sec 
The PCR reaction was loaded onto a 1.0% (w/v) agarose gel (BioRad), containing ethidium 
bromide, separated by electrophoresis (45 min, 100V) and a gel image was acquired at a UV-gel 
documentation station. The presence of a 132 bp amplicon in the ATP1A1 knockout PCR defined 
the ATP1A1+/- genotype. 
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2.2.20.3.2. Evaluation of RSV replication in ATP1A1+/- mice 
6-week old mice were genotyped (as described above in section 2.2.20.3.1) and separated 
into two groups by their genotype as wildtype (ATP1A1 +/+) and heterozygous knockout (ATP1A1 
+/-). All mice were inoculated intranasally with 106 PFU of rRSV-GFP diluted in 75 µl L15 medium. 
4 d p.i. the animals were euthanized with CO2 and nasal turbinate and lung tissues were collected. 
The tissues were homogenized in L15 medium added in a 1:10 weight to volume ratio, 
clarified by centrifugation and the PFU titer was determined by plaque assay titration on Vero cells 
(see 2.2.12). The titer of each individual animal was reported as PFU per gram of tissue. 
 
2.2.21. Statistical analysis 
All results shown are derived from at least three independent replicates, except otherwise 
stated. Error bars shown in each graph indicate the standard deviation (SD) for each group. 
GraphPad Prism was used to create all graphs and to perform the statistical analysis described 
in the corresponding figure legends. P-values are shown for each comparison and p-values 
smaller than 0.05 were considered as statistically significant.  
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3. Results 
3.1. Role of ATP1A1 in the macropinocytic entry of RSV  
The cellular protein ATP1A1 was identified as a presumptive pro-viral host factor in a high-
throughput siRNA screen in human airway epithelial A549 cells infected with RSV-GFP, with GFP 
expression as reporter for viral infection. Knockdown of the ATP1A1 gene expression reduced 
RSV infection. Of the top 65 genes identified, ATP1A1 knockdown had the greatest inhibitory 
effect on viral GFP expression, with minimal effects on cell viability, and was chosen for further 
characterization. 
 
3.1.1. Knockdown of ATP1A1 expression by siRNA transfection 
Three siRNAs with the greatest effect on ATP1A1 expression, without affecting cell viability, 
were used for further experiments. The efficiency of ATP1A1 knockdown was confirmed both at 
the mRNA and protein levels. A549 cells were transfected with individual ATP1A1-specific siRNAs 
or with an individual nonspecific scrambled negative siRNA as a control. Two different negative 
siRNAs (Neg. siRNA 1 and 2) were used to control for any off-target effects of the negative siRNA 
itself. At various time points, total cell-associated RNA was isolated, ATP1A1 mRNA was 
quantified by a TaqMan assay and reported relative to Neg. siRNA 1 (Figure 14A). At 24 h p.t. the 
level of ATP1A1 mRNA was reduced to below 5% compared to Neg. siRNA 1 and showed only 
modest further reductions at 48 and 72 h p.t. 
To measure the expression of ATP1A1 protein, A549 cell lysates were prepared at 24, 48 
and 72 h p.t. and subjected to Western blot analysis. Figure 14B shows a representative blot of 
ATP1A1 and alpha-tubulin (loading control). The band intensities were quantified and presented 
relative to Neg. siRNA 1 (Figure 14C). At 24 h p.t. the ATP1A1 protein amount was reduced about 
50% for all three ATP1A1-specific siRNAs (siRNA 1 - 3). The protein expression of ATP1A1 was 
further reduced at 48 h p.t. to 39% (siRNA 1 and 3) and 35% (siRNA 2) and did not show any 
further reduction at 72 h p.t. 
It was critical to evaluate cell viability as this could cause negative effects on virus infection 
potentially arising from siRNA off-target effects or the reduced ATP1A1 protein expression. The 
transfected cells showed no visible cytotoxicity or morphological changes over the period of 72 h 
p.t. For a more sensitive evaluation, an ATP-based viability assay was performed. Cellular ATP, 
as correlate for cell viability, was measured with a luciferase-based assay in cell lysates at 72 h 
p.t. The luciferase activity was quantified in relative light units (RLU) by an ELISA reader and were 
reported relative to mock-transfected cells (treated with transfection reagent only) (Figure 14D). 
The ATP1A1 siRNA knockdown showed only minimal reductions in cell viability (Figure 14D). The 
greatest reduction was observed for siRNA 1 at 18%, while siRNA 2 and 3 had reductions of 11% 
and 5%, respectively (Figure 14D).  
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Figure 14: ATP1A1 knockdown by siRNA transfection. A549 cells were transfected with three different 
siRNAs (siRNA 1 - 3) targeting the ATP1A1 mRNA. Cells were harvested 24, 48 and 72 h p.t. and the 
mRNA and protein levels of ATP1A1 were quantified. As negative control, cells were transfected with two 
different negative siRNAs (Neg. siRNA 1 and 2) with no known target in human cells. (A) Relative 
quantification of ATP1A1 mRNA. Total cell-associated RNA was isolated and was reverse transcribed. 
The amount of ATP1A1 mRNA was quantified by an ATP1A1 mRNA-specific TaqMan Assay, values were 
normalized to 18S rRNA and expressed as mean values relative to Neg. siRNA 1 assigned the value of 1.0, 
with error bars indicating the standard deviation (SD) of three independent experiments. (B) Western blot 
analysis of ATP1A1 expression. Cells were lysed in 1x LDS buffer and subjected to Western blotting with 
an anti-ATP1A1 rabbit monoclonal antibody (MAb) and a corresponding infrared fluorescent dye (IRDye) 
680RD-conjugated goat anti-rabbit secondary antibody. Alpha-tubulin was used as a loading control and 
was detected by an anti-alpha-tubulin MAb and an IRDye 800CW-conjugated goat anti-mouse secondary 
antibody. A representative blot is shown. (C) Relative quantification of ATP1A1 protein expression. The 
protein levels of three independent Western blot analyses, as described in part B, were quantified, 
normalized to alpha-tubulin, and reported relative to Neg. siRNA 1 assigned the value of 1.0, with error bars 
indicating the SD. (D) Cell viability. An ATP-based cell viability assay [CellTiter-Glo (Promega)] was 
performed 72 h p.t. to evaluate the viability of the transfected cells. Cells were lysed, the ATP concentration 
was determined by ATP-dependent luciferase activity, which was detected with an ELISA reader, and the 
luciferase activity (RLU, relative light units), reflecting the viability, was reported relative to mock-transfected 
cells assigned the value of 1.0. 
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3.1.2. Effect of ATP1A1 knockdown on RSV infection 
A549 cells were transfected with the three siRNAs targeting ATP1A1 (siRNA 1 - 3), and 
the two negative control siRNAs (Neg. siRNA 1 and 2), and 48 h later the cells were infected with 
RSV-GFP at an MOI of 1.0 PFU/cell. The efficiency of virus infection and replication were 
evaluated at 17 h post inoculation (p.i.) by GFP expression quantified by an ELISA reader, and 
24 h p.i. by flow cytometry, shown in Figure 15A and C, respectively. All three ATP1A1-specific 
siRNAs reduced the intensity of GFP expression by about 45 to 70% compared to Neg. siRNA 1. 
This level of reduction was substantial given that the residual level of ATP1A1 expression 
remained 35% or greater, as previously shown in Figure 14C. To determine if this effect was RSV-
specific, vesicular stomatitis virus expressing GFP (VSV-GFP) was included for comparison. 
ATP1A1 knockdown had no effect on GFP expression by VSV-GFP (Figure 15B). This suggested 
that the reduction in GFP expression observed with RSV-GFP was specific to RSV, did not affect 
VSV, and was not due to some general effect on cellular functions. The analysis of cells infected 
with RSV-GFP (MOI = 1.0 PFU/cell) by flow cytometry 24 h p.i. showed that knockdown of 
ATP1A1 resulted in a broad reduction of GFP expression in the infected cell population rather 
than a reduction in the number of GFP-expressing cells (Figure 15C). 
 
Figure 15: Effect of ATP1A1 knockdown on infection by RSV-GFP (A, C, D) and VSV-GFP (B). A549 
cells were transfected with the indicated siRNAs and 48 h later were infected with 1.0 PFU/cell RSV-GFP 
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(A, C, D) or 0.5 PFU/cell VSV-GFP (B). (A and B) Quantification of viral GFP expression. The GFP 
intensity of the total well was quantified by scanning with an ELISA reader at 17 h p.i. (C) Flow cytometry 
analysis of RSV-GFP expression. In addition, RSV-GFP expression also was examined and quantified 
by flow cytometry at 24 h p.i. (D) Titer of progeny RSV-GFP. The production of infectious RSV at 24 h p.i. 
was quantified by plaque titration on Vero cells. All data in A-D are derived from at least three independent 
experiments and, in A-C, are shown as mean values relative to Neg. siRNA 1 assigned the value of 1.0, 
with error bars indicating the SD. The statistical significance of difference was determined by one-way 
analysis of variance (ANOVA) with Dunnett’s multiple comparison post-test and p-values are shown for 
each comparison. 
The effects on the production of progeny RSV were assessed 24 h p.i. The infected cells 
were scraped off, followed by vortexing of the cell suspension to release bound virions, and virus 
titers of the clarified supernatants were determined by plaque titration on Vero cells. RSV-GFP 
plaques were quantified and titers reported as PFU/ml (Figure 15D). The RSV titers were reduced 
between 5- (siRNA 3) and 42-fold (siRNA 2) compared to Neg. siRNA 1 at 24 h p.i., an effect that 
was even more dramatic than the reduction in GFP expression described above (Figure 15D 
versus Figure 15A and C); ATP1A1 siRNA 2 showed the strongest effect in both cases. These 
data suggest that ATP1A1 has an important role in the RSV replication cycle and that the amount 
of ATP1A1 expressed by the host cell is a crucial factor for efficient RSV infection. 
 
3.1.3. RSV replication in ATP1A1+/- mice 
To evaluate the effect of reduced ATP1A1 protein level on RSV infection and shedding in 
vivo, a heterozygous ATP1A1 knockout mouse strain was obtained and a breeding colony was 
established. The homozygous knockout is lethal at the preweaning stage and therefore, a 
heterozygous ATP1A1+/- genotype is the only available mouse strain with a reduced ATP1A1 
expression level. 
The mutant mice were bred and genotyped post-weaning at 21 days of age. The ATP1A1 
protein levels in lung tissue lysates of mutant ATP1A1+/- and wild-type ATP1A1+/+ mice were 
determined by Western blotting (Figure 16A). Due to the heterozygous knockout the ATP1A1 level 
was reduced only modestly, to 65 - 70% compared to wild-type mice. Thus, following knockdown, 
the level of residual expression of ATP1A1 in vivo (65 - 70%, Figure 16A) was substantially greater 
than that observed in vitro (35 - 39%, Figure 14C). 
Nevertheless, the mice that were obtained were used for a pilot study to determine the 
effects of the modest reduction of ATP1A1 protein expression in these heterozygous knockout 
mice on RSV infection and shedding. 6-week-old ATP1A1+/- and wild-type litter mates were 
inoculated intranasally with 106 PFU of RSV-GFP. Virus shedding in the lung and nasal turbinate 
tissues was determined by plaque titration on Vero cells 4 d p.i. (Figure 16B). The mean titers in 
the lung tissue for ATP1A1+/- and wild-type mice were 8.8 x 103 PFU/g and 1.4 x 104 PFU/g, 
respectively. RSV titers in the nasal turbinate tissues were slightly higher as compared to the titers 
in the lungs and were, for ATP1A1+/- and wild-type mice, 2.4 and 2.5 x104 PFU/g, respectively. 
Thus, RSV shedding was similar for ATP1A1+/- and the control wild-type litter mates, with no 
significant difference in the infectious virus titers in the lung or nasal turbinate tissues. This was 
Results  59 
not surprising, since the heterozygous knockout only showed a modest reduction in ATP1A1 
expression, which apparently was sufficient for infectivity and shedding similar to wild-type mice. 
Due to the modest ATP1A1 reduction, experimentation in this murine model was not continued. 
 
Figure 16: Heterozygous ATP1A1 knockout mice. ATP1A1 mutant mice were genotyped by a diagnostic 
PCR (ATP1A1 genotype: +/-, heterozygous knockout; +/+, wild-type). (A) ATP1A1 protein expression 
level in lung tissue of ATP1A1+/- mice. ATP1A1 protein level in lysates of lung tissues was quantified by 
Western blotting as described for Figure 14B. A representative blot is shown. (B) Replication of RSV-GFP 
in ATP1A1+/- mice 4 d p.i. Groups of 6-week-old ATP1A1 +/- and +/+ mice were inoculated intranasally 
with 106 PFU of RSV-GFP. Lung and nasal turbinate tissues were collected 4 d p.i. and RSV replication 
was evaluated by plaque titration of tissue homogenates on Vero cells and was reported as PFU per gram 
tissue. LOD, limit of detection. 
 
3.1.4. Cellular distribution of ATP1A1 during RSV infection 
To gain insight into the role of ATP1A1 in the RSV replication cycle, the ATP1A1 
distribution in RSV-infected A549 cells was examined by fluorescence confocal microscopy. A549 
cells were infected with wt RSV (MOI = 5 PFU/cell), fixed at 2 h and 5 h p.i., and subjected to 
immunofluorescence staining for ATP1A1 and RSV F protein. In uninfected cells (Mock), ATP1A1 
was homogenously distributed on the plasma membrane (Figure 17A, top row). Upon infection 
with wt RSV, ATP1A1 clusters were observed that were visible as early as 2 h p.i. (Figure 17A, 
middle row) and were clearly different, more abundant than anything seen in the uninfected cells. 
With time, the ATP1A1 clusters became more prominent and numerous, as shown for 5 h 
compared to 2 h p.i. (Figure 17A, bottom row versus middle row). Some ATP1A1 clusters, but not 
all, partially co-localized with RSV F protein (Figure 17A, indicated by arrows). The localization of 
clustered ATP1A1 in close proximity to RSV F became more noticeable at later time points such 
as 5 h p.i. (Figure 17A, bottom panel). Localization of ATP1A1 clusters close to RSV N protein 
also could be observed (Figure 18 and Figure 20), suggesting that the RSV-specific staining most 
likely reflects enveloped virions which had not yet fused. Cross-sections (Figure 17B) of the RSV-
infected A549 cells 5 h p.i. indicated that the ATP1A1 clustering occurred at the cell surface and 
was localized close to the RSV virions. Similar ATP1A1 clustering also was observed for UV-
inactivated wt RSV (Figure 18), suggesting that the staining mostly detected virus particles derived 
from the inoculum and that virus gene expression or replication was not required to trigger 
clustering. Given the very early appearance of ATP1A1 clusters, independent of viral transcription 
or replication, it was hypothesized that ATP1A1 might be involved in an early step of infection, 
such as viral entry.  
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Figure 17: RSV infection triggers ATP1A1 clustering. (A) A549 cells were inoculated with wt RSV (MOI 
= 5 PFU/cell) and incubated for 2 or 5 h. Cells were fixed with 4% (w/v) PFA, permeabilized with 0.1 %  (v/v) 
Triton X-100 and stained for ATP1A1 (green) with an anti-ATP1A1 rabbit MAb (ab76020) and Alexa Fluor 
(AF) 488-conjugated donkey anti-rabbit secondary antibody. RSV F (red) was detected with anti-RSV F 
mouse MAb #1129 (Beeler and van Wyke Coelingh 1989) and an AF594-conjugated donkey anti-mouse 
secondary antibody. The cell nuclei were stained with DAPI (blue). Images (z-stacks) were acquired on a 
Leica SP5 confocal microscope, with a 63x objective (numerical aperture [NA] 1.4) and a zoom of 3.0. 
Arrows indicate examples of co-localization of ATP1A1 and RSV F. (B) Cross-sectional image of the marked 
area in A of RSV-infected cell at 5 h p.i. Scale bars, 10 µm. 
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Figure 18: ATP1A1 clustering induced by UV-inactivated RSV. A549 cells were inoculated with wt RSV 
(MOI = 5 PFU/cell) and incubated for 5 h. Additional cultures were inoculated with wt RSV that had been 
UV-inactivated (0.5 J/cm2) using a Stratalinker UV Crosslinker 1800 (Agilent, UV wt RSV). Loss of plaque-
forming activity in the UV wt RSV inoculum was confirmed by plaque titration on Vero cells. Cells were fixed 
with 4% (w/v) PFA and subjected to immunofluorescence staining. ATP1A1 (green) was detected with an 
anti-ATP1A1 rabbit MAb (ab76020) and AF488-conjugated donkey anti-rabbit secondary antibody. RSV N 
(red) was detected by an anti-RSV N mouse MAb (ab94806) and an AF568-conjugated donkey anti-mouse 
secondary antibody. The cell nuclei were stained with DAPI (blue). Arrows indicate co-localization of 
ATP1A1 and RSV N. Scale bars, 10 µm. 
 
3.1.5. Investigation of ATP1A1 interactions with RSV glycoproteins 
If ATP1A1 is involved in early steps of infection, it was hypothesized that one or more of 
the RSV surface glycoproteins F, G, and/or SH, might interact with ATP1A1. Various 
immunoprecipitation assays were performed to investigate possible interactions. For example, the 
human lung epithelial cell line H1299 ATP1A1-YFP (Sigal et al. 2006, Frenkel-Morgenstern et al. 
2010), that chromosomally expressed ATP1A1 genetically fused to a yellow fluorescent protein 
(YFP) tag, was used for various co-immunoprecipitation assays. These cells were infected with 
RSV, lysed, and subjected to co-immunoprecipitation with YFP-specific antibodies, followed by 
Western blotting with antibodies specific to RSV glycoproteins. Similar co-immunoprecipitation 
experiments were performed in which, prior to lysis, the cells were treated with the permeable, 
reversible cross-linker dithiobis(succinimidyl propionate) to covalently link proteins that were close 
to each other to stabilize and detect any weak or transient interactions [ReCLIP assay, (Smith et 
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al. 2011)]. In other experiments, RSV virions were incubated with purified ATP1A1 that was 
immobilized on beads to detect any RSV-ATP1A1 interactions in a cell-independent manner. 
However, no evidence of binding between ATP1A1 and RSV proteins could be detected in these 
experiments (data not shown). 
A cell-based binding assay also was performed (Figure 19), which had been adapted from 
an assay described by Martinez and colleagues (Martinez and Melero 2000). In brief, A549 cells 
were transfected with ATP1A1-specific siRNAs to knock down ATP1A1 protein expression. 48 h 
post siRNA transfection, cells were detached and incubated with the RSV inoculum (MOI = 10 
PFU/cell) on ice for 30 min. Cells were extensively washed and the bound virus was detected with 
a pool of RSV F-specific mouse MAbs #1129, 1269 and 12443 (Beeler and van Wyke Coelingh 
1989) and an AF647-conjugated donkey anti-mouse secondary antibody. The samples were 
analyzed on Canto II flow cytometer and the median fluorescence intensity (MFI) of AF647 was 
reported relative to Neg. siRNA 1-transfected cells (Figure 19). ATP1A1 knockdown did not show 
an appreciable reduction in RSV binding, indicating that ATP1A1 likely did not contribute to RSV 
attachment. This experiment also was done with the additional step of treating of the cells with 
heparinase I prior to RSV exposure to remove cell surface GAGs, which was done to eliminate 
GAG-mediated RSV attachment: this also did not reveal any contribution of ATP1A1 to RSV 
attachment (data not shown). Therefore, there was no evidence of stable binding of any RSV 
surface protein to ATP1A1. 
 
Figure 19: Effect of ATP1A1 knockdown on RSV binding on the cell surface. A549 cells were 
transfected with the indicated siRNAs targeting the ATP1A1 mRNA (siRNA 1 - 3) or unspecific negative 
siRNA (Neg. siRNA 1 and 2). 48 h p.t. cells were detached with 1 mM EDTA in 1x PBS and the suspended 
cells were incubated with wt RSV (MOI = 10 PFU/cell) on ice for 30 min. Cells were washed to remove any 
unbound virus and stained for RSV F with a pool of RSV F-specific mouse MAb [#1129, 1269, and 1243 
(Beeler and van Wyke Coelingh 1989)] followed by an AF647-conjugated donkey anti-mouse secondary 
antibody. Cells treated with trypsin prior to incubation with virus served as a negative control for virus binding. 
Cells were analyzed by flow cytometry and the MFI of AF647 was reported relative to Neg. siRNA 1-
transfected cells assigned the value of 1.0. Protocol was adapted from (Martinez and Melero 2000). 
Another way to investigate the involvement of viral surface glycoproteins that might be 
involved in triggering ATP1A1 clustering was to use recombinant RSV mutants with deletion of 
the small hydrophobic protein gene (dSH) or the combined deletion of SH and the attachment G 
glycoprotein genes (dSH/dG). A deletion of RSV F was not feasible since a virus without F protein 
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would not be infectious. A549 cells were infected with wt RSV, RSV dSH, or RSV dSH/dG (MOI 
= 10 PFU/cell) and incubated for 5 h. The infected cells were fixed, permeabilized, and 
immunostained with MAbs specific to ATP1A1 (green) and RSV N (red). The ATP1A1 clustering 
was examined by fluorescence confocal microscopy (Figure 20).  
 
Figure 20: RSV G is required for ATP1A1 clustering. A549 cells were inoculated with wt RSV, RSV dSH 
or RSV dSH/dG (MOI = 10 PFU/cell) and incubated for 5 h. Cells were fixed with 4% (w/v) PFA and 
subjected to immunofluorescence staining. ATP1A1 (green) was detected with an anti-ATP1A1 rabbit MAb 
(ab76020) and an AF568-conjugated donkey anti-rabbit secondary antibody. RSV N (red) was detected 
with an anti-RSV N mouse MAb (ab94806) and an AF647-conjugated donkey anti-mouse secondary 
antibody. The cell nuclei were stained with DAPI (blue). Images (z-stacks) were acquired on a Leica SP8 
confocal microscope, with a 63x objective (NA 1.4) and a zoom of 3.0. Scale bars, 10 µm. 
Wt RSV was included as a reference that induced increased cluster formation compared 
to Figure 17, which may have been due to the increased MOI of 10 PFU/cell compared to 5 
PFU/cell used previously. Clustering induced by RSV dSH virus was similar to that observed with 
wt RSV, suggesting that the deletion of the SH protein had no effect on ATP1A1 clustering. On 
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the other hand, the dSH/dG virus did not induce any ATP1A1 clusters (Figure 20, bottom panel) 
and the aggregates of viral protein thought to be virions, stained for RSV N in red, were reduced 
in amount and much more dispersed compared to wt RSV and the dSH virus. The lack of ATP1A1 
cluster formation with the dSH/dG virus suggested that RSV G protein is required for triggering 
ATP1A1 clustering. 
3.1.6. Effects of ouabain and PST2238 on RSV infection 
The described clustering of ATP1A1 in response to RSV exposure is reminiscent of the 
clustering that is generally observed for cell surface receptors known to facilitate intracellular 
signaling in response to ligand binding (Gopalakrishnan et al. 2005). Formation of ATP1A1 
clusters pointed to a possible role for ATP1A1 as a signal transducer. As described in the 
introduction, the only known signaling function for ATP1A1 is in response to binding of CTS, such 
as ouabain, with the ATP1A1 extracellular domain. A synthetic digitoxigenin derivative named 
PST2238 is an ouabain antagonist and competes with its binding site at ATP1A1 (Ferrari et al. 
1998). Due to their specific interaction with ATP1A1 and the association with ATP1A1-mediated 
signaling cascades, ouabain and PST2238 were tested for their effects on RSV infection. 
Serial dilutions of ouabain and PST2238 were evaluated for cytotoxicity on A549 cells and 
primary human small airway epithelial cells (HSAEC), following a 24 h incubation, by an ATP-
based viability assay (Figure 21). 
 
Figure 21: Cytotoxicity of ouabain and PST2238 on A549 cells and primary human small airway 
epithelial cells (HSAEC). A549 cells (solid line) and HSAEC (dotted line) were treated with serial dilutions 
of ouabain (A) and PST2238 (B) for 24 h. For each cell type, cell viability was determined in triplicates for 
each concentration by the ATP-based viability assay CellTiter-Glo. The results were reported relative to 
mock-treated cells assigned the value 1.0, with error bars indicating the SD. The horizontal dotted line 
indicates 80% viability. 
Based on the viability curves in Figure 21 A and B, regression analysis was used to 
calculate the maximal concentrations of ouabain and PST2238 that could be used for a 24 h 
treatment without reducing the cell viability below 80% relative to mock-treated cells (Table 19). 
Surprisingly, the chemical concentrations tolerated by HSAEC were 16.3-fold (ouabain) and 8.4-
fold (PST2238) lower than for A549 cells. In order to maintain greater than 80% viability, 
concentrations of 25 nM ouabain and 20 µM PST2238 were used for subsequent experiments in 
A549 cells, with maximum treatment periods of 24 h. 
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Table 19: Calculated1) maximal concentration for ouabain or PST2238 to maintain 80% viability of 
A549 cells or HSAEC after a 24 h treatment: 
Cells Ouabain [nM] PST2238 [µM] 
A549 44.0 22.7 
HSAEC 2.7 2.7 
1) Concentrations were calculated by regression 
analysis with GraphPad Prism 7 based on the 
viability curves shown in Figure 21. 
The effects of ouabain and PST2238 on the cellular expression of ATP1A1 and EGFR 
were analyzed by immunofluorescence microscopy using antibodies specific for each protein 
(Figure 22). EGFR was evaluated in addition to ATP1A1 because it previously had been shown 
to be important for RSV entry and it had been reported to be associated with the ATP1A1-
signalosome, as described in the Introduction. In mock-treated cells, ATP1A1 and EGFR each 
had a homogeneous membrane distribution (Figure 22, left column). After a 24 h treatment with 
ouabain, the ATP1A1 protein level was greatly reduced (Figure 22, middle column, top panel), 
presumably due to the removal of cell-surface Na+, K+-ATPase by clathrin-mediated endocytosis 
induced by ATP1A1 signaling (Introduction), while EGFR expression and localization appeared 
unchanged (Figure 22, middle column, bottom panel). On the other hand, PST2238 (Figure 22, 
right panel) had no discernible effect on the expression and/or localization of ATP1A1 or EGFR. 
PST2238 did not cause removal of ATP1A1 because it does not induce ATP1A1 signaling and 
endocytosis (Introduction). 
 
Figure 22: Effect of ouabain and PST2238 on cellular expression of ATP1A1 and EGFR. Uninfected 
A549 cells were treated for 24 h with either 25 nM ouabain or 20 µM PST2238, fixed with 4% (w/v) PFA, 
and subjected to an immunofluorescence staining. ATP1A1 (green) was detected by an anti-ATP1A1 rabbit 
MAb (ab76020) and an AF488-conjugated donkey anti-rabbit secondary antibody. EGFR (red) was 
detected by and an anti-EGFR rat MAb (ab231) and an AF647-conjugated goat anti-rat secondary antibody. 
The cell nuclei were stained with DAPI (blue). Images (z-stacks) were acquired on a Leica SP8 confocal 
microscope, with a 63x objective (NA 1.4) and a zoom of 3.0. Scale bars, 10 µm. 
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To evaluate possible effects of ouabain and PST2238 on RSV infection, A549 cells were 
pre-treated for 16 h with these ATP1A1-binding compounds, inoculated with RSV-GFP (MOI = 1 
PFU/cell) and incubated with the compounds present throughout. RSV infection was evaluated 
by (i) viral GFP expression 17 h p.i., quantified by an ELISA reader (Figure 23A), and (ii) the yield 
of progeny RSV harvested 24 h p.i., quantified by plaque titration on Vero cells (Figure 23B). Both 
methods correlated well, showing a reduction in RSV replication for each compound that was 
greater than the reduction achieved with the ATP1A1-specific siRNAs (Figure 15). Ouabain had 
the stronger effect; It reduced the viral GFP expression by 96% and virus yield by almost 3.0 log10 
compared to mock-treated cells. PST2238 reduced viral GFP expression by 89% and virus yield 
by 2.0 log10 compared to cells that were mock-treated. Overall, both compounds showed very 
strong inhibitory effects on RSV infection.  
 
Figure 23: Effect of ouabain and PST2238 on RSV infection. A549 cells were pre-treated for 16 h with 
either 25 nM ouabain or 20 µM PST2238 and subsequently were inoculated with RSV-GFP (MOI = 1 
PFU/cell). Infectivity was quantified by: (A) GFP intensity of the total well, scanned by an ELISA reader, 17 
h p.i. and reported relative to mock-treated infected cells as 1.0; and (B) virus titer determined by plaque 
titration on Vero cells 24 h p.i. 
To determine the stage of RSV infection that is inhibited by these compounds, a “time of 
addition” experiment was performed. A549 cells were infected with RSV-GFP (MOI = 3 PFU/cell) 
and at different times p.i. ouabain (Figure 24A and B) or PST2238 (Figure 24C and D) was added. 
Cells were incubated for a total of 24 h p.i. and the GFP intensity of single, live, GFP+ cells was 
analyzed by flow cytometry. For both compounds, the strongest inhibitory effect was observed 
when the inhibitor was added simultaneously with RSV-GFP at 0 h, showing 85% and 66% 
reduction of GFP expression by ouabain and PST2238, respectively (Figure 24A-D). The inhibition 
of infection continued to diminish with increasingly later addition of the drugs, and was almost 
completely lost when the drug was added at 10 h p.i. These results suggested a role for ATP1A1 
early in infection, such as in uptake and entry. 
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Figure 24: Time of addition experiment for ouabain and PST2238 during RSV infection. A549 cells 
infected with RSV-GFP (MOI = 3 PFU/cell) were incubated in the presence of 25 nM ouabain (A, B) or 20 
µM PST2238 (C, D) beginning simultaneously with infection (0 h) or at the indicated times p.i. The GFP 
intensity of single, live, GFP+ cells was quantified by flow cytometry at 24 h p.i. The GFP-MFI was reported 
relative to mock-treated RSV-infected cells (shown in gray in the histogram) assigned the value of 1.0, with 
error bars indicating the SD. 
The concentration-dependence of the antiviral efficacy (50% inhibitory concentration; IC50) 
on RSV-GFP infection was determined for ouabain and PST2238 on A549 cells and HSAEC 
(Figure 25). A549 cells and HSAEC were inoculated with RSV-GFP (MOI = 1 PFU/cell) in the 
presence of serially-diluted ouabain (Figure 25A) or PST2238 (Figure 25B), which was added 
simultaneously with the inoculum. The cytotoxicity of ouabain and PST2238 was previously 
evaluated and is shown above in Figure 21A and B, respectively. The viral GFP expression was 
quantified by an ELISA reader 24 h p.i. and reported relative to mock-treated RSV-infected cells.  
 
Figure 25: Concentration-dependence of the antiviral efficacy of ouabain and PST2238 on A549 and 
HSAEC. A549 cells (solid line) and HSAEC (dotted line) treated with serial dilutions of ouabain (A) and 
PST2238 (B) were infected with RSV-GFP (MOI = 1 PFU/cell) and incubated for 24 h. GFP expression, as 
an indicator of viral infection, was quantified by an ELISA reader and reported relative to mock-treated 
infected cells assigned the value of 1.0, with error bars indicating the SD. Cytotoxicity of the same serial-
dilutions of ouabain and PST2238 on A549 cells and HSAEC were determined in Figure 21 and the maximal 
concentration for 80% viability (Table 19) for each cell line is indicated by vertical dotted lines. 
Ouabain and PST2238 showed an increased inhibition of RSV-GFP with increasing 
concentration and reached almost maximal inhibition before affecting the cell viability by more 
than 20%. The inhibition of RSV-GFP in primary HSAEC was more effective compared to A549 
cells for both compounds. The efficacy curves for ouabain (Figure 25A) and PST2238 (Figure 25B) 
were used to calculate the respective IC50 values (Table 20) using the software Prism 7 (GraphPad 
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Software, Inc.). This showed that the IC50 values were lower in HSAEC than A549 cells by 4.9-
fold for ouabain and 8.2-fold for PST2238. 
 
Table 20: Calculated1) IC50 for RSV-GFP in A549 and HSAEC cells: 
Cells Ouabain [nM] PST2238 [µM] 
A549 12.7 14.8 
HSAEC 2.6 1.8 
1) IC50 values were calculated with GraphPad Prism 7  
based on the efficacy curves shown in Figure 25. 
 
The effect of PST2238 on the phenomenon of ATP1A1 clustering during RSV infection, 
which was described above (Figure 17), also was investigated. PST2238 was used since it had 
no visible effect on the expression level of ATP1A1 on the plasma membrane (Figure 22). A549 
cells were pre-treated with PST2238 for 16 h and infected with wt RSV (MOI = 5 PFU/cell). 5 h 
p.i. the cells were fixed, permeabilized, immunostained with antibodies specific to ATP1A1 and 
RSV F protein, as described above, and analyzed by confocal fluorescence microscopy. PST2238 
had no apparent effect on the clustering of ATP1A1 compared to mock-treated infected cells (data 
not shown). This indicated that clustering of ATP1A1 was not affected by the presence of 
PST2238, and thus the inhibitory mechanism of PST2238 on RSV infection presumably acts 
downstream of ATP1A1 clustering. 
 
3.1.7. ATP1A1-mediated signaling during RSV infection 
The observed ATP1A1 clustering as well as the inhibitory effects of ouabain and PST2238 
pointed towards a role of ATP1A1 in RSV-induced signaling cascades that might be involved in 
early steps of RSV infection. Therefore, the downstream signaling pathways of ATP1A1 that might 
be involved in ATP1A1-dependent RSV entry were investigated. 
 
3.1.7.1. Effects of Src-kinase inhibition on RSV infection 
As described in the Introduction, ATP1A1 does not contain a known signaling domain, 
such as kinase activity. However, ATP1A1 located in the caveolae is associated with cellular c-
Src – a non-receptor tyrosine kinase - that is activated by the binding of ouabain to ATP1A1. To 
test the hypothesis that RSV might use an ATP1A1-associated signaling pathway for entry, the 
requirement of c-Src activity during RSV infection was examined. Two Src-kinase inhibitors, PP2 
and Src-Inhibitior-I (SrcI-I), were used to evaluate the effects on RSV. A549 cells were pre-treated 
with non-cytotoxic concentrations (see Figure 39 for an evaluation of cytotoxicity) of these 
inhibitors separately or together (SrcI-I +PP2) for 5 h, followed by infection with RSV-GFP (MOI = 
1.0 PFU/cell) in the continued presence of the indicated inhibitors. The efficiency of RSV infection 
was evaluated by (i) GFP expression at 17 h p.i. for all treatments measured by an ELISA reader 
(Figure 26A), and (ii) production of infectious RSV at 24 h p.i. for cells that had been treated with 
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both inhibitors (SrcI-I + PP2), assayed by plaque titration (Figure 26B). Each Src inhibitor showed 
a modest, but significant (p < 0.0001) reduction in GFP intensity of 23% (SrcI-I) and 33% (PP2) 
relative to mock-treated infected cells. When added together (SrcI-I + PP2), the inhibitory effect 
was additive reaching 45% reduction compared to mock-treated infected cells. The RSV titer for 
the combined Src-inhibitor treatment showed a 2-fold, significant (two-tailed, unpaired t-test, p = 
0.0014) reduction compared to mock-treated infected cells (Figure 26B). These data confirmed 
that Src-kinase activity contributes to RSV infection. 
 
Figure 26: Src-kinase activity is required for efficient RSV infection. A549 cells were pre-treated (5 h) 
with the indicated Src-kinase inhibitors (PP2 [12.5 µM], SrcI-I [6.25 µM] or both) or were mock-treated 
(DMSO carrier control), and were inoculated with RSV-GFP (MOI = 1 PFU/cell) in medium containing the 
indicated inhibitors. (A) GFP intensity of the total well, scanned by an ELISA reader 17 h p.i. and expressed 
relative to mock-treated infected cells assigned the value of 1.0. (B) The production of infectious RSV at 24 
h p.i. was quantified by plaque titration on Vero cells. The statistical significance of differences was 
determined by one-way ANOVA with Tukey’s multiple-comparison post-test, and p-values are shown for 
each comparison. 
 
3.1.7.2. Effects of EGFR knockdown on RSV infection. 
It was investigated whether EGFR, a potential downstream signaling partner of c-Src 
kinase, was involved in RSV infection. If RSV uses an ATP1A1 signaling pathway, possibly similar 
to that induced by ouabain, then the downstream presence of EGFR, and transactivation of EGFR 
by c-Src, might be necessary to facilitate RSV entry.  
Commercially available EGFR-specific siRNAs were evaluated for the ability to knock 
down expression of EGFR, and a siRNA was identified that reduced EGFR protein expression in 
A549 cells at 48 h p.t. to 15% compared to Neg. siRNA 1 (Figure 27A), with minimal effects on 
cell viability (Figure 28C). A549 cells were transfected with the indicated siRNAs and the effects 
on the cellular expression of the non-targeted protein was examined by immunofluorescence 
staining 48 h p.t. ATP1A1-specific and EGFR-specific siRNAs greatly reduced the expression of 
their corresponding target proteins (Figure 27B, ATP1A1 top panel; EGFR: bottom panel) without 
affecting the non-targeted EGFR and ATP1A1, respectively, whose expression remained similar 
to that of Neg. siRNA 1. This suggested that the ATP1A1 knockdown has no visible effect on the 
cellular expression of EGFR, or vice versa. 
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Figure 27: Expression of ATP1A1 and EGFR proteins in A549 cells following knockdown with EGFR- 
and ATP1A1-specific siRNAs. (A) Western blot analysis of EGFR expression. A549 cells were 
transfected with an EGFR-specific siRNA, and at 48 h p.i. the cells were lysed in 1x LDS buffer. The lysates 
were subjected to Western blot analysis with an EGFR-specific mouse MAb (ab181822) and a 
corresponding IRDye 680RD-conjugated goat anti-mouse secondary antibody. Alpha-tubulin was used as 
loading control and was detected by an anti-alpha-tubulin mouse MAb and the same secondary antibody 
as EGFR. (B) Immunofluorescence microscopy. A549 cells transfected with ATP1A1-specific, EGFR-
specific, or negative control siRNA (Neg. siRNA 1) were fixed with 4% (w/v) PFA 48 h p.t and subjected to 
an immunofluorescence staining as described in the Materials and Methods. ATP1A1 (green) and EGFR 
(red) were detected with MAbs as described for Figure 22. The cell nuclei were stained with DAPI (blue). 
Images (z-stacks) were acquired on a Leica SP5 confocal microscope with 63x objective (NA 1.4) and 2.0x 
zoom. Scale bars, 10 µm. 
To determine the role of EGFR in a possible ATP1A1-signaling pathway involved in RSV 
entry, a RSV infection assay was performed following knockdown of EGFR expression. A549 cells 
were transfected with the EGFR-specific siRNA, or with the negative control Neg. siRNA 1, and 
incubated for 48 h. In addition, cells transfected with ATP1A1 siRNA 2, which had the strongest 
inhibitory effect on RSV-GFP infection (as shown in Figure 15), were included as reference. 
Knockdown cells were infected with RSV-GFP and the infection was evaluated by viral GFP 
intensity at 17 h p.i., quantified by an ELISA reader (Figure 28A), and by virus titer at 24 h p.i. 
determined by plaque titration on Vero cells (Figure 28B). EGFR knockdown resulted in a nearly 
50% reduction in viral GFP expression (Figure 28A) as compared to Neg. siRNA 1 (p < 0.0001). 
This reduction observed with EGFR knockdown was less than that observed for ATP1A1 siRNA 
2-transfected cells. There also was a significant 38% reduction in RSV titer in EGFR siRNA-
transfected cells compared to Neg. siRNA 2- (p = 0.0015) or mock-transfected (p = 0.0001) cells 
(Figure 28B), but this was substantially less than that observed for the ATP1A1 knockdown. There 
was a modest but consistent reduction in RSV titer for Neg. siRNA 1 for reasons unknow, and 
hence the reduction in RSV titer for EGFR siRNA-transfected cells was not significantly reduced 
as compared to this particular control siRNA (ns, p = 0.9891), but as noted above the reduction in 
GFP expression was highly significant. In summary, these data confirmed that EGFR plays a role 
during RSV infection. 
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Figure 28: Effect of EGFR knockdown on RSV infection. (A and B) Efficiency of infection by RSV-
GFP. A549 cells were transfected with an EGFR-specific siRNA or Neg. siRNA 1 or 2, and at 48 h p.i. the 
cells were infected with RSV-GFP (MOI = 1 PFU/cell). The ATP1A1 siRNA 2 knockdown was included as 
reference. Infectivity was quantified by: (A) GFP intensity of the total well at 17 h p.i., scanned by an ELISA 
reader, and reported relative to Neg. siRNA 1-transfected cells assigned the value of 1.0; and (B) virus titer 
at 24 h p.i., determined by plaque titration on Vero cells. Data were derived from three independent 
experiments. The statistical significance of differences was determined by one-way ANOVA with Tukey’s 
multiple-comparison post-test, and the p-value for each comparison is indicated. (C) Cell viability. An ATP-
based cell viability assay (CellTiter-Glo) was performed 72 h p.t. to evaluate the viability of the transfected 
cells. Cells were lysed, the ATP-concentration was determined by luciferase activity, reflecting the viability, 
and reported relative to mock-transfected cells assigned the value of 1.0. 
 
3.1.7.3. EGFR phosphorylation in response to RSV infection. 
An EGFR phosphorylation antibody array (RayBiotech, Inc.) was used to investigate 
EGFR phosphorylation during RSV infection. The array contained phospho-specific antibodies 
against 17 different specific phosphorylation sites of the human EGFR family, plus a positive 
control antibody that binds EGFR irrespective of phosphorylation, which were spotted in duplicate 
on a nitrocellulose membrane. Replicate membranes were incubated with the individual cell 
lysates from independent experimental samples. The bound EGFR was quantified by binding with 
a second, biotinylated, pan-EGFR antibody, followed by binding with horseradish peroxidase-
conjugated streptavidin, and luminescence was detected with an X-ray film.  
For the experiments, A549 cells were serum-starved for 16 h and infected with wt RSV 
(MOI = 5 PFU/cell). 5 h p.i. cell lysates of the infected-cells were prepared and subjected to the 
EGFR phosphorylation antibody array. Both uninfected and RSV-infected A549 cells had 
detectable ErbB2 phosphorylation at Thr686 and Ser1113 (Figure 29, blue box), which was not 
affected by RSV infection (note that ErbB2 is a member of the EGFR family of receptor tyrosine 
kinases). However, RSV induced the phosphorylation of EGFR Tyr845, which was not observed 
in mock-treated uninfected cells (Figure 29 and Figure 30). Tyr845 also was the only 
phosphorylation site, among the 17 screened sites (see Figure 29B), that showed any detectable 
increase in EGFR phosphorylation induced by RSV infection (Figure 29A, red box). 
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Figure 29: Detection of EGFR phosphorylation using an EGFR phosphorylation antibody array 
(RayBiotech, Inc.) against 17 potential phosphorylation sites of the EGFR family. 
(A) X-ray film exposures of arrays incubated with uninfected (left) versus RSV-infected (right) A549 
cell lysates. Representative image of the EGFR phosphorylation antibody array probed with uninfected or 
RSV-infected (MOI = 5 PFU/cell, harvested for analysis after 5 h incubation) A549 cell lysates are shown. 
Arrays were processed as described in the Materials and Methods, and X-ray films are shown that reveal 
the binding of phosphorylated sites. The red boxes indicate duplicate spots (coordinates F1/2) 
demonstrating phosphorylation of EGFR Tyr845 in response to RSV infection. The blue boxes indicate 
duplicate spots at coordinates E5/6 and F5/6 demonstrating phosphorylation of ErbB2 at Thr686 and 
Ser1113, respectively. (B) Array layout. The layout of the EGFR phospho-specific antibodies and the 
control spots on the array are shown. Each antibody is present in duplicate. In parentheses the 
phosphorylation site of EGFR, Erb2, ErbB3 and ErbB4 is specified. The specificity of the duplicate spots in 
coordinates F1/2 are indicated in red (EGFR Tyr845) and E5/6, F5/6 are indicated in blue (ErbB2 Thr686 
and Ser1113). P1 - P4 are internal positive controls with decreasing intensity. Neg is the internal negative 
control. 
The phosphorylation of EGFR Tyr845 during RSV infection also was examined under 
various conditions (ATP1A1 siRNA knockdown, ouabain or PST2238 treatment, and Src-kinase 
inhibition). Prior to infection, A549 cells were transfected with ATP1A1-specific siRNAs (siRNA 1-
3) or Neg. siRNAs and incubated for 48 h. For the chemical compounds, the cells were pretreated 
with ouabain or PST2238 for 16 h, or with the Src-kinase inhibitors SrcI-I + PP2 for 5 h, as 
described above. The cells were then infected with wt RSV (MOI = 5 PFU/cell) and lysates were 
prepared at 5 h p.i. The lysates were analyzed using the EGFR phosphorylation antibody array to 
quantify the level of EGFR Tyr845 phosphorylation. The arrays were processed as described in 
the Materials and Methods, and the spots were detected and quantified by X-ray films and 
densitometry. The spot intensity of pTyr845 for each treatment was normalized to internal array 
controls and to the total amount of EGFR present in the lysates. Values were reported relative to 
Neg. siRNA 1 (for siRNA-treated samples, Figure 30B) or to mock-treated infected cells (for 
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chemical compound-treated samples, Figure 30C). The level of pTyr845 was found to be 
significantly (p < 0.0001) reduced in cells treated with ATP1A1-specific siRNA, to an average of 
35% (siRNA 1), 22% (siRNA 2), and 33% (siRNA 3) relative to Neg. siRNA 1-transfected RSV-
infected cells (Figure 30B). The phosphorylation of Tyr845 in mock-treated RSV-infected cells 
was similar to Neg. siRNA 1-infected cells. While phosphorylation of Tyr845 was slightly reduced 
for Neg. siRNA 2, the difference was not significant (p = 0.3651) compared to Neg. siRNA 1. A 
significant reduction in Tyr845 phosphorylation also was observed when the cells were treated 
with ouabain, PST2238, or Src-kinase inhibitors (SrcI-I +PP2) prior to infection with RSV (Figure 
30C). The phosphorylation level of Tyr845 in cells that were treated with ouabain and PST2238 
was reduced to 27% and 26%, respectively, compared to mock-treated RSV-infected cells; the 
reduction was similar to that observed for ATP1A1 knockdown. Inhibiting the Src-kinase activity 
(SrcI-I+PP2) reduced the Tyr845 phosphorylation to 12% compared to mock-treated infected cells 
(Figure 30C). 
 
Figure 30: EGFR phosphorylation at Tyr845 during RSV infection. A549 cells were treated as indicated 
(either siRNA knockdown for 48 h, or pre-treatment with the chemical compounds ouabain [25 nM], 
PST2238 [40 µM] or Src Inhibitor-I (SrcI-I, 6.25 µM) and PP2 (12.5 µM) for 5 h pre-inoculation) and serum-
starved for 16 h pre-inoculation, and then the cells were inoculated with wt RSV (MOI = 5 PFU/cell). Cells 
were lysed 5 h p.i. and subjected to analysis with the EGFR phosphorylation antibody array.  
(A) Representative array spots of pTyr845 EGFR and its corresponding pan EGFR for each treatment 
are shown. (B and C) Relative quantification of pTyr845 EGFR. The pTyr845 signals of three 
independent experiments were normalized to internal positive controls and pan EGFR. pTyr845 
phosphorylation was reported relative to Neg. siRNA 1-transfected (B) or mock-treated (C) RSV-infected 
samples assigned the value of 1.0. The statistical significance of differences was determined by one-way 
ANOVA with Dunnett multiple-comparison test and the p-values are indicated for each comparison. 
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In summary, it was shown that RSV-induced phosphorylation of EGFR Tyr845 could be 
reduced either by decreasing ATP1A1 expression or by ATP1A1- or Src-specific inhibitors. This 
suggested that EGFR pTyr845 is ATP1A1-dependent and that c-Src kinase serves as a signaling 
effector to transactivate EGFR by Tyr845 phosphorylation. 
 
3.1.8. Investigation of the RSV uptake mechanism 
As described in the Introduction, EGFR activation can induce different endocytic pathways, 
including clathrin-mediated endocytosis and macropinocytosis [reviewed in (Tomas et al. 2014)]. 
Macropinocytosis is a non-specific fluidic uptake mechanism and was previously described as a 
possible mode of RSV entry (Krzyzaniak et al. 2013). On the other hand, clathrin-mediated 
endocytosis also has been postulated to mediate RSV for entry (Kolokoltsov et al. 2007). Thus, it 
was not clear whether either or both mechanisms are involved in RSV entry. Therefore, the mode 
of RSV uptake in response to ATP1A1-mediated signaling was investigated. 
 
3.1.8.1. Evaluation of the mode of uptake using inhibitors 
To reproduce previously described findings on the mode of RSV uptake, the effects on 
RSV infection of the most commonly used inhibitors for each uptake pathway - chlorpromazine 
for clathrin-mediated endocytosis and EIPA (5-(N-Ethyl-N-isopropyl)amiloride) for 
macropinocytosis - were tested. A549 cells were pre-treated for 5 h with serially-diluted inhibitor 
concentrations and inoculated with RSV-GFP (MOI = 1 PFU/cell) in the continuous presence of 
the inhibitor. RSV infection was evaluated by GFP intensity 17 h p.i., quantified by an ELISA 
reader and reported relative to mock-treated RSV-infected cells (Figure 31, solid lines). The 
cytotoxicity for A549 cells of the various inhibitor concentrations after a 24 h treatment was 
evaluated by the ATP-based viability assay, as described above, and reported relative to mock-
treated cells (Figure 31, dotted lines).  
 
Figure 31: Effects on RSV-GFP expression and cell viability of inhibitors of clathrin-mediated 
endocytosis (chlorpromazine) and macropinocytosis (EIPA) on A549 cells. A549 cells were pre-
treated for 5 h with serially-diluted concentrations of chlorpromazine or EIPA [5-(N-Ethyl-N-isopropyl) 
amiloride] and inoculated with RSV-GFP (MOI = 1 PFU/cell) while the inhibitor was continuously present. 
GFP was quantified by an ELISA reader 17 h p.i. (solid line) and cell viability was evaluated for each 
concentration by the ATP-based viability assay CellTiter-Glo (dotted line). GFP-intensity and luciferase 
activity was reported relative to mock-treated cells assigned the value of 1.0, with error bars indicating the 
SD. The dashed horizontal line reflects 80% viability. 
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Chlorpromazine did not significantly affect GFP expression at any non-cytotoxic 
concentration (Figure 31A). Reduced GFP intensity correlated with reduced viability with 
increasing concentrations of chlorpromazine, suggesting that the observed effects on viral GFP 
expression were likely a result of cytotoxicity rather than due to a specific inhibition of clathrin-
mediated endocytosis. 
The macropinocytosis inhibitor EIPA showed a sigmoid inhibitor response curve (Figure 
31B). The GFP intensity was reduced to 63% compared to mock-treated RSV-infected cells at a 
concentration of 25 µM EIPA that had only minimal effects on the viability (91% viable compared 
to mock-treated cells). However, the nuclear morphology of EIPA-treated cells observed after 
DAPI staining by fluorescence microscopy showed a drastic change (Figure 32). The EIPA-treated 
cells had a diffused DAPI staining across the entire cytoplasm and lacked the distinct nuclear 
staining compared to mock-treated cells, suggesting that the nucleus had lost its integrity and the 
nuclear content was distributed in the cytoplasm. This observation indicated that even an 
apparently non-cytotoxic concentration of EIPA (Figure 31B), based on the ATP-based viability 
assay, might have generalized effects on cell viability that might reduce RSV infection, regardless 
of the mode of entry. 
 
Figure 32: Effect of EIPA treatment on A549 cells. A549 cells were treated for 10 h with EIPA (25 µM), 
fixed with 4% (w/v) PFA and the nuclei were stained with DAPI (blue). The nuclear morphology of EIPA-
treated cells was compared to mock-treated cells. Scale bars, 20 µm. 
Wortmannin, a PI3K inhibitor, also was tested (data not shown) and also showed high 
cytotoxicity on A549 cells and did not have any appreciable effect on RSV infection at non-
cytotoxic concentrations. Due to the high cytotoxicity and the unspecific side effects of the tested 
endocytic pathway inhibitors on A549 cells, it was not feasible to make any conclusions, based 
on these results, on the mode of RSV uptake. 
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3.1.8.2. Characterization of macropinocytosis as possible mode for RSV uptake 
To assess macropinosome formation during RSV infection and the role of ATP1A1 in this 
process, fluorescent dye-conjugated dextran was used as a fluidic uptake marker for 
macropinocytosis that was visualized with fluorescence confocal microscopy. A549 cells were 
infected with wt RSV (MOI = 5 PFU/cell) in the presence of AF568-conjugated dextran (10,000 
MW, dextran-AF568). At 5 h p.i., cells were washed and fixed, nuclei were counterstained with 
DAPI, and the uptake of dextran was analyzed by fluorescence confocal microscopy and 
quantified with the image processing software Imaris. Cells that had been mock-infected, 
contained dextran-positive vesicles that were small, round, and homogeneous in size, with an 
average volume of ~ 0.5 µm3 (Figure 33, top panel) and reflected the basal level of cellular dextran 
uptake. This phenotype changed dramatically with wt RSV infection by 5 h p.i (Figure 33, bottom 
panel). The dextran-positive vesicles were much bigger (average volume of ~5.7 µm3), irregular 
in shape, and reflected the typical morphology of macropinosomes. This suggested that RSV 
infection triggered macropinosome formation in A549 cells.  
 
Figure 33: RSV induces macropinosome formation in respiratory epithelial A549 cells.  A549 cells 
were serum-starved for 16 h and either mock-infected or infected with wt RSV (MOI = 5 PFU/cell) in medium 
containing AF568-conjugated dextran (10,000 MW, Dextran-AF568, cyan). Cells were fixed with 4% (w/v) 
PFA 5 h p.i., nuclei were counterstained with DAPI (blue), and the cells were imaged (z-stacks) on a Leica 
SP5 confocal microscope with a 40x objective (NA 1.3) and 2.0x zoom. Scale bars, 10 µm. 
Additional A549 cells were infected with RSV in the presence of dextran-AF568 and fixed 
5 h p.i. The fixed cells were subjected to an immunofluorescence staining for ATP1A1 (green) and 
RSV N (marker of RSV virions; red), and visualized by fluorescence confocal microscopy (Figure 
34A). As noted earlier, 5 h p.i. is very early in RSV infection and the detected RSV N protein would 
be mostly derived from the inoculum, as was confirmed earlier with UV-inactivated virus (Figure 
18). Clusters of ATP1A1 were observed co-localized with RSV N protein in dextran-positive 
macropinosomes (cyan) (Figure 34A, indicated by arrows), suggesting that RSV was taken up by 
macropinocytosis. Co-staining for RSV F and N also was performed and showed that both 
proteins were co-localized in the dextran-positive macropinosomes (Figure 34B, indicated by 
Results  77 
arrows). The co-localization of RSV F and N suggested that the RSV-specific staining, detected 
in the macropinosomes, reflected enveloped RSV virions, suggesting that fusion and release of 
nucleocapsid presumably occurred subsequently in these internalized vesicles rather than at the 
plasma membrane. 
 
Figure 34: Co-localization of RSV virions and ATP1A1 in macropinosomes during RSV uptake.  
(A) Co-localization of ATP1A1 (green) RSV N (red) and dextran-AF568 (cyan) in RSV-infected (MOI = 
5 PFU/cell) A549 cells at 5 h p.i. Cells were infected as described for Figure 33 and fixed with 4% (w/v) 
PFA 5 h p.i. Fixed cells were permeabilized with 0.1 % (v/v) Triton X-100 and subjected to 
immunofluorescence staining with an anti-ATP1A1 rabbit MAb (ab76020) and an anti-RSV N mouse MAb 
(ab94806), followed by AF488-conjugated goat anti-rabbit and AF647-conjugated goat anti-mouse 
secondary antibodies. Images (z-stacks) were acquired on a Leica SP8 confocal microscope with 63x 
objective (NA 1.4) and 3.0x zoom. Arrows indicate examples of co-localization of ATP1A1 and RSV N in 
dextran-AF568-positive vesicles. (B) Co-localization of RSV F (green) and RSV N (red) with dextran-
AF568 (cyan) in RSV-infected (MOI = 5 PFU/cell) A549 cells at 5 h p.i. Cells were stained as described 
above for part A. RSV F was detected with an AF488-conjugated anti-RSV F MAb (#1129). RSV N was 
detected with an allophycocyanin (APC)-conjugated anti-RSV N MAb (Novus Biologicals, LLC). Image 
acquisition and analysis were performed as described for part A. Arrows indicate examples of co-localization 
of RSV F and RSV N in dextran-AF568-positive vesicles. All scale bars, 10 µm. 
To examine the role of ATP1A1 in this putative uptake mechanism, ATP1A1 protein 
expression was knocked down by an ATP1A1-specific siRNA (siRNA 2 was used, since it showed 
the strongest effect in all other assays) or the cells were pre-treated with the ATP1A1-binding 
compounds ouabain or PST2238. The treated cells were infected with wt RSV in the presence of 
dextran-AF568, as described above. Macropinosome formation was quantified by fluorescence 
confocal microscopy. Multiple random z-stack images were acquired and the total amount of 
dextran uptake was quantified. Dextran-positive vesicles were identified by Imaris imaging 
software, and the total fluorescence intensity of dextran-AF568-containing vesicles was quantified. 
Vesicles smaller than 1.0 µm3 were excluded to omit the basal level of dextran uptake (as shown 
in Figure 33, top panel) and to focus on the large vesicles that were induced by RSV and are 
typical for macropinosomes. The total intensity of dextran-AF568 within vesicles larger than 1.0 
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µm3 was determined per field, normalized to the number of DAPI-stained nuclei, and expressed 
relative to Neg. siRNA 1-transfected or mock-treated cells (Figure 35). This showed that dextran 
uptake was increased 4-fold in RSV-infected cells as compared to uninfected cells, both of which 
had been both transfected with Neg. siRNA 1 (Figure 35A), confirming the visual observation of 
an increased dextran-AF568 uptake in response to RSV infection (Figure 33). On the other hand, 
knockdown of ATP1A1 in RSV-infected cells caused a significant (p = 0.0003) reduction of 33% 
compared to Neg. siRNA 1 (Figure 35A). Ouabain and PST2238 caused an even greater 
reduction in macropinosomes in RSV-infected cells to less than 50% compared to mock-treated 
RSV-infected cells (Figure 35B). These results suggested that macropinocytosis is induced by 
RSV, and that it involves ATP1A1 and is responsible for virion uptake. 
 
Figure 35: Relative quantification of dextran-AF568 uptake during RSV infection. (A) ATP1A1 siRNA 
knock down. A549 cells were transfected with ATP1A1 siRNA 2 or Neg. siRNA 1 and 48 h p.t. the cells 
were inoculated with wt RSV (MOI = 5 PFU/cell) in dextran-AF568 containing medium, and 5 h p.i. were 
analyzed as described below. (B) ATP1A1-binding compounds. A549 cells were pre-treated with ouabain 
or PST2238 for 16 h, inoculated with wt RSV (MOI = 5 PFU/cell) in dextran-AF568 containing medium, and 
5 h p.i. were analyzed as described below. (C) Role of RSV G. Untreated A549 cells were infected with wt 
RSV or RSV dSH/dG (MOI = 5 PFU/cell) in dextran-AF568 containing medium, and 5 h p.i. were analyzed 
as described below. 
For all treatments (A-C) cells were fixed 5 h p.i. and counterstained with DAPI, and multiple random z-
stacks were acquired on a Leica SP8 confocal microscope with 63x objective (NA 1.4) and 1.0x zoom. For 
each treatment, the uptake of dextran-AF568 in vesicles greater than 1.0 µm3 was quantified as described 
in detail in the Materials and Methods. Mean values were reported relative to RSV-infected cells transfected 
with Neg. siRNA 1 (A), mock-treated RSV-infected cells (B), or wt RSV-infected cells (C). Error bars indicate 
the SD of at least three independent experiments. The statistical significance of differences was determined 
for (A) and (B) by one-way ANOVA with Tukey’s multiple comparison post-test and for (C) by two-tailed 
unpaired t-test. P-values are shown for each comparison. 
Since RSV G was found to be important for triggering ATP1A1 activation, as observed by 
the loss of clustering with the dSH/dG mutant (Figure 20), the role of G in the induction of 
macropinocytosis also was evaluated. If RSV G protein plays a role in activating the ATP1A1-Src-
EGFR pathway culminating in RSV uptake by macropinocytosis, an RSV mutant lacking G should 
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be inefficient in activating macropinocytosis. To examine this, macropinosome formation was 
quantified, as described above for Figure 35A and B, in A549 cells infected with wt RSV or the 
dSH/dG RSV mutant. This showed that macropinosome formation indeed was significantly (p = 
0.0039) reduced for the dSH/dG virus as compared to wt RSV (Figure 35C), consistent with a role 
of the G protein in activating the pathway leading to macropinocytosis. 
 
3.1.9. Effects of cholesterol depletion on RSV infection 
As described in the Introduction, ATP1A1-Src-EGFR signaling characteristically is 
associated with caveolae. The structural integrity of caveolae depends on the presence of 
cholesterol, and its depletion with a cholesterol-sequestering drug, such as methyl-beta-
cyclodextrin (MBCD), disrupts caveolae at the plasma membrane (Rothberg et al. 1992, 
Hailstones et al. 1998). Therefore, the effects of cholesterol depletion on RSV infection were 
evaluated. Cholesterol was depleted in A549 cells prior to infection by treatment with MBCD and 
Mevinolin, individually or in combination, at non-cytotoxic concentrations (Figure 39). MBCD 
removes cholesterol from the plasma membrane whereas Mevinolin inhibits its biosynthesis. First, 
cholesterol-depleted A549 cells were infected with RSV-GFP (MOI = 1 PFU/cell) and GFP 
expression was quantified 17 h p.i. by an ELISA reader (Figure 36A). 
 
Figure 36: Effects of cholesterol depletion on RSV infection. A549 cells were cholesterol depleted by 
treatment with methyl-beta-cyclodextrin (MBCD) and Mevinolin in combination or separately. (A) GFP 
expression by RSV-GFP in cholesterol-depleted A549 cells. A549 cells were pre-treated for 5 h with the 
indicated cholesterol-depleting compounds and infected with RSV-GFP (MOI = 1 PFU/cell) while the 
cholesterol-depleting compounds were present. Viral GFP expression was quantified 17 h p.i. by an ELISA 
reader and reported relative to mock-treated infected cells assigned the value of 1.0. (B) Quantification of 
macropinosome formation in cholesterol-depleted RSV-infected A549 cells. A549 cells were pre-
treated with the indicated cholesterol-depleting compounds for 16 h and infected with RSV (MOI = 5 
PFU/cell) in the presence of AF568-conjugated dextran (Dextran-AF568). 5 h p.i the cells were fixed with 
4% (w/v) PFA and nuclei were counterstained with DAPI. The total intensity of dextran-AF568 in vesicles 
larger than 1.0 µm3 was quantified, as described in detail in Materials and Methods, and reported relative 
to mock-treated infected cells assigned the value of 1.0. The statistical significance of differences was 
determined by one-way ANOVA with Tukey’s multiple-comparison post-test and p-values are shown for 
each comparison. (C) EGFR Tyr845 phosphorylation in cholesterol-depleted cells. A549 cells were pre-
treated with MBCD + Mevinolin for 16 h and infected with wt RSV (MOI = 5 PFU/cell). The phosphorylation 
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of EGFR Tyr845 was quantified by an EGFR phosphorylation antibody array, as described in the Materials 
and Methods. The level of pTyr845 was reported relative to mock-treated infected cells. The statistical 
significance of difference was determined by a two-tailed unpaired t-test. 
With each of the cholesterol-depleting compounds, alone or in combination, GFP 
expression was reduced to approximately 50 - 60% compared to mock-treated RSV-infected cells. 
Next, the level of RSV-induced macropinocytosis in cholesterol-depleted cells was quantified by 
dextran-AF568 uptake, as described above. Macropinosome formation was reduced by each of 
the cholesterol-depletion treatments, with the most significant (p < 0.0001) reduction of 59% 
observed for the combined MBCD-Mevinolin treatment (Figure 36B). The phosphorylation of 
EGFR Tyr845 also was determined in RSV-infected cells pre-treated with MBCD + Mevinolin. A 
modest but significant (two tailed t-test, p = 0.0163) reduction in pTyr845 was observed (Figure 
36C). These results showed that cholesterol depletion results in reduced EGFR transactivation, 
reduced macropinocytosis, and reduced RSV infection, consistent with caveolae as the site of 
ATP1A1 signaling. 
 
3.1.10. Confirmation of the role of ATP1A1 in RSV infection using primary human small airway 
epithelial cells (HSAEC). 
All experiments described above were performed with the human airway epithelial A549 
cell line, which is generally considered to be the most relevant cell line available for studies 
involving respiratory viruses. In order to confirm that the described findings derived from A549 
cells truly represented a pathway for RSV entry in human airway epithelial cells, some of the major 
findings were recapitulated using commercially-obtained (ATCC) primary HSAEC from a 16-year 
old healthy male donor (Figure 37).  
 
Figure 37: Confirmation of the results obtained in the A549 cell line by experiments in primary 
HSAEC. Experiments were performed as described for A549 cells in the Materials and Methods and 
preceding figure legends. (A) ATP1A1 siRNA knockdown. HSAEC were transfected with ATP1A1-specific 
siRNAs (siRNA 1 - 3) or Neg. siRNAs, and analyzed 48 h p.t. by Western blot analysis as in Figure 14.  
(B) RSV infection assay. Efficiency of RSV infection in HSAEC cells following knockdown of ATP1A1 
expression using the indicated siRNAs. Viral GFP expression was quantified by an ELISA reader, as in 
Figure 15A. (C) EGFR Tyr845 phosphorylation. HSAEC were transfected with ATP1A1-specific siRNA 
(siRNA 2), and EGFR Tyr845 phosphorylation was quantified as in Figure 30. 
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It was possible to knock down ATP1A1 protein expression in HSAEC, by transfection with 
individual ATP1A1 siRNAs, to 25 – 30% compared to Neg. siRNA 1 (Figure 37A), which was 
slightly more than the reduction obtained in A549 cells (35 - 39%; Figure 14). Following the same 
assay protocols as used for A549 cells, the results in HSAEC showed that (i) knockdown of 
ATP1A1 expression reduced RSV-GFP expression to 29 - 42 % relative to the control Neg. siRNA 
1 (Figure 37B), similar to what was observed with A549 cells (Figure 15A). (ii) RSV-induced 
phosphorylation of EGFR Tyr845 was significantly (p = 0.0038) reduced in HSAEC that were 
transfected with ATP1A1-specific siRNA (siRNA 2) prior to RSV infection (Figure 37C), similar to 
what was seen in A549 cells (Figure 30). (iii) The inhibitory effects of ouabain and PST2238 on 
the expression of RSV-GFP were even stronger in HSAEC than in A549 cells, as already shown 
in Figure 25 and Table 20. (iv) The RSV-induced ATP1A1 clustering and colocalization of ATP1A1 
and RSV N also was observed in HSAEC (Figure 38), similar to A549 cells (Figure 17). Thus, the 
experiments performed in primary HSAEC cells confirmed the results obtained in the A549 cell 
line. 
 
Figure 38: Confirmation of RSV-induced ATP1A1 clustering in primary HSAEC. HSAEC were 
inoculated with wt RSV (MOI = 5 PFU/cell), as described for A549 cells (Figure 17), and incubated for 5 h. 
Cells were fixed with 4% (w/v) PFA, permeabilized with 0.1 % (v/v) Triton X-100 and stained for ATP1A1 
(green) with an anti-ATP1A1 rabbit MAb (ab76020) and AF488-conjugated donkey anti-rabbit secondary 
antibody. RSV N (red) was detected by an anti-RSV N mouse MAb (ab94806) and an AF594-conjugated 
anti-mouse secondary antibody. The cell nuclei were stained with DAPI (blue). Images (z-stacks) were 
acquired on a Leica SP5 confocal microscope, with a 63x objective (NA 1.4) and a zoom of 3.0. Arrows 
indicate examples of co-localization of ATP1A1 and RSV N. Scale bars, 10 µm. 
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3.1.11. Cytotoxicity assay of chemical compounds on A549 cells 
The chemical compounds used in this study were evaluated in dilution series on A549 
cells (data not shown) and non-cytotoxic working concentrations were determined. The working 
concentration of each compound had to affect the cell viability less than 20% as compared to 
mock-treated cells in order to be used. A549 cells were treated with the selected working 
concentrations for 24 h and viability was determined by the ATP-based viability assay CellTiter-
Glo (Figure 39).  
 
Figure 39: Cytotoxicity of chemical compounds on A549 cells. A549 cells were treated for 24 h with 
each compound at the highest concentrations used in this study. Cell viability was determined in triplicates 
for each compound by the ATP-based viability assay CellTiter-Glo and was reported relative to mock-
treated cells assigned the value of 1.0, with error bars indicating the SD. 
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3.2. Development and pre-clinical evaluation of a live-attenuated mucosal HPIV1-
vectored vaccine against EBOV 
Recombinant HPIV1 vectors, bearing the attenuating CΔ170 mutation, expressing EBOV 
GP were generated by reverse genetics, as described in section 2.2.6 of the Materials and 
Methods. The EBOV GP ORF was modified by the insertion of an additional A residue (mRNA-
sense) at the gene editing site to obtain translation of full-length membrane-anchored EBOV GP. 
The ORF also was codon-optimized for human expression by GenScript. With the goal to enhance 
EBOV GP incorporation into the rHPIV1 vector particle, the TMCT domain of EBOV GP was 
substituted with that of HPIV1 F protein as shown in Figure 12C. The ORF encoding GP or GP-
TMCT was inserted either at the pre-N (Figure 12A) or between the N-P position (Figure 12B) of 
the HPIV1-CΔ170 genome as an additional gene under the control of HPIV1 GS and GE 
transcription signals. All constructs were successfully recovered. After an additional single 
passage on LLC-MK2 cells to obtain working pools, the viral genome consensus sequences were 
determined by automated Sanger sequencing of uncloned RT-PCR products, and were found to 
be free of adventitious mutations.  
The viruses were named based on the position and form of EBOV GP that was expressed. 
The rHPIV1-CΔ170 vectors expressing full-length EBOV GP from the first (pre-N) or second (N-P) 
position of their genome were named GP1 and GP2, respectively. The vectors expressing the 
chimeric form of EBOV GP containing the HPIV1 F TMCT from the first or second position of the 
HPIV1 genome were called GP-TMCT1 and GP-TMCT2, respectively. 
 
3.2.1. Characterization of the HPIV1-vectored EBOV vaccine candidates in vitro 
3.2.1.1. Multi-cycle growth kinetics 
The ability of vaccine candidates to efficiently replicate in vitro, critical for vaccine 
manufacture, was assessed by determining their multistep growth kinetics on Vero cells (Figure 
40). Wt HPIV1 and rHPIV1-C∆170 were included as the parental references. The growth kinetics of 
the viruses were similar with peak titers between 6.5 log10TCID50/ml (GP-TMCT1) and 8.0 
log10TCID50/ml (rHPIV1-C∆170) and none of the viruses showed a substantial attenuated phenotype 
in Vero cells. The GP1 virus with full-length EBOV GP in the pre-N position was significantly (p < 
0.0001) slower on day 2, with more than 1.0 log10TCID50/ml lower titer than the other viruses, but 
reached peak titer similar to rHPIV1-C∆170 on day 3. The lowest peak titer was observed for GP-
TMCT1, but this was only slightly lower than the other viruses. 
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Figure 40: Multistep growth kinetics of rHPIV1 expressing EBOV GP in Vero cells. Vero cells were 
infected in triplicate with an MOI of 0.01 TCID50/cell with each indicated HPIV1-C∆170 virus expressing EBOV 
GP or GP-TMCT. The cells were incubated at 32°C and aliquots of culture supernatant were collected at 
24 h intervals over 6 days. Virus titers were determined by limiting dilution on LLC-MK2 cells using an 
hemadsorption assay. Titers are reported as log10TCID50 per ml. Mean titers are shown with the SD as 
vertical error bars. The statistical significance of differences between EBOV GP viruses (GP1, GP-TMCT1, 
GP2, GP-TMCT2) and the rHPIV1-C∆170 empty backbone was determined by two-way ANOVA with Tukey’s 
multiple-comparisons post-test and is shown in the table beside the graph. The limit of detection (1.2 
log10TCID50/ml) is marked as a horizontal dotted line in the graph. 
 
3.2.1.2. Stability of EBOV GP expression by the HPIV1 vectors 
To examine the plaque phenotype and stability of EBOV GP expression, a double- 
immunostaining plaque assay was performed. Primary antibodies specific to EBOV GP and 
HPIV1 proteins, with corresponding secondary antibodies conjugated to different fluorochromes, 
were used as described in the Methods (2.2.12). The stained plaques were pseudo-colored to 
appear red and green for HPIV1 and EBOV GP, respectively. HPIV1 plaques expressing EBOV 
GP appeared yellow and those not expressing EBOV GP would be red. This allowed evaluation 
of the percentage of infectious HPIV1 particles that expressed GP. For all viruses, no plaques 
were detected that did not express GP (Figure 41A), suggesting approximately 100% expression. 
The pre-N viruses (GP1 and GP-TMCT1) had an overall reduced plaque size as compared to N-
P viruses (GP2 and GP-TMCT2), suggesting that GP insertion in the promoter-proximal position 
reduced virus replication and/or spread. The plaque size was further reduced for the GP-TMCT 
versions as compared to their full-length GP counterparts (Figure 41A), suggesting an attenuating 
effect of TMCT. 
Due to the micro-plaque phenotype of the TMCT viruses, it was difficult to accurately 
determine the stability of GP expression for these viruses by the dual-stained plaque assay. 
Therefore, a flow cytometry-based assay was performed. Vero cells were infected with the various 
vectors at an MOI of 5 TCID50/cell and incubated at 32˚C for 24 h. The cells were stained for 
HPIV1 F and EBOV GP protein and analyzed by flow cytometry. For all constructs, >99% of HPIV1 
F+ cells (~15,000 cells analyzed for each construct) also expressed EBOV GP (Figure 41B). Thus, 
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the plaque assay and flow cytometric analysis showed that essentially all viruses maintained 
stable expression of EBOV GP or GP-TMCT during in vitro replication. 
 
Figure 41: Stability of EBOV GP expression by HPIV1 vectors. (A) Double-immunostaining plaque 
assay. Vero cells were inoculated with a 10-fold serial dilution of each virus in duplicate and infected 
monolayers were incubated for 6 days under 0.8% (w/v) methylcellulose overlay medium. Immunostaining 
was performed with anti-EBOV GP mouse MAb and goat anti-HPIV1 polyclonal antibodies. Different IRDye-
conjugated antibodies (donkey anti-mouse IRDye 800CW and donkey anti-goat IRDye 680LT) were used 
for detecting and differentiating EBOV GP- and HPIV1- positive plaques. Plaque images were acquired with 
Odyssey infrared imaging system and the percent of plaques expressing EBOV GP was determined. The 
IRDyes were pseudo-colored to appear red and green for HPIV1 and EBOV GP, respectively. On merging 
the colors, the plaques co-expressing GP and HPIV1 antigens would appear yellow and those not 
expressing GP would be red. Representative monolayers with various dilutions of virus are shown as 
examples. (B) Double-immunostaining flow cytometry assay. Vero cells infected with the indicated 
vectors were stained with anti-HPIV1 F and anti-EBOV GP (KZ52) MAbs and corresponding AF-conjugated 
secondary antibodies, as described in the Methods and analyzed on BD FACS Canto II flow cytometer. An 
example of EBOV GP staining of HPIV1 F+, single, live cells is shown as a pair of scatter plots and the 
stability of EBOV GP expression (percentage of EBOV GP+ cells in HPIV1 F+ population) for all vectors is 
shown as a Table. 
 
3.2.1.3. EBOV GP: Expression in infected cell lysates and incorporation into virions 
To visualize and quantify the expression of EBOV GP and HPIV1 vector proteins in 
infected cells, Vero cells were infected with the various vectors at an MOI of 3.0 TCID50/cell and 
subjected to Western blot analysis at 48 h p.i. (Figure 42A). Full-length GP (also called GP0) and 
the larger cleaved subunit GP1 were detected with an MAb specific to both proteins; in the Western 
blot of cell-associated protein in Figure 42A, these two species appear as an unresolved GP0 / 
GP1 smear (top panel), which is likely due to the glycosylation of the GP protein. GP2 was not 
detected by this MAb. All of the constructs, with or without the TMCT modification, expressed a 
considerable amount of this cell-associated GP0 / GP1 protein. 
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The HPIV1 genome is a single-stranded negative-sense RNA and has a gradient of gene 
expression, with the greatest expression for 3’ proximal genes as compared to the downstream 
genes. Thus, a gene inserted closer to the 3’ end would be expected to express more protein than 
from a downstream location. However, such a gradient effect was not apparent for the GP and 
GP-TMCT proteins, which were expressed at similar levels for the pre-N and N-P constructs 
(Figure 42A, top panel). In contrast, expression of the vector genes exhibited a gradient effect. All 
viruses bearing a GP or GP-TMCT insert had reduced expression of downstream vector proteins 
as compared to wt HPIV1 and HPIV1-C∆170 empty vector (Figure 42A, 2nd, 3rd, 4th, and 5th panels 
from the top). This reduction was greater for the pre-N as compared to the N-P viruses and a 
further reduction in expression was seen with GP-TMCT versions as compared to their respective 
full-length GP constructs. The reduction due to the TMCT swap was likely not an effect of the 
transcriptional gradient, since the number of genes was not affected. Thus, the insert position (i.e. 
pre-N position compared to N-P) appeared to have little or no effect on EBOV GP or GP-TMCT 
expression, but did reduce vector protein expression. 
The goal of making EBOV GP-TMCT versions (expressed by the GP-TMCT1 and GP-
TMCT2 vectors) was to increase the packaging of GP into the vector virion by making the TMCT 
domain of GP HPIV1-specific and therefore compatible with the HPIV1 virion proteins that are 
involved in virion morphogenesis. To assess packaging of EBOV GP into the vector particles, 
each virus was propagated in LLC-MK2 cells for 7 days and sucrose gradient-purified as 
described in section 2.2.8 of the Materials and Methods. The resulting partially-purified virus 
preparations were lysed, and 1 µg of total virion protein was analyzed by Western blotting. 
Full-length GP0 / GP1 protein (without the TMCT modification) appeared to be incorporated 
in substantial amounts into the HPIV1 virions when expressed from the pre-N position (GP1 vector, 
Figure 42B, top panel, and C), but it was unclear whether this could be increased. Surprisingly, 
the TMCT modification did not appear to further enhance GP incorporation (vectors GP1 vs. GP-
TMCT1). Unexpectedly, the efficiency of GP packaging was substantially reduced when 
expressed from the N-P position, and surprisingly this was not increased by the TMCT 
modification. The amount of GP packaged for the pre-N viruses (GP1, GP-TMCT1) was on 
average 6.3-fold higher than that of N-P viruses (GP2, GP-TMCT2) (Figure 42C). This was 
calculated relative to the HPIV1 P protein (Figure 42B, 3rd panel from the top), whose efficiency 
of packaging was expected to remain unchanged among the various GP-expressing constructs. 
Expression of the GP and GP-TMCT proteins had effects on the incorporation of vector 
proteins into the vector virion, as compared to wt HPIV1 and the empty vector rHPIV1- C∆170. 
Viruses expressing GP showed dramatic reductions in the incorporation of vector HN (Figure 42B, 
4th panel from the top). In addition, for the N-P viruses (GP2, GP-TMCT2) the level of HPIV1 F 
incorporation was substantially lower (Figure 42B, 5th panel from the top). Another interesting 
observation was that, for the N-P viruses (GP2, GP-TMCT2) that had less GP incorporation, most 
of the HPIV1 F in the virions was in the cleaved form (F1) with very little F0. In contrast, the pre-N 
viruses (GP1, GP-TMCT1), that had considerably higher GP incorporation, had more uncleaved 
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HPIV1 F0 protein in the virions. This may suggest that the higher level of EBOV GP processing 
and incorporation due to its greater abundance may result in reduced cleavage of the vector F 
protein. Wt HPIV1 and HPIV1- C∆170 also had a substantial amount of F0 in the particles: these 
vectors expressed an overall higher amount of all vector proteins including F, and thus the higher 
F0 could be due the overall higher amount of F. 
 
Figure 42: Western blot analysis of infected cell lysates and sucrose gradient purified virions.  
(A) Cell lysates: Vero cells were infected with an MOI of 3.0 TCID50/cell with the indicated viruses and 
incubated for 48 h, after which cells were lysed in 1x LDS buffer, denatured and reduced, and analyzed by 
Western blotting. EBOV GP was detected with an anti-GP mouse MAb (4F3) and IRDye 680RD-conjugated 
donkey anti-mouse secondary antibody. Individual HPIV1 proteins were detected with rabbit polyclonal 
hyperimmune sera raised individually against peptides derived from HPIV1 N, P, F, and HN proteins, as 
previously described (Mackow et al. 2015), and an IRDye 800CW-conjugated donkey anti-rabbit secondary 
antibody. Tubulin was detected on all blots, as a loading control, using an anti-tubulin mouse MAb and 
IRDye 680RD-conjugated goat anti-mouse secondary antibody. A representative set of blots is shown: each 
panel is from a different Western blot with the antibody specificity and identified proteins indicated to the 
right of Part B (B) Sucrose gradient-purified virus particles: LLC-MK2 cells were infected at an MOI of 
0.1 TCID50 per cell with the indicated viruses and incubated for 6 days. Virus particles were purified by 
sucrose step gradient centrifugation. For each virus, 1.0 µg of total protein, measured by BCA assay, was 
analyzed by Western blotting using the same antibodies as described for part A. (C) Relative 
quantification of EBOV GP incorporation into HPIV1 virions. EBOV GP signals were quantified (Image 
Studio) for three independent experiments as in Part B, top panel, and normalized to HPIV1 P, which was 
detected simultaneously on each blot. Quantification is shown relative to EBOV GP packaged in GP1 
particles assigned the value of 1.0. The statistical significance of differences in the amount of virion-
packaged GP was determined by one-way ANOVA with Tukey’s multiple-comparisons post-test and p-
values are shown for each comparison. 
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The antiserum that was used to detect the HPIV1 F protein (Figure 42A and B, 5th panel 
from the top) had been raised against a synthetic peptide (YTLESRMRNPYMGNNSN) 
representing the C-terminus of the HPIV1 F protein. Therefore, in addition to detecting HPIV1 F0 
and F1, this antiserum also recognized the forms of GP0 and GP2 that contained the TMCT 
modification (Figure 42A and B, 5th panel from the top, EBOV GP0 TMCT and EBOV GP2 TMCT). 
This confirmed that GP containing the HPIV1 F TMCT domain was expressed and incorporated 
in the virions. In the blot of intracellular protein shown in Figure 42A, this antiserum detected a 
large amount of GP0-TMCT protein for the GP-TMCT1 virus, and an even larger amount for the 
GP-TMCT2 virus, as well as a large amount of the GP2 band that was similar in abundance for 
both viruses. In the blot of purified viruses in Figure 42B, a trace of the GP0-TMCT smear was 
detected for the GP-TMCT1 virus but not the GP-TMCT2 virus, and a large amount of the GP2-
TMCT band was observed for both viruses. Thus, for the GP-TMCT1 virions, both the GP0 / GP1 
smear (top panel) and the GP2-TMCT band (5th panel) were very abundant, whereas for the GP-
TMCT2 virions, the GP0 / GP1 smear was much less abundant, but the GP2-TMCT band was 
similar in abundance (Figure 42B). 
The amount of incorporated GP2-TMCT appeared to be similar for the  viruses GP-TMCT1 
and GP-TMCT2 (Figure 42B, 5th panel from the top) despite a much higher amount of incorporated 
GP0-TMCT/GP1-TMCT protein for GP-TMCT1 versus GP-TMCT2, as detected with the GP0 / GP1-
specific MAb (Figure 42, top panel). This suggests that the GP-TMCT1 virus particles contained 
a higher proportion of uncleaved full-length GP0-TMCT versus GP1-TMCT compared to the GP-
TMCT2 virus. Therefore, the GP2-TMCT protein detected by the HPIV1 F antiserum, does not 
fully reflect the total amount of incorporated GP in the particles. This GP2-TMCT fragment also 
was detected in the infected cell lysates for GP-TMCT viruses (Figure 42A, 5th panel from the top). 
 
3.2.2. Evaluation of the HPIV1-vectored EBOV vaccine candidates in AGMs 
Replication and immunogenicity of the HPIV1-C∆170 vectors expressing EBOV GP or GP-
TMCT were evaluated in AGMs (Cercopithecus aethiops). Four animals per group were infected 
intranasally and intratracheally with 106 TCID50 of virus per site. As a reference, two animals were 
infected with wt HPIV1 to determine the level of attenuation of the vaccine candidates resulting 
from C∆170 mutation and EBOV GP insertion. Two additional animals were infected with the 
previously developed rHPIV3/EboGP, consisting of wt rHPIV3 that expresses full-length EBOV 
GP from the third gene position (P-M) (Bukreyev et al. 2006). Four weeks after the initial 
inoculation, two animals per group were boosted by reinfection with the same virus, using the 
same routes and dose as the first inoculation. 
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3.2.2.1. Virus shedding in the upper and lower respiratory tract 
Nasopharyngeal swabs (NP) of the upper respiratory tract (URT) and tracheal lavage (TL) 
samples of the lower respiratory tract (LRT) were collected daily and every other day, respectively, 
for 14 d following initial- and boost- inoculation. Virus shedding was quantified by determining the 
virus titers of the samples by hemadsorption assay (described in section 2.2.11) and were 
reported as log10TCID50/ml (Figure 43).  
 
Figure 43: Replication of rHPIV1 expressing EBOV GP in AGMs. Groups of four animals were inoculated 
with the indicated HPIV1-C∆170 viruses expressing EBOV GP or GP-TMCT via the intranasal and 
intratracheal routes with 106 TCID50 in 1 mL at each site. Two animals were inoculated in the same way 
with wt HPIV1, and another two with HPIV3/EboGP. Nasopharyngeal swabs (NP) (A) were collected daily 
and tracheal lavages (TL) (B) were performed every other day over two weeks post inoculation (p.i.). Virus 
titers were determined by limiting dilution on LLC-MK2 cells and hemadsorption. The average titers are 
shown as log10 TCID50/ml with the standard error of mean indicated by error bars. Note: values indicate 
virus titers after first dose; replication of the booster dose could not be detected and is not shown. 
All four HPIV1-C∆170 EBOV GP constructs (GP1, GP-TMCT1, GP2 and GP-TMCT2) were 
attenuated in the URT (NP samples) and grew to a peak titer of approximately 3 log10TCID50/ml 
as compared to wt HPIV1, which grew to a titer of 5 log10TCID50/ml (Figure 43A). Virus constructs 
with GP or GP-TMCT in the N-P position (GP2 and GP-TMCT2) appeared to replicate faster in 
the URT as compared to those in the pre-N position (GP1 and GP-TMCT1). Specifically, the N-P 
viruses were recovered at higher titers during days 1 - 3 p.i.; by day 4 p.i. the pre-N and N-P 
viruses reached similar titers; and thereafter the titers of the pre-N viruses generally were higher. 
In the LRT (TL samples), there was little evidence of attenuation of the HPIV1-based GP and GP-
TMCT constructs compared to wt HPIV1, and all of these constructs reached peak titers of 
approximately 4 log10TCID50/ml on day 6 p.i. (Figure 43B). The replication of the N-P constructs 
in the LRT was more efficient during the first few days after infection, similar to what was observed 
in the URT. rHPIV3/EboGP replicated to significantly higher titers than the HPIV1-based vectors, 
reaching a peak titer of 6.0 and 7.0 log10TCID50/ml in URT (NP samples) and LRT (TL samples), 
respectively. The greater replication of rHPIV3/EboGP presumably reflects its wt HPIV3 backbone 
90   Results 
compared to the attenuated HPIV1-C∆170 backbone. In addition, it has been previously reported 
that AGMs are more permissive to HPIV3 than to HPIV1 replication and therefore result in 10- to 
30-fold higher wt HPIV3 titers than for wt HPIV1 (Durbin et al. 2000). 
NP and TL samples also were collected after inoculation of the booster dose, as described 
for the first infection. Replication of the booster dose was undetectable by a limiting dilution assay 
in LLC-MK2 cells with hemadsorption (limit of detection ≤ 1.2 log10TCID50 /ml) of the NP and TL 
samples of all animals (data not shown), indicating a substantial restriction of replication and 
shedding due to the pre-existing immune status resulting from the first inoculation. 
 
3.2.2.2. Immunogenicity 
3.2.2.2.1. Analysis of EBOV GP-specific serum IgG by ELISA 
For the evaluation of the EBOV-specific serum antibody response, serum samples were 
collected weekly from the immunized AGMs described in the section above. Sera were collected 
on days 28, 35, and 56 p.i. and were subjected to an EBOV GP-specific IgG ELISA (Figure 44). 
 
 
Figure 44: EBOV GP-specific serum IgG titer. Sera of the immunized AGMs were collected on days 28 
(immediately before a second boosting inoculation), 35 (7 d post-boost) and 56 (28 d post-boost) after the 
first immunization were analyzed by an EBOV GP capture ELISA specific for IgG (Alpha Diagnostic 
International, Inc.). Titers for individual animals are shown by symbols. Open circles indicate animals that 
did not receive the booster dose on day 28. Horizontal bars indicate the mean titer and error bars show the 
SD for samples on day 28 p.i. Values are reported as reciprocal titer of OD450=1.0. 
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For sera collected at day 28 (immediately before the booster administration), modest titers 
of EBOV GP-specific IgG were detected for all the HPIV1-based constructs, compared to high 
titers with the non-attenuated rHPIV3/EboGP construct. However, animals immunized with 
HPIV1-based constructs that received a booster dose had a 10-fold increase in antibody titers at 
day 35 (7 days post boost), reaching levels similar to those of rHPIV3/EboGP. No detectable 
difference was observed between the GP1 and GP-TMCT1 titers, and the titers did not increase 
further by the end of the study at day 56. AGMs immunized with GP2 or GP-TMCT2 showed only 
a modest increase in titer at day 35 and only that of GP-TMCT2 showed a slight increase between 
day 35 and 56. In contrast, rHPIV3/EboGP induced high IgG titers after the first dose at 28 days, 
with the booster inducing only a minimal increase at 7 and 28 days post-boost. 
Overall, the ELISA results (Figure 44) indicate that two doses of attenuated rHPIV1 vectors 
expressing GP, particularly GP1 and GP-TMCT1, are able to elicit EBOV GP-specific IgG titers 
similar to those of an non-attenuated candidate (rHPIV3/EboGP) as early as 7 days post boost. 
 
3.2.2.2.2. Evaluation of the EBOV-neutralizing serum antibody response 
A neutralization assay was developed to evaluate the ability of serum antibodies from the 
AGM study to bind and neutralize viruses bearing EBOV GP. The same sera that had been 
analyzed by ELISA (Figure 44) were evaluated with this assay. To develop an EBOV 
neutralization assay that does not require a biosafety level (BSL)-4 facility, an EBOV-pseudotyped 
HPIV3 virus (called rHPIV3/NotI ∆F-HN/EboGP) was constructed in which the two HPIV3 surface 
protein genes F and HN were deleted and replaced by a gene encoding full-length wt EBOV GP 
as the sole virion surface envelope glycoprotein to mediate attachment and entry (construct 
design is described in Appendix 6.4 and shown in Figure 48). This virus is very similar to another 
version reported previously (Bukreyev et al. 2009). rHPIV3/NotI ∆F-HN/EboGP was readily 
recovered from cDNA in cell culture. Although slightly attenuated as compared to wt HPIV3, this 
virus was capable of efficiently infecting cells and grew to high titers (~7.5 log10 PFU/ml) and 
formed distinct plaques in a conventional plaque assay, indicating that EBOV GP in the virion 
particles was functional and likely retained the neutralization epitopes. 
Several control antibodies were used to confirm the specificity of this neutralization assay 
based on rHPIV3/NotI ∆F-HN/EboGP. The EBOV GP-specific antibody KZ52, a human IgG MAb 
isolated from an EBOV survivor (Maruyama et al. 1999), was used as a positive control to 
demonstrate that rHPIV3/NotI ∆F-HN/EboGP can be neutralized by EBOV GP-specific antibodies 
(Figure 45A). It also was important to determine if the HPIV1-specific antibodies, generated in the 
immunized AGMs due to the HPIV1 vectors, could neutralize rHPIV3/NotI ∆F-HN/EboGP, which 
lacks the HPIV3 F and HN neutralization antigens but carries all of the HPIV3 internal proteins. 
Although HPIV1 and HPIV3 are distinct serotypes and do not cross-protect, they belong to the 
same genus Respirovirus and share a low-to-moderate level of amino acid sequence relatedness. 
In addition, to enable the analysis of sera from rHPIV3/EboGP-immunized animals, it was 
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necessary to confirm that the HPIV3-specific antibodies induced by rHPIV3/EboGP would not 
neutralize this EBOV-pseudotyped virus. To address this, the neutralization assay was performed 
with hyperimmune sera to HPIV1 (titer of 7.3 log2 PRNT60 against HPIV1) and HPIV3 (titer of >13 
log2 PRNT60 against HPIV3). Neither antiserum had any detectable neutralizing activity against 
rHPIV3/NotI ∆F-HN/EboGP (Figure 45A). Therefore, rHPIV3/NotI ∆F-HN/EboGP could be used 
in a neutralization assay to detect EBOV-specific antibodies without confounding neutralization 
by HPIV1- or HPIV3-specific antibodies. 
 
Figure 45: EBOV GP-specific 60% plaque reduction neutralization (PRNT60) assay using rHPIV3/NotI 
∆F-HN/EboGP, an HPIV3 virus expressing EBOV GP as the sole surface glycoprotein. Serum samples 
were analyzed using rHPIV3/NotI ∆F-HN/EboGP virus. (A) Validation of the neutralization assay. KZ52, 
an anti-EBOV GP human MAb, known to have GP-neutralizing activity, was used as a positive control to 
confirm neutralization of rHPIV3/NotI ∆F-HN/EboGP. Rabbit hyperimmune sera against HPIV1 and HPIV3 
were included as negative controls to confirm a lack of neutralizing activity of HPIV1- and HPIV3-specific 
antibodies for rHPIV3/NotI ∆F-HN/EboGP. (B) Sera from the immunized AGMs. Sera collected 28 d, 35 
d (7 d post-boost), and 56 d (28 d post-boost) after the first immunization were analyzed to determine the 
PRNT60 titers for rHPIV3/NotI ∆F-HN/EboGP in the presence of guinea pig complement. Open circles 
indicate animals that did not receive a booster on day 28 post primary immunization. Average PRNT60 
values for each group are shown with the horizontal bars. 
The sera of the AGMs were analyzed with this neutralization assay (Figure 45B). At 28 d 
p.i., no significant serum neutralization activity could be detected for any of the rHPIV1 EBOV GP 
constructs, whereas rHPIV3/EboGP induced a PRNT60 of approximately 6.0 log2. However, the 
animals that had received a second dose of GP1 virus reached, on average, similar neutralization 
titer as that of rHPIV3/EboGP-boosted animals as early as 7 days post boost. The boosts with the 
GP-TMCT1 and GP-TMCT2 viruses did induce an increase in virus neutralization titers but were 
Results  93 
lower than those of GP1. Animals that had not received a second dose showed undetectable (limit 
of detection: 3.0 log2 PRNT60) or very low neutralizing activity. The virus neutralization titers 
closely reflected the ELISA results and showed that within 7 days post-boost the attenuated GP1 
vaccine candidate conferred neutralizing titers comparable to those of the non-attenuated 
rHPIV3/EboGP virus that had been previously shown to protect NHPs against EBOV challenge 
(Bukreyev et al. 2006). Although GP-TMCT1 induced ELISA IgG titers similar to those of GP1, its 
neutralizing titers were slightly lower. Similar to the ELISA results, the virus neutralizing titers also 
did not substantially increase between 7 and 28 days post boost, suggesting that the maximum 
attainable titers were achieved by one week after the booster dose. 
 
3.2.2.3. Stability of EBOV GP expression during replication in the respiratory tract 
The stability of expression of EBOV GP during replication in AGMs was evaluated by a 
double-immunostaining plaque assay. The assay was used to analyze NP and TL samples of all 
animals in each group (GP1, GP-TMCT1, GP2 and GP-TMCT2) collected during the peak of viral 
shedding, defined by the replication curve of Figure 43. Samples from the day of peak shedding 
for each particular animal (P2) as well as for the preceding day (P1) and the following day (P3), 
were analyzed, and the percentage of HPIV1 plaques co-expressing EBOV GP was determined 
(Table 21). Representative images of double-immunostained plaques are shown for each 
construct (Figure 46). 
 
Figure 46: Representative results of the double-immunostaining plaque assay used to determine the 
stability of EBOV GP expression during replication in AGMs. Vero cells were infected with serially 
diluted NP or TL samples, incubated for 6 days under a methylcellulose overlay medium, fixed, and 
subjected to immunostaining against EBOV GP (green) and HPIV1 (red) as described in the Methods. 
Plaques that stained for both HPIV1 and EBOV GP appeared yellow; plaques in which expression of EBOV 
GP was lost appeared red. The following representative examples of double-immunostained Vero 
monolayers are shown from the experiment in Table 21: (A) wt HPIV1, animal #32956, TL, day P2; (B) 
GP1, animal #7856, NP, day P1; (C) GP-TMCT1, animal #8392, NP, day P3; (D) GP2, animal #62403, NP, 
P2; (E) GP-TMCT2, animal #8232, NP, day P2. P2 is the day of peak shedding for that particular animal; 
P1 is the day before the peak of shedding; P3 is the day following peak shedding. The complete results of 
the experiment are summarized in Table 21.  
Overall, the constructs expressing full-length EBOV GP from either the pre-N or N-P 
position (GP1 and GP2) had a more stable GP expression than their TMCT counterparts (GP-
TMCT1 and GP-TMCT2). In the case of GP1, 3 of 4 animals (#7856, 7867, and 8172) had an 
average stability of 95% for both the NP and TL samples; the remaining animal (#8054) of this 
group had a reduced stability of 70% in the NP samples, but was more stable at 92% in the TL 
samples. GP-TMCT1 was substantially less stable, especially in the NP samples with the stability 
ranging from 15 - 75% with an average of 45%, whereas TL samples were more stable at 90%. 
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Similar to GP1, GP2 had relatively stable expression of GP: 3 of 4 animals (#8401, 62403, and 
8246) had an average stability of 97% in both the NP and TL samples. The remaining animal 
(#8555) had only 50% GP expression in the NP sample but 99% stable GP expression in the TL 
sample. Similar to GP-TMCT1, a tendency of reduced stability also was observed for GP-TMCT2, 
with an average of 53% and 93% GP expression in the NP and TL samples, respectively. Although 
the TMCT modification did not increase GP incorporation in the particles and had no evidence of 
instability during in vitro growth, it seemed to encourage in vivo selection of virus progeny with 
silenced GP expression. 
 
Table 21: Percentage of HPIV1-C∆170 GP plaques expressing EBOV GP after replication in AGMs, 
determined by a double-immunostaining plaque assay. 
  % plaques positive for EBOV GPa 
  Nasopharyngeal swabs  Tracheal lavage 
Virus Monkey ID # P1b P2 P3  P1 P2 P3 
GP1 7856 98 100 97  90 67 (3)c 100 (5) 
 8054 65 75 70 (10)  81 94 100 
 7867 95 87 92  100 98 98 
 8172 99 99 97  100 97 99 
         
GP-TMCT1 8445 56 52 71  100 96 100 (9) 
 8195 33 41 47  86 89 79 
 8392 75 36 47  92 91 99 
 8258 50 19 15  83 67 (6) 93 
         
GP2 8555 67 (3) 50 (8) 33 (3)  97 100 100 
 8401 90 100 100 (4)  100 96 94 
 62403 98 92 98  100 97 100 
 8246 100 (2) 99 100  99 98 95 
         
GP-TMCT2 8577 ND 50 (6) 100  91 84 95 
 8573 23 91 14 (7)  100 98 100 
 57413 0 (10) 60 (5) ND  67 (3) 100 100 (4) 
 8232 74 56 66  97 96 91 
a Vero cell monolayers were infected with serially diluted samples of NP and TL specimens from the 
indicated animals (from the experiment shown in Figure 43), incubated for 6 days under a methylcellulose 
overlay medium, fixed, and subjected to immunostaining against EBOV GP (green) and HPIV1 (red). 
Plaques that stained for both appeared yellow; plaques in which expression of GP was lost appeared red. 
The percentage of plaques positive for expression of EBOV GP was the number of yellow plaques divided 
by the total number of plaques (red and yellow). 
b P2, P1, and P3 are the day of peak shedding (P2), the day before the peak shedding (P1), and the day 
after the peak shedding (P3) for that particular animal. 
c For samples with ≤ 10 plaques: total number of plaques are shown in parenthesis 
ND, not determined because plaque titer was below the limit of detection. 
Underlined values represent samples also shown in Figure 46. 
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4. Discussion 
4.1. Role of ATP1A1 in the macropinocytic entry of RSV  
4.1.1. ATP1A1 is a pro-viral host factor, involved in RSV entry 
Advancing our understanding of the RSV replication cycle and how the virus utilizes host 
proteins for efficient replication may identify new targets for antiviral drug development. An effort 
was made to identify, in an unbiased high-throughput fashion, the host proteins utilized by RSV 
for replication. A genome-wide siRNA screen was performed, where the expression of individual 
genes was knocked down in human airway epithelial A549 cells, followed by infection with a 
recombinant RSV that expressed GFP. 
Expression knockdown of the gene encoding ATP1A1 provided the greatest reduction in 
viral GFP expression, with minimal effects on cell viability. ATP1A1 is the major subunit of the Na+, 
K+-ATPase complex, a transmembrane complex that is an ATPase and an ion channel, but is also 
involved in signal transduction (Reinhard et al. 2013). ATP1A1 also has been implicated in the 
infection cycle for EBOV (Garcia-Dorival et al. 2014) coronavirus (Burkard et al. 2015), hepatitis 
C virus (Lussignol et al. 2016), and mammarenaviruses (Iwasaki et al. 2018) but the mechanism 
of its involvement for these viruses remained largely unknown. 
This study provides evidence that ATP1A1 is involved in RSV entry. A reduction of the 
cellular ATP1A1 level diminished the ability of RSV to infect host cells, an inhibition that was RSV-
specific and had no effect on VSV infection. A striking phenomenon of ATP1A1 clustering in the 
plasma membrane was observed within a few hours following cellular exposure to RSV particles. 
This also was observed for UV-inactivated RSV, and therefore the induction of ATP1A1 clustering 
was independent of virus transcription or replication. This phenotype was reminiscent of the 
behavior of signaling receptors in response to ligand binding and suggested a possible physical 
interaction between the virions and the cell surface that triggered ATP1A1 clustering. 
It was not possible to detect physical interaction between ATP1A1 and any of the RSV 
surface glycoproteins (G, F or SH) by co-immunoprecipitation techniques (data not shown). 
However, by using RSV deletion mutants, it was demonstrated that RSV G protein is required to 
trigger ATP1A1 clustering, implying that an initial virus attachment event, facilitated by G, is 
needed to initiate ATP1A1 clustering, but the mechanistic details of this process remains unknown. 
It may be that interaction of RSV and ATP1A1 does occur but is insufficiently stable for detection 
by the co-immunoprecipitation and Western blotting methods that were used, or that there may 
be intermediate steps involved between the initial binding of RSV G and clustering of ATP1A1. 
For signaling receptors in general, clustering is known to increase ligand binding and signal 
transduction of signaling receptors (Chu et al. 2004) by reducing the effective dissociation rate 
through enhancing rebinding within the receptor cluster (Gopalakrishnan et al. 2005). This 
phenomenon would be beneficial for RSV infection as it would enhance ATP1A1-mediated 
signaling that is required for viral uptake. 
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Total loss of ATP1A1 expression with homozygous ATP1A1 knockout mice was previously 
found by others to result in pre-weaning lethality (Lexicon Genetics Inc. 2005), indicating that 
ATP1A1 is an essential cellular protein. Therefore, complete knockout in vitro or in the mouse 
model was not feasible. However, an ATP1A1 heterozygous knockout mouse had been 
developed in which one ATP1A1 allele is knocked out and only one functional allele is expected 
to sustain reduced expression of ATP1A1. This heterozygous knockout mouse strain was used to 
evaluate the effects on RSV infection. Unfortunately, only a modest reduction in ATP1A1 
expression was observed in the lung tissue. Consistent with this inefficient knockdown of ATP1A1 
expression, we did not observe any reduction in RSV infection or shedding in the heterozygous 
mice as compared to wt mice. Therefore, it was not possible to investigate and confirm the role of 
ATP1A1 in RSV infection in vivo. 
 
4.1.2. RSV infection triggers ATP1A1-mediated signaling 
Treatment with the cardiotonic steroid ouabain and the synthetic digitoxigenin derivative 
PST2238, that both specifically act on ATP1A1, also reduced RSV infection. Ouabain has a 
hormone-like effect on the Na+, K+-ATPase when present in sub-nanomolar concentrations (Xie 
and Cai 2003, Reinhard et al. 2013), that are non-inhibitory for its ion-channel function and do not 
alter the cytosolic Na+ and K+ levels (Liu et al. 2000), but can initiate signaling cascades, as 
described in the Introduction in greater detail (Haas et al. 2000, Aydemir-Koksoy et al. 2001, Haas 
et al. 2002). The ouabain-induced ATP1A1 signaling results in the removal of ATP1A1 from the 
plasma membrane by endocytic uptake and lysosomal degradation (Cherniavsky-Lev et al. 2014). 
Ouabain and PST2238 inhibited RSV infection efficiently and acted early during infection. 
PST2238 has been characterized as an anti-hypertension drug and antagonizes ouabain by 
competitive binding to its ATP1A1 binding site (Quadri et al. 1997, Ferrari et al. 1998). PST2238 
shares a common binding site with ouabain on the extracellular domain of ATP1A1 and blocks 
ATP1A1-mediated signaling in response to ouabain or RSV. Note that reduced ATP1A1 
expression in the plasma membrane was observed after 24 h ouabain treatment but its antiviral 
effect was evident even if added simultaneously with the virus inoculum, suggesting reduced 
ATP1A1 surface expression is likely not the basis of its anti-RSV activity. The possible mechanism 
of inhibition by ouabain is discussed later in section 4.1.5. PST2238 treatment inhibited RSV 
infection to levels similar to ouabain but it did not reduce ATP1A1 on the plasma membrane, 
consistent with its lack of stimulation of ATP1A1 signaling and downstream effects including 
increased endocytosis. The robust ATP1A1 clustering observed soon after infection, and the 
ouabain and PST2238 time-of-addition experiments, both pointed to a role of ATP1A1 as a 
signaling molecule with a role in an early stage of infection, i.e. entry.  
Ouabain binds to ATP1A1 and signals via the ATP1A1-Src-EGFR signaling cascade 
(described in the Introduction) resulting in endocytosis and degradation of the surface ATP1A1 as 
a mechanism of regulating blood pressure (Xie and Cai 2003, Reinhard et al. 2013). It was 
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hypothesized that RSV may utilize this signaling properties of ATP1A1 to induce endocytosis as 
a mechanism for entry. This potentially could involve any of various pathways including clathrin- 
or caveolin-mediated endocytosis or macropinocytosis. This study demonstrated that ATP1A1 
signaling indeed was induced and was required for RSV infection. Src-kinase activity was found 
to play an important role in RSV infection, and inhibiting c-Src reduced the efficiency of RSV 
infection. It also was confirmed that EGFR is essential for RSV infection, as previously shown 
(Krzyzaniak et al. 2013), but is not sufficient alone and required the upstream activation of 
ATP1A1 and c-Src for efficient RSV infection. This conclusion was made by examining the 
activation of EGFR following exposure of cells to RSV. It showed that EGFR Tyr845 was 
phosphorylated early during RSV infection, detectable at 5 h p.i. This phosphorylation was 
dependent on ATP1A1 and was significantly reduced in cells whose ATP1A1 expression was 
knocked down with siRNAs or in which ATP1A1 signaling was reduced by treatment with ouabain 
or PST2238. EGFR Tyr845 phosphorylation also was dependent on c-Src kinase activity, the 
downstream signaling effector of ATP1A1. Inhibition of the c-Src kinase abolished the pTyr845 
below detectable levels, suggesting that EGFR Tyr845 is phosphorylated by the ATP1A1-
activated c-Src kinase.  
ATP1A1-mediated signaling cascades have been reported to take place in the cholesterol-
rich microdomains called caveolae (Liu et al. 2003, Wang et al. 2004). Due to the spatial 
sequestration of caveolae, it is believed that it serves as a region to integrate multiple signaling 
pathways by concentrating signaling proteins and creating temporal and spatial patterns of cell 
regulation (Ostrom et al. 2001). Many proteins associated with signaling functions are present in 
the caveolae, including ATP1A1, EGFR and c-Src (Anderson 1998, Razani et al. 2002, Reinhard 
et al. 2013). It also has been described that cholesterol is needed for the ouabain-induced 
ATP1A1-Src-EGFR signaling cascade and that depletion of cholesterol reduced the recruitment 
of c-Src and therefore reduced ATP1A1 signaling (Wang et al. 2004). Interestingly, it also has 
been reported that the cholesterol-rich lipid rafts are required as a docking platform for RSV entry 
(Chang et al. 2012, San-Juan-Vergara et al. 2012). It was investigated whether caveolae were 
the sites of ATP1A1-Src-EGFR signaling required for RSV entry by depleting cholesterol, which 
is essential to maintain the caveolar structural integrity. Cholesterol depletion indeed reduced the 
efficiency of RSV infection, which also was associated with decreased EGFR Tyr845 
phosphorylation (reflecting reduced ATP1A1 signaling) induced by RSV. This provided evidence 
that caveolae are the likely sites where ATP1A1 signaling occurs and are thus important for RSV 
entry. Although significantly reduced, the magnitude of reduction for EGFR pTyr845 was modest 
as compared to that of RSV-GFP expression. While the reason for this difference is unclear, these 
data may suggest that, although ATP1A1-mediated EGFR phosphorylation is more efficient in the 
presence of cholesterol, the complexes might also be signaling in the absence of cholesterol, 
presumably outside of caveolae. 
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4.1.3. RSV-induced ATP1A1 signaling results in the macropinocytic uptake of RSV 
RSV uptake into the host cell to initiate infection has been controversially suggested to occur by 
clathrin-mediated endocytosis (Kolokoltsov et al. 2007) or macropinocytosis (Krzyzaniak et al. 
2013). Some of the evidence provided in these studies for clathrin-mediated endocytosis and 
macropinocytosis were based on the use of inhibitors to distinguish between these entry pathways. 
To confirm these findings, chlorpromazine and EIPA were used in the present study as inhibitors 
of the clathrin-mediated endocytosis and macropinocytosis, respectively, in A549 cells. Both 
chemical compounds showed high cytotoxicity at the concentrations used in these previous 
studies, which used HeLa cells instead of A549 cells. It might be that HeLa cells are more resistant 
as compared to A549 cells and their viability is less affected by these inhibitors. Chlorpromazine-
treated A549 cells showed an inhibition of RSV-GFP expression, but this correlated with the 
reduction in cellular viability, suggesting an unspecific inhibition of RSV due to cell damage rather 
than a specific inhibition of clathrin-mediated endocytosis. EIPA, on the other hand, showed a 
reduction of RSV-GFP at non-cytotoxic concentrations, but fluorescence microscopy showed that 
even the “non-cytotoxic” concentration caused pathological changes in the cells, indicated by the 
loss of integrity of the nuclear membrane. Thus, because of these non-specific and generalized 
effects on the viability of the A549 cells, it could not be inferred if these inhibitors could block one 
or the other endocytic pathway to affect RSV infection, and therefore this was not further pursued. 
Macropinocytosis can be induced through components of the ATP1A1 signaling pathway. 
For example, it has been described that phosphorylation of EGFR Tyr845 by c-Src, in an EGF-
independent manner, can induce macropinocytosis (Biscardi et al. 1999, Donepudi and Resh 
2008). Src kinase activity plays an important role during macropinosome formation and trafficking 
(Kasahara et al. 2007), and can synergistically enhance macropinocytic induction (Mercer and 
Helenius 2009). Based on the findings of the present study, it was postulated that, upon RSV 
binding, ATP1A1-induced signaling transactivates EGFR via c-Src resulting in the macropinocytic 
uptake of RSV. Typical macropinosomes are formed as a result of extensive, unspecific fluidic 
uptake at the plasma membrane [reviewed in (Swanson and Watts 1995, Conner and Schmid 
2003, Mercer and Helenius 2009)] that engulfs fluid and solid cargo from outside of the cell into 
cytoplasmic vesicles. They are heterogeneous in size and are larger than other endocytic vesicles, 
with diameters of 0.5 - 5 µm. To assess if the activation of the ATP1A1-Src-EGFR pathway leads 
to macropinocytosis and uptake of RSV, the fluidic uptake and macropinosome formation were 
visualized with fluorochrome-conjugated dextran, which is generally used as a marker for 
macropinosomes (Mercer and Helenius 2009). RSV infection clearly induced extensive 
macropinocytosis, and a large number of dextran-filled vesicles (macropinosomes) were 
detectable very early in infection. This finding is in agreement with the previously described mode 
of RSV uptake reported by Krzyzaniak and colleagues (Krzyzaniak et al. 2013). Co-
immunostaining showed that RSV F protein (marker of viral envelope) and RSV N protein (marker 
of viral nucleocapsid) were present in the dextran-positive macropinosomes, together with 
ATP1A1. This supports the model that RSV virions are taken up by the macropinosomes, and the 
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membrane fusion and release of the nucleocapsid presumably takes place at a later step after the 
macropinocytic uptake. Further analysis showed that macropinosome formation was dependent 
upon ATP1A1 activation and was significantly reduced if the ATP1A1 expression was decreased 
by siRNA knockdown or if the cells were treated with the ATP1A1-binding compounds ouabain or 
PST2238. 
Cholesterol depletion was observed to have a greater effect on reducing macropinosome 
formation and viral entry than it did on reducing EGFR Tyr845 phosphorylation, as mentioned 
earlier. It is known that macropinosome formation itself also depends on the presence of 
cholesterol (Grimmer et al. 2002). Therefore, the effects of cholesterol depletion on ATP1A1 
signaling combined with direct effects on macropinocytosis may explain the greater inhibition on 
macropinosome formation and viral entry compared to EGFR Tyr845 phosphorylation. 
 
4.1.4. Model of ATP1A1-mediated entry of RSV 
The following model, illustrated in Figure 47, is proposed for RSV entry into the human 
airway epithelial cells:  
 
Figure 47: Proposed model of ATP1A1-dependent macropinocytic entry of RSV. Exposure to RSV 
triggers the clustering and activation of ATP1A1 in the plasma membrane through an unknown mechanism. 
ATP1A1 then signals via Src kinase and transactivates EGFR by phosphorylation at Tyr845. Upon 
activation, EGFR signaling causes cytoskeletal rearrangement resulting in plasma membrane ruffling and 
formation of membrane extensions (Hewlett et al. 1994, Swanson and Watts 1995, Donepudi and Resh 
2008) that engulf fluid and RSV into macropinosomes. Note that RSV is taken up into the macropinosome 
in its enveloped state suggesting that it does not fuse at the cell surface; fusion and release of nucleocapsid 
likely occur within the internalized macropinosome. Illustration for this thesis by Ryan Kissinger (Visual & 
Medical Arts, RTB, NIAID) 
RSV infection triggers ATP1A1 clustering and activates ATP1A1 signaling by an unknown 
mechanism that involves RSV G protein and does not require viral RNA synthesis or replication. 
ATP1A1 activation leads to Src-kinase activation, presumably by autophosphorylation of c-Src at 
Tyr418, as described previously for ouabain-induced signaling (Haas et al. 2000, Haas et al. 2002), 
followed by transactivation of EGFR by phosphorylation of Tyr845. Signaling events downstream 
of EGFR cause actin rearrangement and ruffling at the plasma membrane (Hewlett et al. 1994, 
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Swanson and Watts 1995, Donepudi and Resh 2008) where membrane extensions engulf fluid 
and RSV into large vesicles, the macropinosomes. RSV is taken up in its enveloped form into the 
macropinosome followed by fusion and entry into the host cell cytoplasm. EGFR is essential for 
RSV infection, but not sufficient alone and requires transactivation by ATP1A1-activated c-Src for 
initiating macropinocytic uptake of RSV. This study also provided evidence that the ATP1A1-Src-
EGFR signaling occurs predominantly in the cholesterol-rich domains of the caveolae which are 
thus important for efficient infection. 
 
4.1.5. PST2238 – an ouabain antagonist as potential antiviral drug 
This study provided evidence that RSV induces an ATP1A1-mediated signaling cascade 
to enter airway epithelial cells (Figure 47). This provides a new target for the development of anti-
RSV drugs. Ouabain and PST2238 specifically act on ATP1A1 and decrease the efficiency of 
infection by reducing the RSV-induced ATP1A1 signaling needed for entry, and thus might be 
further developed as antiviral drugs for RSV. 
It was surprising that both ouabain and PST2238 inhibited RSV infection, since they have 
opposite effects on ATP1A1 signaling, namely that ouabain induces and PST2238 inhibits. The 
mechanism by which PST2238 inhibits RSV seems to be straight-forward, specifically, blockade 
of RSV-induced ATP1A1 signaling. The mechanism by which ouabain inhibits RSV is less clear, 
since both ouabain and RSV individually induce ATP1A1 signaling. Ouabain binding can induce 
several signaling pathways (Reinhard et al. 2013) which may be distinct in some aspects as 
compared to that induced by RSV. This is evident by the different outcomes: ouabain-induced 
signaling results in clathrin-mediated endocytosis, whereas RSV-induced signaling results in 
macropinocytosis. In addition, ouabain has been described to cause EGFR phosphorylation 
(Haas et al. 2000, Haas et al. 2002), but phosphorylation of Tyr845, which occurred in response 
to RSV-induced ATP1A1 signaling, was not detected with ouabain treatment (data not shown). 
Therefore, it is proposed that ouabain initiates an ATP1A1-mediated signaling pathway that is 
distinct from that induced by RSV, and that induction by ouabain competes with and thereby 
reduces induction by RSV.  
Ouabain has been described to have antiviral properties for several viruses, namely 
herpes simplex virus (Dodson et al. 2007, Su et al. 2008), chikungunya virus (Ashbrook et al. 
2016), human immunodeficiency virus (Wong et al. 2013), adenovirus (Grosso et al. 2017) and 
porcine reproductive and respiratory syndrome virus 1 (Karuppannan et al. 2012 ), but the 
mechanism of inhibition was not conclusively identified in any of these studies. Ouabain itself 
might not be a good candidate drug, since it causes hypertension if present in elevated levels in 
the blood, as described earlier. Nevertheless, the application intranasally, for example with a 
nebulizer, has not been evaluated. This route of application might not affect the blood pressure, 
since most likely the amount absorbed from the lung into the blood stream would be small and 
might not cause hypertension. 
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However, PST2238 might be a more promising candidate drug since it is already evaluated 
as an anti-hypertensive drug in phase II clinical trials for ouabain- and adducin- induced 
hypertension patients (Lanzani et al. 2010). Hence, the safety of PST2238 as a drug for humans 
already has been evaluated. It does not have any known adverse effects and does not lower the 
blood pressure of healthy humans (Ferrari et al. 2006) and therefore could be repurposed as 
antiviral drug. To the best of our knowledge, PST2238 has not previously been evaluated for 
antiviral activity against any virus, including RSV, and it may indeed inhibit the replication of other 
viruses that are ouabain-sensitive and use ATP1A1-mediated signaling for viral entry. 
In conclusion, this study identified ATP1A1 as a signaling mediator of RSV entry and a 
new potential target for the development of an antiviral drug against severe RSV disease. The 
pharmacological characteristics for a potential antiviral treatment targeting ATP1A1 have not been 
addressed and need to be characterized in future studies. 
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4.2. Development and pre-clinical evaluation of a live-attenuated mucosal HPIV1 vaccine 
against EBOV 
This EBOV vaccine project was initiated in response to the devastating EBOV outbreak in 
West Africa in 2014, with the goal to provide an additional, alternative EBOV vaccine strategy. 
Respiratory tract immunization with a live-attenuated vector offers several advantages over 
parenteral vaccines that are currently under development as EBOV vaccines, as described in the 
Introduction. Replication-competent live virus-based intranasal vaccines induce both systemic 
and mucosal antibody responses and respiratory tract resident CD4+ and CD8+ T cells (Meyer et 
al. 2015), which would be expected to protect against EBOV infection via aerosol, skin, or mucosal 
routes. The availability of an intranasal needle-free vaccine would eliminate the need for trained 
professionals or the risk of spreading blood-borne pathogens in the EBOV endemic areas.  
The goal of this study was to develop an intranasal vaccine against EBOV based on an 
attenuated HPIV1-C∆170 backbone expressing EBOV GP. One aspect of this study was to improve 
safety by using an attenuated virus instead of a wt virus as was previously used in rHPIV3/EboGP 
(Bukreyev et al. 2006). Also, it is not possible to predict whether a particular vector backbone (e.g., 
HPIV1 versus HPIV3) might have better performance in humans. HPIV1-C∆170 is well-attenuated 
in NHPs (Bartlett et al. 2008) and is expected to have increased safety in humans, including elderly 
and HPIV1-naïve children. Another aspect of this study was to enhance EBOV GP 
immunogenicity by increasing its packaging in the vector particle by a TMCT modification. As 
described in the Introduction, it was previously shown that TMCT modification improved the 
incorporation of RSV F protein into PIV vector particles which enhanced the quantity and quality 
of the RSV neutralizing antibody response (Liang et al. 2016). In a previous study, EBOV GP was 
found to be incorporated into HPIV3 particles, but the efficiency of incorporation was only 13% 
that of the HPIV3 HN protein (Bukreyev et al. 2006). Therefore, increased incorporation would be 
desirable to increase the immunogenicity. To achieve this, the GP TMCT domain was substituted 
with that of HPIV1 F protein to enhance GP packaging into HPIV1 virions. A third aspect of this 
study was to evaluate two different insertion sites for the EBOV GP gene into the HPIV1 genome, 
namely the pre-N position, which placed the EBOV GP gene in the first, promoter-proximal 
position, and the N-P position where EBOV GP was inserted between the N and P genes. The 
EBOV GP ORF was modified to match an “edited” transcript expressing the full-length trans-
membrane EBOV GP protein, and the ORF was codon-optimized for efficient human expression. 
 
4.2.1. In vitro characterization of the HPIV-C∆170 vectors expressing EBOV GP 
In this study four different constructs were developed to evaluate two main variables: (i) 
the position effect (pre-N versus N-P) in the vector genome and (ii) the effect of EBOV GP TMCT 
modification in comparison with a respective full-length EBOV GP. All four constructs were 
recovered successfully by reverse genetics. In vitro replication in Vero cells did not show a 
substantial attenuation with regard to final titers, which were similar to wt HPIV1. There was some 
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evidence of modest attenuating effects in replication kinetics due to the EBOV GP insert. Viruses 
with EBOV GP at the pre-N position showed a delay in replication kinetics in vitro, with the TMCT 
version being the slower of the two. Both TMCT constructs had smaller plaque size indicating a 
slight reduction in replication or spread. 
EBOV GP has no essential role for vector replication and therefore has the potential to 
accumulate mutations that might silence its expression. It is important for a vectored vaccine to 
maintain antigen expression during manufacturing to ensure the highest possible load of antigen. 
Each of the four constructs maintained stable EBOV GP expression during replication in Vero 
cells, determined by dual-immunostaining plaque assay and flow cytometry, with no detectable 
loss of EBOV GP expression. 
The level of EBOV GP expression in infected Vero cells was analyzed by Western blotting 
and was found to be similar for all constructs at 48 h p.i. The similar expression level regardless 
of the genome position [3’ proximal EBOV GP (pre-N) compared to the more-distal EBOV GP (N-
P)] suggests that either the expected polar transcription gradient was not observed or that the 
pre-N viruses were slightly attenuated and thereby the expression of EBOV GP was reduced to a 
level similar to that of the N-P virus. This also is consistent with the previous findings for RSV F 
protein expressed by HPIV-C∆170 (Mackow et al. 2015). In contrast, Western blot analysis of 
sucrose-purified virion lysates did show a gradient effect, with 6.3-fold more EBOV GP 
incorporated in the pre-N as compared to N-P viruses. This contrast between infected cell lysate 
and purified virus EBOV GP may reflect differences in kinetics and timing of accumulation. 
Specifically, the Western blot analysis of the cell lysates provided a snapshot of protein 
accumulation at 48 h p.i., whereas the virus particles were purified after 7 days of propagation. It 
could be that the overall EBOV GP accumulation over 7 days was higher for the pre-N as 
compared to N-P viruses, which was reflected by purified virions. This gradient likely was not 
apparent in the infected cell lysates at 48 h p.i. due to the initial slow growth of pre-N constructs 
during the first two days. Another important observation was that EBOV GP was readily detected 
in virions for each of the constructs, as also had been observed in a previous study with HPIV3 
(Bukreyev et al. 2006), and that the amount of EBOV GP in virions of GP-TMCT1 and GP-TMCT2 
was similar to that in GP1 and GP2, respectively. This indicates that, contrary to expectations, the 
TMCT modification did not increase the incorporation of EBOV GP into the HPIV1 virions. 
 
4.2.2. HPIV1-C∆170 GP1 was the most immunogenic vaccine candidate in AGMs 
In vivo replication of the four constructs was evaluated in AGMs. All HPIV1-C∆170 viruses 
expressing EBOV GP replicated over several days to peak titers of approximately 3.0 
log10TCID50/ml in the URT (NP swabs) and 4.0 log10TCID50/ml in the LRT (TL sample). Compared 
to wt HPIV1, all four constructs were attenuated approximately 100-fold in the URT, but did not 
appear to be attenuated in the LRT. The HPIV1-based constructs replicated to titers that were 
approximately 1000-fold lower in both URT and LRT as compared to rHPIV3/EboGP. The 
104   Discussion 
difference in replication reflects the presence of an attenuating mutation in the HPIV1 constructs 
but not the HPIV3 constructs and a greater permissiveness of AGMs for HPIV3 versus HPIV1 
(Durbin et al. 2000). The administration of a booster dose with the same respective constructs 28 
d after first immunization did not result in any detectable shedding of infectious virus. This 
indicated that the first dose was sufficiently immunogenic to strongly restrict replication of the 
booster dose. This restriction was most likely due to the induced immunity against the HPIV1 
vector, but also might be partially facilitated by antibodies against the expressed EBOV GP. 
The EBOV GP-specific antibody response was evaluated by an ELISA and virus 
neutralization assay. The ELISA captured any IgG antibodies directed against EBOV GP 
regardless of their neutralization activity. At 28 d p.i., all HPIV1-C∆170 constructs expressing EBOV 
GP showed only modest levels of EBOV GP-specific IgG titer. In comparison, HPIV3/EboGP 
induced a higher titer, likely reflecting its much higher (1000-fold) replication in AGMs compared 
to the attenuated HPIV1-C∆170. At 28 days, two animals per group received a booster dose while 
two remained un-boosted for comparison. Despite the lack of infectious booster virus shedding, 
evaluation of serum samples taken seven days following the boost revealed increases of 5.5- and 
10.4-fold in IgG titers for GP1 and GP-TMCT1, respectively, which reached titers similar to those 
of rHPIV3/EboGP. These titers did not further increase between 7 and 28 d post-boost indicating 
that the maximum titers had already been attained by 7 days post boost inoculation. The N-P 
constructs also showed a slight increase in IgG titers after boost but the magnitude was lower 
than those of the pre-N viruses, which might possibly be explained by the higher amount of EBOV 
GP incorporated into the virions at pre-N as compared to N-P position. The rapid increase of IgG 
titers within 7 days post-boost suggests that, while the first dose did not induce a robust response 
by day 28, it did prime for an anamnestic response to the booster dose. Thus, two doses of HPIV1 
constructs were necessary, but sufficient, to boost the EBOV GP-specific antibodies to titers 
comparable to those of rHPIV3/EboGP. In addition, since the boost required only 7 additional days 
to achieve a robust response, this would not be a major impediment to immunization. Furthermore, 
it likely would be possible to provide the boost earlier than 28 days following the primary 
immunization. 
To determine the EBOV-neutralization activity of these serum antibodies, a neutralization 
assay was established using the pseudotyped rHPIV3/NotI ∆F-HN/EboGP construct, from which 
the surface HPIV3 F and HN proteins have been deleted and replaced by EBOV GP as the sole 
viral surface glycoprotein. This obviated the need to evaluate neutralization using infectious EBOV, 
which is a BSL-4 agent as well as a Select Agent requiring strict inventory controls (Centers for 
Disease Control and Prevention (CDC)). In contrast, the expression of the EBOV GP protein 
previously was shown to have no evident effect on the replication and tissue tropism of HPIV3 in 
vivo, and therefore did not confer increased virulence and did not necessitate increased 
containment (Bukreyev et al. 2006, Bukreyev et al. 2009). Thus, neutralization assays with the 
rHPIV3/NotI ∆F-HN/EboGP construct could be performed at BSL-2 laboratory. Antibodies to GP, 
but not HPIV1 or HPIV3, neutralized this virus, validating this assay for measuring GP-specific 
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neutralizing serum antibodies in the AGM serum samples without confounding effects from 
HPIV1- and HPIV3-specific antibodies. The PRNT60 titers correlated with the ELISA titers and 
showed a similar relative profile. At 28 d p.i. only rHPIV3/EboGP had induced detectable 
neutralization activity. At 7 d post-boost, the PRNT60 of GP1-vaccinated animals increased to titers 
similar to those of rHPIV3/EboGP, which had been shown to protect NHPs against EBOV 
challenge (Bukreyev et al. 2006). Although GP-TMCT1 had ELISA IgG titers similar to those of 
GP1 at 7 days post-boost, its neutralizing titers were lower, suggesting a loss of neutralizing 
epitopes by the TMCT modification. Interestingly, despite the delayed replication of pre-N viruses 
in AGMs, their antibody titers were higher than those of the N-P viruses, possibly reflecting an 
overall higher amount of GP incorporated in the virions, which in turn may be taken up efficiently 
by antigen presenting cells. Although animals in each group showed a similar trend, no statistical 
analyses were possible due to the limited animal number (two per group). 
The observation that the second dose of the HPIV1-based constructs did not result in 
shedding detectable by an infectivity assay, and yet resulted in substantial antibody boosts, is 
reminiscent of previous findings with the HPIV3/EboGP vector (Bukreyev et al. 2010). In that 
previous study, inoculation of HPIV3-experienced rhesus monkeys with two doses of 
HPIV3/EboGP vector given at an interval of 28 days did not result in any shedding detectable by 
an infectivity assay, and yet each dose induced an increase in EBOV GP-specific antibodies. In 
that study, further analysis of the NP and TL specimens by quantitative RT-PCR showed that in 
fact viral RNA was shed following each dose in HPIV3-experienced animals, probably in the form 
of virus that was neutralized by antibodies present in the respiratory secretions. The ability of 
HPIV1 and HPIV3 to reinfect virus-experienced hosts is not unexpected, since reinfection by 
HPIVs is common in humans. The ability of HPIV1 and HPIV3 to reinfect virus-experienced hosts 
sufficiently well to be immunogenic suggests that they can be successfully used as vectors in the 
general population. 
 
4.2.3. TMCT modification did not increase incorporation into virions and immunogenicity of 
EBOV GP 
Modification of EBOV GP to contain the TMCT domains of HPIV1 F protein conferred 
neither enhancement of particle incorporation nor an increase in the immunogenicity of EBOV GP. 
This was incongruous to previous findings from this laboratory with RSV F in HPIV1 and HPIV3 
vectors, and previous findings of others (Park et al. 2006). It might be that the TMCT modification 
was successful in the case of RSV F protein because the native RSV F has very inefficient 
packaging into the HPIV vector particles, making the improvement by swapping TMCT dramatic 
(Liang et al. 2016). In sharp contrast, native full-length EBOV GP was moderately efficient in 
packaging into the HPIV3 and HPIV1 vectors, and perhaps this could not be improved by TMCT 
modification. It is known that the GP of EBOV and other members of the family Filoviridae contain 
a pre-transmembrane region (pre-TM), spanning residues 640-657 (DNDNWWTGWRQWIPAGIG) 
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and rich in aromatic amino acids, that adopts an a-helical conformation and possesses a strong 
affinity to partition into membrane interfaces (Saez-Cirion et al. 2003). This unique pre-TM might 
be driving efficient EBOV GP membrane incorporation and virion packaging that may be 
independent of the TMCT domain. A very different possibility is that TMCT modification of RSV F 
not only enhances virion packaging, but also partially stabilizes it in its highly immunogenic pre-F 
conformation, which together could account for the observed greater immunogenicity. Such an 
effect may not occur with EBOV GP. In addition, EBOV GP has a uniquely short CT domain 
containing only four amino acids (KFVF). The TMCT modification replaced this with a 36-residue 
HPIV1 F CT domain, which may have destabilized or altered EBOV GP structure and antigenicity. 
This would be consistent with a previous report that changes in the TMCT region of EBOV GP 
affected its functionality (Medina et al. 2003). This also is supported by the evidence, that, despite 
several attempts, it was not possible to rescue an HPIV3/∆F-HN construct, in which the vector F 
and HN genes were deleted and the sole surface glycoprotein gene expressed a chimeric EBOV 
GP in which either the CT or the TMCT domains were substituted with those of HPIV3 F protein 
(data not shown). In contrast, this same backbone expressing full-length EBOV GP was readily 
rescued, suggesting that the chimeric GP forms with the foreign TMCT domains had structural 
changes that rendered them non-functional and likely also resulted in the loss of protective 
epitopes. In line with this, the slightly attenuated replication and smaller plaque sizes of the TMCT 
versions, compared to full-length EBOV GP, suggest that the TMCT form may be non-functional 
and even a disadvantage for the vector. 
 
4.2.4. Summary 
Overall, the results here showed that two doses of the attenuated HPIV1-based GP1 
construct were capable of stimulating high titers of EBOV GP-neutralizing antibodies that were 
similar in magnitude to those induced by wt rHPIV3/EboGP, previously shown to protect against 
EBOV challenge (Bukreyev et al. 2006). This was the case despite the relatively attenuated (1000-
fold reduced) replication of GP1 in AGMs compared to wt rHPIV3/EboGP. The HPIV1 vector in 
the present study has the advantage of bearing a C∆170 mutation in the P/C gene that confers 
restricted replication and attenuation needed for safety, although this was evident only in the upper 
respiratory tract of this particular study. In addition, the fact that HPIV1 naturally is less permissive 
for replication in AGMs than HPIV3 might suggest that the immunogenicity of the HPIV1-based 
constructs probably is substantially under-estimated in this animal model. To further enhance 
immunogenicity that might eliminate the need for two doses, the GP1 vaccine candidate could be 
administered as an aerosol using a nebulizer, which primes the respiratory tract more robustly, as 
was recently shown for rHPIV3/EboGP (Meyer et al. 2015).  
In conclusion, this study identified GP1 as an immunogenic and promising intranasal 
EBOV vaccine candidate expected to be well-tolerated in humans, including children and the 
elderly and is available for clinical evaluation in humans. 
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6. Appendix 
6.1. Abbreviations 
The International System of Units (SI units) was used and chemicals, nucleotides and 
amino acids were abbreviated based on the International Union of Pure and Applied Chemistry 
(IUPAC) nomenclature and are not included in the list of abbreviations. Any other abbreviation 
used in the dissertation thesis is listed in the following table. 
 
Abbreviation Meaning 
AF Alexa Fluor 
AGM African green monkey 
AGO endonuclease argonaute 
ALRI acute lower respiratory infection 
AMPV avian metapneumovirus 
ANOVA analysis of variance 
AP2 adaptor protein-2 
APC Allophycocyanin 
ARP2 actin-related protein 2 
ATCC American Type Culture Collection 
ATP adenosine triphosphate 
ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 
BCA bicinchoninic acid 
bp base pair 
BSA bovine serum albumin 
BSL biosafety level 
CDC Centers for Disease Control and Prevention 
cDNA complementary DNA 
CDRs complementarity-determining regions 
CID Compound ID 
CT cytoplasmic tail  
Ct threshold cycle 
CTS cardiotonic steroids 
DAG 1,2-diacylglyerol 
DAPI 4′,6-diamidino-2-phenylindole 
dH2O ultrapure water 
Dicer ribonuclease III-like enzyme 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dsRNA double-stranded RNA 
e.g. for example 
EBOV Ebola virus 
EDTA Ethylenediaminetetraacetic acid 
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Abbreviation Meaning 
EGFR Epidermal growth factor receptor 
EIPA 5-(N-Ethyl-N-isopropyl)amiloride 
ELISA enzyme linked immunosorbent assay 
FBS fetal bovine serum 
FI-RSV formalin-inactivated RSV 
FSC forward scatter 
GAGs glycosaminoglycans 
gDNA genomic DNA 
GE gene end 
GFP green fluorescent protein 
Grb2 growth factor receptor-bound protein 2 
GS gene start 
GSopt GenScript-optimized 
HAD hemadsorption 
HAI hemagglutination inhibition 
HMPV human metapneumovirus 
HPIV1 human parainfluenza virus type 1 
HPIV2 human parainfluenza virus type 2 
HPIV3 human parainfluenza virus type 3 
HSAEC human small airway epithelial cells 
i.e. in other words 
IACUC Institutional Animal Care and Use Committee 
IC50 half maximal inhibitory concentration 
IG intergenic region 
IgG immunoglobulin G 
IP3 inositol 1,4,5 triphosphate 
IRDye infrared fluorescent dye 
kb kilo base 
kDa kilo Dalton 
LDS loading dye solution 
LID Laboratory of Infectious Diseases 
LRI lower respiratory tract infection 
MAb monoclonal antibody 
MAPK mitogen activated protein kinase 
MBCD Methyl-beta-cyclodextrin 
MEK mitogen-activated protein kinase kinase 
MFI median fluorescence intensity 
MGI Mouse Genome Informatics 
miRNA micro RNA 
MMRRC Mutant Mouse Resource & Research Centers 
MOI multiplicity of infection 
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Abbreviation Meaning 
mRNA messenger RNA 
MW molecular weight 
NA numeric aperture 
NCATS National Center for Advancing Translational Sciences 
NDV Newcastle disease virus 
NHPs non-human primates 
NIAID National Institute of Allergy and Infectious Diseases 
NIH National Institutes of Health 
NP nasopharyngeal 
nt nucleotides 
OBN ouabain 
OD absorbance at the indicated wavelength 
ORF open reading frame 
p.i. post inoculation 
p.t. post transfection 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PFU plaque forming units 
PI3K Phosphoinositide 3-kinase 
PIP2 Phosphatidylinositol 4,5-biphosphate 
PKR dsRNA-dependent protein kinase 
PLC-g Phospholipase C-gamma 
Pri-miRNA primary-miRNA 
PRNT60 60% plaque reduction neutralization titer  
RBC red blood cells 
RdRp RNA-dependent RNA polymerase 
RIPA radioimmunoprecipitation assay buffer 
RISC RNA-induced silencing complex 
RLU relative light units 
RNA ribonucleic acid 
RNAi RNA interference 
RNP ribonucleoprotein 
rpm revolutions per minute 
RSV respiratory syncytial virus 
rxt reaction 
SARS-CoV severe acute respiratory syndrome coronavirus 
SD standard deviation 
SDS Sodium dodecyl sulfate 
shRNA short hairpin RNA 
siRNA small interfering RNA 
SOS Son of Sevenless 
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SrcI-I Src-Inhibitor-I 
TA annealing temperature 
TCID50 50% tissue culture infective dose 
TL tracheal lavage 
TM transmembrane  
TMCT transmembrane and cytoplasmic tail 
UR uncertainty range 
URI upper respiratory tract infection 
UTR untranslated region 
v/v volume per volume 
VSV vesicular stomatitis virus 
w/v weight per volume 
WHO World Health Organization 
wt wild-type 
YFP yellow fluorescent protein 
 
  
Appendix  v 
6.2. EBOV GP sequences 
6.2.1. Wt EBOV GP ORF 
The EBOV GP ORF was derived from the EBOV strain Mayinga (GenBank ID: 
AF086833.2) and was modified by the insertion of a single A residue at the editing site to encode 
full-length GP. The stabilized editing site (Bukreyev et al. 2006) is bold and underlined. 
 
ATGGGCGTTACAGGAATATTGCAGTTACCTCGTGATCGATTCAAGAGGACATCATTCTTTCTT
TGGGTAATTATCCTTTTCCAAAGAACATTTTCCATCCCACTTGGAGTCATCCACAATAGCACATTACAG
GTTAGTGATGTCGACAAACTAGTTTGTCGTGACAAACTGTCATCCACAAATCAATTGAGATCAGTTGG
ACTGAATCTCGAAGGGAATGGAGTGGCAACTGACGTGCCATCTGCAACTAAAAGATGGGGCTTCAG
GTCCGGTGTCCCACCAAAGGTGGTCAATTATGAAGCTGGTGAATGGGCTGAAAACTGCTACAATCTT
GAAATCAAAAAACCTGACGGGAGTGAGTGTCTACCAGCAGCGCCAGACGGGATTCGGGGCTTCCCC
CGGTGCCGGTATGTGCACAAAGTATCAGGAACGGGACCGTGTGCCGGAGACTTTGCCTTCCATAAA
GAGGGTGCTTTCTTCCTGTATGATCGACTTGCTTCCACAGTTATCTACCGAGGAACGACTTTCGCTGA
AGGTGTCGTTGCATTTCTGATACTGCCCCAAGCTAAGAAGGACTTCTTCAGCTCACACCCCTTGAGA
GAGCCGGTCAATGCAACGGAGGACCCGTCTAGTGGCTACTATTCTACCACAATTAGATATCAGGCTA
CCGGTTTTGGAACCAATGAGACAGAGTACTTGTTCGAGGTTGACAATTTGACCTACGTCCAACTTGAA
TCAAGATTCACACCACAGTTTCTGCTCCAGCTGAATGAGACAATATATACAAGTGGGAAAAGGAGCAA
TACCACGGGAAAACTAATTTGGAAGGTCAACCCCGAAATTGATACAACAATCGGGGAGTGGGCCTTC
TGGGAAACTAAGAAGAACCTCACTAGAAAAATTCGCAGTGAAGAGTTGTCTTTCACAGTTGTATCAAA
CGGAGCCAAAAACATCAGTGGTCAGAGTCCGGCGCGAACTTCTTCCGACCCAGGGACCAACACAAC
AACTGAAGACCACAAAATCATGGCTTCAGAAAATTCCTCTGCAATGGTTCAAGTGCACAGTCAAGGAA
GGGAAGCTGCAGTGTCGCATCTAACAACCCTTGCCACAATCTCCACGAGTCCCCAATCCCTCACAAC
CAAACCAGGTCCGGACAACAGCACCCATAATACACCCGTGTATAAACTTGACATCTCTGAGGCAACT
CAAGTTGAACAACATCACCGCAGAACAGACAACGACAGCACAGCCTCCGACACTCCCTCTGCCACG
ACCGCAGCCGGACCCCCAAAAGCAGAGAACACCAACACGAGCAAGAGCACTGACTTCCTGGACCCC
GCCACCACAACAAGTCCCCAAAACCACAGCGAGACCGCTGGCAACAACAACACTCATCACCAAGATA
CCGGAGAAGAGAGTGCCAGCAGCGGGAAGCTAGGCTTAATTACCAATACTATTGCTGGAGTCGCAG
GACTGATCACAGGCGGGAGAAGAACTCGAAGAGAAGCAATTGTCAATGCTCAACCCAAATGCAACCC
TAATTTACATTACTGGACTACTCAGGATGAAGGTGCTGCAATCGGACTGGCCTGGATACCATATTTCG
GGCCAGCAGCCGAGGGAATTTACATAGAGGGGCTAATGCACAATCAAGATGGTTTAATCTGTGGGTT
GAGACAGCTGGCCAACGAGACGACTCAAGCTCTTCAACTGTTCCTGAGAGCCACAACTGAGCTACG
CACCTTTTCAATCCTCAACCGTAAGGCAATTGATTTCTTGCTGCAGCGATGGGGCGGCACATGCCAC
ATTCTGGGACCGGACTGCTGTATCGAACCACATGATTGGACCAAGAACATAACAGACAAAATTGATC
AGATTATTCATGATTTTGTTGATAAAACCCTTCCGGACCAGGGGGACAATGACAATTGGTGGACAGG
ATGGAGACAATGGATACCGGCAGGTATTGGAGTTACAGGCGTTATAATTGCAGTTATCGCTTTATTCT
GTATATGCAAATTTGTCTTTTAGTGA 
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6.2.2. GenScript-optimized EBOV GP ORF 
The EBOV GP ORF was codon-optimized for human expression by GenScript, with the 
exception of the stabilized editing site AAGAAGAA sequence (bold and underlined) (Bukreyev et 
al. 2006), which was left undisturbed. The EBOV GP TMCT domain sequence is bolded and 
italicized. 
 
ATGGGGGTGACCGGAATCCTGCAGCTGCCTAGAGACAGGTTTAAGAGGACATCATTCTTTCT
GTGGGTCATCATTCTGTTCCAGCGCACTTTTAGCATCCCACTGGGGGTCATTCACAATTCAACACTGC
AGGTGAGCGACGTCGATAAGCTGGTGTGTCGGGACAAACTGAGCTCCACCAACCAGCTGAGAAGCG
TCGGCCTGAATCTGGAGGGGAACGGAGTGGCAACCGATGTCCCAAGCGCCACAAAGAGATGGGGC
TTTCGCTCCGGGGTGCCACCTAAAGTGGTCAATTACGAGGCCGGGGAATGGGCTGAGAATTGCTAT
AACCTGGAAATCAAGAAACCTGACGGATCCGAGTGTCTGCCCGCCGCTCCTGATGGCATTAGGGGG
TTCCCACGCTGCCGATACGTGCACAAGGTCTCTGGCACCGGGCCATGTGCAGGCGACTTCGCATTT
CATAAAGAAGGGGCTTTCTTTCTGTACGATAGACTGGCATCCACCGTGATCTATAGGGGCACCACAT
TCGCAGAGGGAGTGGTCGCTTTTCTGATTCTGCCACAGGCCAAGAAAGACTTCTTTTCTAGTCATCC
ACTGCGGGAACCCGTGAACGCTACCGAGGATCCCTCAAGCGGCTACTATAGCACTACCATCAGATA
CCAGGCCACAGGATTCGGCACCAATGAGACAGAATACCTGTTTGAAGTGGACAACCTGACATATGTC
CAGCTGGAGTCCAGGTTCACTCCCCAGTTTCTGCTGCAGCTGAATGAAACTATCTATACCAGCGGGA
AGCGCTCCAATACAACTGGAAAGCTGATTTGGAAAGTGAACCCTGAGATCGATACCACAATTGGCGA
ATGGGCCTTTTGGGAGACCAAGAAGAACCTGACACGGAAGATCAGATCTGAGGAACTGAGTTTCAC
CGTGGTCTCTAATGGAGCCAAAAACATTTCCGGCCAGTCTCCCGCTCGGACTTCCTCTGACCCTGGC
ACCAATACTACCACAGAAGATCACAAGATCATGGCCAGCGAGAACAGTTCAGCAATGGTGCAGGTCC
ACAGTCAGGGGAGAGAGGCAGCCGTGTCACATCTGACTACCCTGGCCACAATCTCTACTAGTCCTCA
GTCTCTGACAACTAAGCCTGGACCAGACAATAGTACCCATAACACACCAGTGTACAAACTGGATATTA
GTGAAGCCACCCAGGTCGAGCAGCACCATCGGAGAACAGACAATGATAGTACTGCCTCAGACACCC
CAAGCGCTACCACAGCTGCAGGCCCACCCAAGGCTGAGAATACTAACACCTCAAAAAGCACCGACTT
TCTGGATCCAGCAACTACCACATCCCCCCAGAACCACTCTGAGACAGCCGGAAACAATAACACTCAC
CATCAGGATACCGGCGAGGAATCTGCCAGCAGCGGCAAGCTGGGCCTGATCACAAATACTATTGCT
GGGGTGGCAGGACTGATCACAGGCGGGAGGCGCACTCGACGAGAAGCTATTGTGAACGCACAGCC
TAAATGCAATCCAAACCTGCACTATTGGACTACCCAGGACGAGGGAGCAGCTATCGGCCTGGCCTG
GATTCCCTACTTCGGCCCTGCAGCCGAAGGGATCTATATTGAGGGACTGATGCATAATCAGGATGGG
CTGATCTGTGGACTGAGGCAGCTGGCAAACGAAACAACTCAGGCCCTGCAGCTGTTCCTGCGAGCT
ACCACAGAGCTGCGGACCTTTAGCATCCTGAATCGCAAGGCAATTGACTTCCTGCTGCAGCGATGG
GGAGGAACCTGCCACATCCTGGGCCCTGACTGCTGTATTGAGCCACATGATTGGACAAAGAACATCA
CTGACAAAATTGATCAGATCATTCACGACTTCGTGGATAAAACACTGCCCGATCAGGGAGACAATGAT
AACTGGTGGACTGGCTGGCGACAGTGGATCCCTGCCGGGATTGGCGTCACTGGAGTCATTATTGCT
GTCATTGCCCTGTTCTGTATTTGTAAGTTCGTCTTCTGATAG 
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6.2.3. GenScript-optimized EBOV GP HPIV1 F TMCT chimera ORF 
The TMCT domain sequence (bold and italic) of the GenScript-optimized EBOV GP ORF 
(6.2.2) was replaced with the following GS-optimized HPIV1 F TMCT sequence to create the 
chimeric EBOV GP TMCT ORF: 
CAGATCATTATGATCATTATCGTGTGCATTCTGATTATCATTATCTGTGGCATCCTGTACTATC
TGTACCGAGTGCGGAGACTGCTGGTCATGATTAACAGCACCCACAATTCCCCCGTCAACGCCTACAC
ACTGGAGTCTAGGATGCGCAATCCTTATATGGGGAACAATAGCAACTGATAGTGA 
 
6.3. Primer Sequences 
6.3.1. ATP1A1+/- mice genotyping primers 
Name Sequence (5'-3') 
128-5' CCTTTTCTCAAGTGTCATCTAGGG 
LTR-rev  ATAAACCCTCTTGCAGTTGCATC 
128-3' TCCAGGAATGATTCAGCAAGCTGG 
 
6.3.2. RSV genome sequencing primers 
Name and 5' nt location Sequence (5'-3') 
RSV_3UTR_FOR_13 GCGTACAACAAACTTGCATAAACC 
RSV_NS1_REV_94 AATGAATTGCTGCCCATCTCTA 
RSV_NS1_FOR_102 GGCAGCAATTCATTGAGTATGA 
RSV_NS1_REV_221 GATTGTATGTATCACTGCCTTAGCC 
RSV_NS1_FOR_354 GGAGGTTATATATGGGAAATGATGG 
RSV_NS1_REV_394 TGTCATCTAGTAGACCATTAGGTTGAG 
RSV_NS2_FOR_710 CATCACTAACCAGAGACATCATAACAC 
RSV_NS2_REV_710 GTGTTATGATGTCTCTGGTTAGTGATG 
RSV_NS2_FOR_990 TCTCAATCCATAAATTTCAACACAA 
RSV_N_REV_1128 GCTAAGAGCCATCTTTGTATTTGC 
RSV_N_FOR_1343 ATATGCGATGTCTAGGTTAGGAAGA 
RSV_N_REV_1432 CCATTAATGTCTTGACGATGTGTTG 
RSV_N_FOR_1681 CCGTGATTAGGAGAGCTAATAATGT 
RSV_N_REV_1819 CCTCTGGTAGAAGATTGTGCTATAC 
RSV_N_FOR_2051 GAACAACCCAAAAGCATCATTATTA 
RSV_N_REV_2164 GCTGCATCATATAGATCTTGATTCC 
RSV_N_FOR_2266 AGGCTATCAAACATCAGCTTAATCC 
RSV_P_REV_2387 TTCTAGGAATTTAGTAGCCCTGTTG 
RSV_P_FOR_2609 AGAAGACCCTACACCAAGTGATAAT 
RSV_P_REV_2688 TTTCTTCGTATGAATAGCTGGATTC 
RSV_P_FOR_3026 GGAAGGGAATGATAGTGACAATG 
RSV_P_REV_3111 GGGTTGGTTAGTTTGTTGGTCTT 
RSV_M_FOR_3254 GGCAAATATGGAAACATACGTGAAC 
RSV_M_REV_3480 CTAGCACTGCACTTCTTGAGTTTAT 
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RSV_M_FOR_3665 GACACTCAACCCTACACATGATATT 
RSV_M_REV_3834 ATCCTGAGTAAGGGATGATTTTTGC 
RSV_M_FOR_3904 ACATAAAGCCACAAAGTCAATTCAT 
RSV_M_FOR_4138 ACTTATCTGAAGTCCCAGATCATCC 
RSV_SH_REV_4231 GTGATTAGTTGGATTTCCTCCAATG 
RSV_SH_REV_4459 GAGCTCTTGGTAACTCAAAGGTTTT 
RSV_SH_FOR_4551 CCCCTACCTCTTTACAACACCTC 
RSV_G_REV_4818 GTTGAGATTATCATTGCCAGAATGG 
RSV_G_FOR_4823 CTGGCAATGATAATCTCAACTTCAC 
RSV_G_FOR_5028 TACTAGCTTCAACAACACCAGGAG 
RSV_G_REV_5237 TGTTTGGTATTCTTTTGCAGATAGC 
RSV_G_FOR_5348 AAATCAAAGGAAGTACCCACCAC 
RSV_F_REV_5652 GGATTAGCAACTCCATTGTTATTTG 
RSV_F_FOR_5798 TGCTCTGAGAACTGGTTGGTAT 
RSV_F_REV_5973 GGTAGTTCTCTTCTGGCTCGATT 
RSV_F_FOR_6147 GAAGTGAACAAGATCAAAAGTGCTC 
RSV_F_REV_6360 CTGCATTAACACTAAATTCCCTGGT 
RSV_F_FOR_6507 CAGCAAAGTTACTCTATCATGTCCA 
RSV_F_REV_6717 GAACTTTACATGTTTCAGCTTGTGG 
RSV_F_FOR_6812 TGACATATTCAACCCCAAATATGAT 
RSV_F_REV_6984 CAGTGTCCATCCCTTTATTTGATAC 
RSV_F_FOR_7104 GTATTCCCCTCTGATGAATTTGATG 
RSV_F_REV_7335 TACCACTCAGTTGATCTTTGCTTAG 
RSV_F_FOR_7465 AAAATCTGAACTTCATCGAAACTCT 
RSV_M2_REV_7645 GACACCTCTTACCATTTAAGCAATG 
RSV_M2_FOR_7828 GGTGTAGTTGGAGTGCTAGAGAGTT 
RSV_M2_REV_7960 CTCTTATCTTGGGTGAATTTAGCTC 
RSV_M2_FOR_8107 CATAAGAGCATAACCATCAACAACC 
RSV_M2_REV_8336 GTCAATCAATTCTTGAGAGGTCCA 
RSV_M2_FOR_8482 CAAGTTGTGGGACAAAATGGAT 
RSV_L_REV_8568 CCTAAAGCATTACACTCTGAGAAAG 
RSV_L_FOR_8888 CTAGGGCTTAAAGAAAAGGACAAGA 
RSV_L_REV_8935 GGTCGTAATAACTGAGTTGTCTTCA 
RSV_L_FOR_9218 GGATTTCAATTTATTTTGAACCAAT 
RSV_L_REV_9291 TTCCATGTCAAGAATTGATTATAGG 
RSV_L_FOR_9476 GAGGGGTTCTACATAATAAAAGAGG 
RSV_L_REV_9590 TCTGAGCTTTATTAGCAGCATCTGT 
RSV_L_FOR_9859 GTTAAGCAGTCTGAGTATGTTAAGAGG 
RSV_L_REV_9931 AGCATTTCTTAAAGTAGGCCATCTG 
RSV_L_FOR_10211 AAATTTTCCGAGAGTGATAAATCAAG 
RSV_L_REV_10300 GGGTTGTTGAGATAACTTTGATTAACT 
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RSV_L_FOR_10530 GTAACAAATCAAATCGCTACAATGA 
RSV_L_REV_10670 ACCAGGAAAATAGAGATTGTACACC 
RSV_L_FOR_10847 CTGTGGACCATAGAAGCTATATCAC 
RSV_L_REV_11085 TTTTACTCATAAATTGCATATCTCGTG 
RSV_L_FOR_11165 GTGGGACCGTGGATAAACACTATAC 
RSV_L_REV_11416 GGGTAAATTCATATACAATGTTAATGCT 
RSV_L_FOR_11516 GAGGCTATAGTTCACTCTGTGTTCA 
RSV_L_REV_11745 GTTTGGAGCTGTACTCAAAACCT 
RSV_L_FOR_11853 CTCATGGGCTAAGAGTTGTTTATG 
RSV_L_REV_12105 CAAGATCTTTCCCTAACATATTTGC 
RSV_L_FOR_12282 GGGTTGGTTCATCTACACAAGAGA 
RSV_L_REV_12382 TCTATAGATGCATACACCCAATCC 
RSV_L_FOR_12662 ATAAGCTTTGGCCTTAGTTTAATGTC 
RSV_L_REV_12766 ATCACCTGTGAATATGGGAGGT 
RSV_L_FOR_13049 TGGGGAGAGGGATATATAACTGAT 
RSV_L_REV_13154 AAGTGTTCATATCACACTCCAGCTT 
RSV_L_FOR_13304 GGATGTCATAGCTTCAAATTATGGT 
RSV_L_REV_13362 ATGTTAACAACCCAAGGGCAAA 
RSV_L_REV_13613 CTAGGGTTTCTGGTGTAGGATGATA 
RSV_L_FOR_13632 CCCTAGAGAATATACTAGCCAATCC 
RSV_L_FOR_13901 TTAGTGCACAATAGCACATCACTTT 
RSV_L_REV_13921 CCAAGGAAGCATGCAGTAAAGT 
RSV_L_REV_14124 GATCATTGCAATCTTTCAGACTTC 
RSV_L_FOR_14272 GTTTGCTGAACCTATCAGTCTTTTT 
RSV_L_REV_14371 ATTAACTGAGGAACAGTACTTGCAC 
RSV_L_FOR_14610 TGCCTAAGAAAGCTGATAAAGAGTC 
RSV_L_REV_14765 AGTTTATTGCTGAAAACTTCATTACG 
RSV_L_FOR_14833 TGTTTTAAATTTCAGATCAACAGAACTA 
RSV_L_REV_14919 AAGTTCATTGGTTGTCAAGCTGT 
RSV_5UTR_FOR_15115 AAGTTATCATTTTAATCTTGGAGGAA 
RSV_5UTR_REV_15188 AAAAAGTGTCAAAAACTAATATCTCGTA 
 
6.3.3. HPIV1 genome sequencing primers 
Name and 5' nt location Sequence (5'-3') 
PIV1_3UTR_FOR_1 ACCAAACAAGAGGAAAAACTTG  
PIV1_3UTR_FOR_78 GGGACAAGTCACAGACATTTGA 
PIV1_N_FOR_153 AGTTCCAGGAGAAGTGAGAGCA 
PIV1_N_REV_223 GGGCCTAATGTGAAGACAGAAA 
PIV1_N_REV_342 GCCATTGCAAGGAGTGATACTAA 
PIV1_N_FOR_389 CACTACAAACGGTGTCAATGCT 
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PIV1_N_FOR_534 ATCAACAAGAACCCATTGTTCC 
PIV1_N_REV_560 TAGATCCGCATTCTCTCTTTGC 
PIV1_N_REV_709 GTTCCATCCTGTCTGAATGCTT 
PIV1_N_REV_720 CACTTTTAACGGTTCCATCCTG 
PIV1_N_FOR_910 CAGGATTAGCATCTTTCATGAACACC 
PIV1_N_FOR_1042 CCCGAGCCCCTTTTATATGT 
PIV1_N_REV_1103 CGTAGCTCCACAGTGCTGGATAG 
PIV1_N_REV_1240 CAGAGCACTGCTGATTTTGG 
PIV1_N_FOR_1316 AAACCTTTCAGGAGGGGATG 
PIV1_N_FOR_1337 TGCGTACCACAAGCCTACAG 
PIV1_N_FOR_1397 AACATTTGGAGTCGAGGACACT 
PIV1_N_FOR_1437 AACTGGACAAATGACAGCAATG 
PIV1_N_REV_1502 CAAGTTCTTCTGCACCACGA 
PIV1_N_FOR_1594 AGAGACTAAGCCAGGCAAACAA 
PIV1_N_REV_1608 TGGTGTCTCGTTTATTGTTTGC 
PIV1_P_REV_1802 TGCTGAGGTATCCACTGTGAAG 
PIV1_P_FOR_1818 TCAGCATCCAAAACTCTCCTTC 
PIV1_P_REV_2006 GCTTGTTTTCTTTTGGGTTGTC 
PIV1_P_FOR_2053 CAAAGACAGAGCAATCTCAACG 
PIV1_P_REV_2210 TGCCCATATTCTCAGGTAGAGG 
PIV1_P_FOR_2251 CGACGAAGATTCTCCAAATGAG 
PIV1_P_FOR_2353 TGAGGGATTTCCAGAAGAGGTA 
PIV1_P_REV_2425 GCTAGTTTCCATGCTTCTTCCA 
PIV1_P_REV_2545 TGATCTTGTTTGGTTACGCTTG 
PIV1_P_FOR_2609 AATAGCTCCAACCTCGAAGACC 
PIV1_P_FOR_2701 CCACAACCACAGAAAAACAAGA 
PIV1_P_REV_2792 ATGTGTTGCTGGTTTCCTCTTC 
PIV1_P_FOR_2944 GACATTTAATCTCTGTGGTATGCTTATATC 
PIV1_P_REV_3015 TATTTCCTCTTGAATTTGTTTAAGTAATG 
PIV1_P_FOR_3045 ATTCATCCAGGGATCTTCACAA 
PIV1_P_REV_3219 GGGTCAAACCTTGTCTTTTTGA 
PIV1_P_FOR_3333 AAAACAACAATGAGCCTCAAGC 
PIV1_P_REV_3509 TGTCTTCCTCGAATAGCTCCAT 
PIV1_P_FOR_3510 TGGAGCTATTCGAGGAAGACAT 
PIV1_M_FOR_3681 TACAGGTTCCCCAGATTCTCAC 
PIV1_M_REV_3695 CCCATTTTCTTCGTGTGAGAAT 
PIV1_M_FOR_3787 TAGGAGATCCTCCAAAACATGG 
PIV1_M_REV_3904 CCGGATCCACAGATTGAATAAC 
PIV1_M_FOR_3933 CCAATTGGCATAGCCAAGTATT 
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PIV1_M_REV_4126 GGGAGACATTGAGGTGCTAGAG 
PIV1_M_FOR_4275 CTGGTTACACTTAGGGCAGGAG 
PIV1_M_REV_4451 ACCTACAAGCCCGAGAGAGAAT 
PIV1_M_FOR_4487 TGTACATGCAACAGGCACATT 
PIV1_M_REV_4668 TTTTGCAACAACATTTGGGTA 
PIV1_M_FOR_4685 AAAAAGCATCGGGAAAATCAG 
PIV1_F_REV_4854 TGCTTAGGCTGAGCTTTTTGA 
PIV1_F_FOR_4859 AAGCTCAGCCTAAGCAGAGAGA 
PIV1_F_REV_5014 TTTTGTTCTTGCCTCCGTTT 
PIV1_F_FOR_5065 TAAACACCAAGATAGAGACAAAAATGC  
PIV1_F_FOR_5267 TGACCTACAAGATGGATGTGGA 
PIV1_F_FOR_5277 GATGGATGTGGAACAACTCAAA 
PIV1_F_REV_5425 GTACCAATGACAGCACCAAAGA 
PIV1_F_FOR_5494 CATTAGCTGAAGCACGAGAAGC 
PIV1_F_REV_5669 TTTCAATGCCGTAGTCTCACAC 
PIV1_F_FOR_5775 ACCTTGCAGGCATTATCATCTC 
PIV1_F_REV_5953 ATCAACACGCCTGGTATTTCTG 
PIV1_F_FOR_6058 CATCCTTAGGAGGTGCAGATGT 
PIV1_F_FOR_6244 TAGTGGCTAATTGCATTGCATC 
PIV1_F_REV_6244 GATGCAATGCAATTAGCCACTA 
PIV1_F_FOR_6295 CAGTGAATCAAGATCGCTCAAG 
PIV1_F_REV_6404 GATGATTTGATTCCCCCAAGTA 
PIV1_F_FOR_6552 GGATGGCACAACACAGAGAGTA 
PIV1_F_REV_6729 TGGAGTTGTTACCCATGTAGGG 
PIV1_F_FOR_6774 TTGTAGCATACATACAACAATCAAATC 
PIV1_HN_FOR_6934 ATTGGTCTACAACCCGAAATGA 
PIV1_HN_REV_7114 TCGTTCATGGAGGATACTGTCA 
PIV1_HN_FOR_7249 AGCAAAGCAGAGATCTCACACA 
PIV1_HN_FOR_7291 ACAGACAGGAATTGGCTCAGAT 
PIV1_HN_REV_7408 AATGAGATATTGGGGTTGTTGC 
PIV1_HN_REV_7623 AATCAGGATACATATCTGAATTTAAGG 
PIV1_HN_FOR_7648 ATGACATCAACGACAACAGGAA 
PIV1_HN_FOR_7720 TGCCCACTGTGAATGAGACTAC 
PIV1_HN_REV_7837 GCAGAAAAAGGATGGTCAAAAG 
PIV1_HN_FOR_7911 CTAGGGTACGGTGGCTTAACAA 
PIV1_HN_REV_8082 TTGTCTCGACAACAATCTTTGG 
PIV1_HN_FOR_8129 TGCCGAAGGTAGGCTACTTAAA 
PIV1_HN_FOR_8197 CCAACCTGCAAATAGGATCATT 
PIV1_HN_REV_8303 TATGCATTCTCTCGGACATCTG 
xii   Appendix 
Name and 5' nt location Sequence (5'-3') 
PIV1_HN_FOR_8403 TCACGTGTTAATCCCACCATAA 
PIV1_HN_FOR_8547 GAAATCAACCAAACCAGCCTTA 
PIV1_HN_REV_8547 TAAGGCTGGTTTGGTTGATTTC 
PIV1_HN_FOR_8627 TTGAGCAGATCAAGACCCAAC 
PIV1_HN_REV_8739 AGGCAGGCATTAACCCTAAGTT 
PIV1_L_REV_8823 CAATCGGAGAGTTCAAGTGACA 
PIV1_L_FOR_8969 GATCAAAATCAGATCGCTAGGC 
PIV1_L_REV_9006 CTTGTTTAAGGATTTTGCCTAGC 
PIV1_L_REV_9182 CCCTTCAACACAGCCTAATTGT 
PIV1_L_FOR_9332 AAAGAATAAGTCGGGGAACCAT 
PIV1_L_REV_9511 CGTCCAGCTGAAGACATATTCC 
PIV1_L_FOR_9597 TTATTTCCCAATCTTGGTGAGG 
PIV1_L_FOR_9761 CACAGATTCAGAAGCAGACAGC 
PIV1_L_REV_9761 GCTGTCTGCTTCTGAATCTGTG 
PIV1_L_FOR_9891 GCTGCCGATAAAGTAAGGACAC 
PIV1_L_REV_9958 ATTGCACAGAAGATTGCATGAC 
PIV1_L_REV_10061 AGAGTTGGATCCTTGTGCATTC 
PIV1_L_REV_10081 GCACATTCATACGAAATTGCAG 
PIV1_L_FOR_10261 TCCCTGAATCAGAAGAGACTCG 
PIV1_L_FOR_10353 GGAGAATGGTTAAATGACGATAGC 
PIV1_L_REV_10453 TGCTAATACCTGGACTGCTCTCA 
PIV1_L_REV_10523 GGTCAATTTCTCCCTTTACCATC 
PIV1_L_FOR_10657 CAAATGGGTATTGGGATGAAAG 
PIV1_L_FOR_10801 CGTTGTTCGGTCAAAGATGTAA 
PIV1_L_REV_10843 GGGTGCATCCAGTTAAAGAAAG 
PIV1_L_REV_10975 TAACCCTCTATTCCCCCTCTTG 
PIV1_L_FOR_10978 GAGGGGGAATAGAGGGTTATTG 
PIV1_L_REV_11168 GGCACCGAAATATCTTGTGATT 
PIV1_L_REV_11363 GTTTTCATCTACAAGAGTCTCTGACC 
PIV1_L_FOR_11396 AGCCAAAGCTATTGAGAATGGA 
PIV1_L_FOR_11556 TGTGCAATATTGATCCCAGCTA 
PIV1_L_REV_11566 CCTCCTATGTTAGCTGGGATCA 
PIV1_L_REV_11721 AGCTTGAGTCTCCTGGTTCTTG 
PIV1_L_FOR_11742 TTCTTAGATTGGGCATCAGACC 
PIV1_L_REV_11927 TACTCTGGGCAATATGGCTTTC 
PIV1_L_FOR_11934 ATATTGCCCAGAGTAGCTCACG 
PIV1_L_REV_12113 CGGTTTTCTGAGTGTCCTTGTT 
PIV1_L_FOR_12233 CCACGGTTTAGAAACTCCAGAC 
PIV1_L_REV_12391 TAAGGGATACGTATGGCAGGAC 
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PIV1_L_FOR_12505 TGGTTTACACTTGGGCTTATGG 
PIV1_L_REV_12555 CCCTGGTTTGAGCTATAAGTGC 
PIV1_L_REV_12728 TCCTGCCTCTTTTAATGCCATA 
PIV1_L_FOR_12732 GCATTAAAAGAGGCAGGAGAGTC 
PIV1_L_REV_12931 TCCTGAGTGATCTCTAAGTCCAATG 
PIV1_L_FOR_12974 TGATCCTGATCCTCTCAAGGAC 
PIV1_L_REV_13228 AATACCCCCGAAAGTGGAAC 
PIV1_L_FOR_13237 TCGGGGGTATTCTAATCAATCA 
PIV1_L_REV_13408 ACAGGCTCTACAACTCCTGCAT 
PIV1_L_REV_13634 TATCTCTGCCAAACTACACAAGTATGC 
PIV1_L_FOR_13665 ACATCTCTCGAACGACTCGAA 
PIV1_L_REV_13848 CATCAGGATCCCAGTCCTCTAA 
PIV1_L_FOR_13860 GATCCTGATGCCGATAGTATGC 
PIV1_L_REV_14044 TATCGCCCATCAAAAGGTAGAG 
PIV1_L_FOR_14086 TTTTCGGGATTAATAGCACCAG 
PIV1_L_FOR_14193 GGTGCAATGCTGTCTTGTTATG 
PIV1_L_REV_14267 TCTCTTTGTCCGTTGAGATCG 
PIV1_L_FOR_14301 CCTTCAGAAGTGGCACTGGTAG 
PIV1_L_FOR_14376 AATGGGAATCCTGGATCAACTT 
PIV1_L_REV_14477 ACATTTGTGTTCTCCACCTTCC 
PIV1_L_REV_14547 TAACGTCCTTATCCCCAACAAG 
PIV1_L_FOR_14598 GGTACAGACTGGACAAAACAATTAAG 
PIV1_L_REV_14818 TTCTCAACTAGAATCCATTTTTCTATC 
PIV1_L_FOR_14861 GAGTGCATCGTCAGGTATGCTA 
PIV1_L_REV_15019 ATCCGAGTCCACTCAAAGATTG 
PIV1_L_FOR_15176 AACAGGGTCATTTCCAGACA 
PIV1_L_FOR_15325 TCTTGACTAAAGAAATAAAAATATTGATGA 
PIV1_L_REV_15376 GCTCTGTCTTGCCCCAAATA 
PIV1_5UTR_REV_15575 ACCAGACAAGAGTTTAAGAAATATCG 
 
6.3.4. HPIV3 genome sequencing primers 
Name and 5' nt location Sequence (5’ to 3’) 
PIV3_3UTR_FOR_1 ACCAAACAAGAGAAGAAACTTGTCTGGG 
PIV3_3UTR_FOR_7 CAAGAGAAGAAACTTGTCTGGGAAT 
PIV3_3UTR_REV_53 CCTTCTAGTCAATGTCTTTAATCCTAAG 
PIV3_N_FOR_67 CATTGACTAGAAGGTCAAGAAAAGG 
PIV3_N_REV_70 TCCCTTTTCTTGACCTTCTAGTCA 
PIV3_N_FOR_138 GCACGTAGGCAAGAAAACATAAC 
PIV3_N_REV_218 ATCAGTTATTGTCGGTCCAAGG 
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PIV3_N_FOR_293 TGAGAAACAACATGCACAAAGG 
PIV3_N_REV_352 TTGTTAGGTAGAGCTCTGGATTGG 
PIV3_N_FOR_513 GACCTGGATTATGATCAGGAAACT 
PIV3_N_REV_778 GAGTTACCAAGCTCTGTTGAGACC 
PIV3_N_FOR_823 CAATGAATACCAGCAGAAATGACC 
PIV3_N_FOR_951 GCAGCTTTGACTCTATCCACTCTC 
PIV3_N_REV_1179 TCCTAGCTGGAACATATCAATGTC 
PIV3_N_FOR_1310 AAACAGTTCAGAGACATCTTTCCA 
PIV3_N_REV_1609 GATCATCTATTTCGTCCTGGTTTG 
PIV3_P_FOR_1720 TATCATACCGGAATATAGGGTGGT 
PIV3_P_REV_1910 GATTGTGTCGTTTTCCGATAAGTC 
PIV3_P_FOR_2083 TGATCAGGAAACTGTACAGAGAGG 
PIV3_P_REV_2112 TACTATCTGAGCTGCTTCTTCTCC 
PIV3_P_FOR_2466 CTTCAACACATCAAGAAGATGACA 
PIV3_P_REV_2466 TGTCATCTTCTTGATGTGTTGAAG 
PIV3_P_FOR_2823 ATGGAAAGGAAAGGAAGGATACAG 
PIV3_P_REV_2858 AGTAATTGCCCTCTCTGTAAATCG 
PIV3_P_FOR_3136 AGAACAACTGTCATTGATCACGTC 
PIV3_P_REV_3215 CATGGATACTCTCTCATTGGATTC 
PIV3_P_FOR_3450 GATCACTAGTTGCAGTCATCAACA 
PIV3_P_REV_3549 TCATTGAACATGTCCATTAATTCAG 
PIV3_M_FOR_3826 TACCACTCAAAGTCAATGAACAGAG 
PIV3_M_REV_3987 AACTTTGTAACTCGGGTCACTGTC 
PIV3_M_FOR_4104 AGAAGAACAGTCAAAGCGAAAGAG 
PIV3_M_REV_4371 AACCCCTGTTTTTATGTGTACCTG 
PIV3_M_FOR_4515 TGTAAACAGAAAATCGAGAAAATGAG 
PIV3_M_REV_4673 GCCCAGATAACTAGATTGAGATGC 
PIV3_F_FOR_4879 AGGACAAAAGAGGTCAATACCAAC 
PIV3_F_REV_4973 TGTTCTGGTGTTCTGTACCTTTTG 
PIV3_F_FOR_5144 CTACAGCACGTAGGTGTATTGGTC 
PIV3_F_REV_5386 CTCCAAAGAATCGTTTTGTTCTG 
PIV3_F_FOR_5489 GCAAGATCAGACATCGAAAAACTC 
PIV3_F_REV_5768 TGTGATATTTGTGCGGTATAATGA 
PIV3_F_FOR_5884 GAATGATTACTCAATCACCCTCCA 
PIV3_F_REV_6135 ATTGGGATATGTTTCCTGATAAGC 
PIV3_F_FOR_6262 TGGTAATAGAATCAATCAACCACCT 
PIV3_F_REV_6525 GTAGTGCTAGATTGATGCCAATTTC 
PIV3_F_FOR_6630 GAATTCAAAAGAGAAATCGAGTGG 
PIV3_HN_REV_6874 TTATTAGTGAGCTTGTTGCCATGA 
PIV3_HN_REV_7078 AGCCTTGTATTCACTCCTGACTGT 
PIV3_HN_FOR_7080 AGTCAGGAGTGAATACAAGGCTTC 
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PIV3_HN_REV_7428 TCCTGACAACCTCGAGTAATTAGAT 
PIV3_HN_FOR_7562 AGGAAGTCATGTTCTCTAGCACTC 
PIV3_HN_REV_7875 TGATTACAGTCTCTCTGTGTTTTCC 
PIV3_HN_FOR_7912 TACTTGGTTTTCAGATAGGAGGATG 
PIV3_HN_FOR_8293 AGACTCACAAAAATCGAGAGTGAAC 
PIV3_HN_REV_8305 GTTATGACTGGGTTCACTCTCGAT 
PIV3_L_REV_8649 AGTGCCATTGTTAGATTCAGTGTC 
PIV3_L_FOR_8764 AGCCTTATGATATGGATGACGACT 
PIV3_L_REV_9126 CCATTTATCTGATTTATAGGTTGTGTG 
PIV3_L_FOR_9149 ATGGTATAATCCATTCAAAACATGG 
PIV3_L_REV_9430 CCACAGGTTATTACCTTTCTGATACA 
PIV3_L_FOR_9472 TGTTTCCAATTATGGGAGAAAAGA 
PIV3_L_FOR_9860 TAACGGATATAGAGAGAGGCATGG 
PIV3_L_REV_9919 AAGCATTTATGATGAATTCGTGTG 
PIV3_L_FOR_10210 TGGATTATGTAGAATCTGGGGACT 
PIV3_L_REV_10399 GTAATTCAATCTCTCCCTTCACCA 
PIV3_L_REV_10576 CCATCATTGTAGATATCCGTTGACT 
PIV3_L_FOR_10615 GCTGTTTCCTAACAACAGATCTCA 
PIV3_L_REV_10899 CAGCTGCTAGATGTATTGCACTTAT 
PIV3_L_FOR_10984 CCACAAGAGTACCCAACAATTATG 
PIV3_L_REV_11294 CATGCATATCCTAGAACAGGTGAA 
PIV3_L_FOR_11356 TTGGGATGAATATCAATCCAACTA 
PIV3_L_FOR_11705 TGTATTACAAGATTCACCAAATCCA 
PIV3_L_REV_11719 ATCCAGATAATAATGGATTTGGTG 
PIV3_L_REV_12074 CCTCCTGATAAATGAATCCACATC 
PIV3_L_FOR_12193 CAGATGGCACAAACCCATATACT 
PIV3_L_REV_12250 ATGACGATATACCTGTTTCTGCTG 
PIV3_L_FOR_12480 TTAACACCGGTAGCTACATCAACA 
PIV3_L_REV_12546 CTCTGATCAATGATGTACTGGAGAA 
PIV3_L_FOR_12845 TTATGATAAAGACCCACTCAAAGATG 
PIV3_L_REV_12920 TGTCAGTATCATCCCAATAATTCATA 
PIV3_L_FOR_13200 ACACTGAGAGATACTTCCCATTCA 
PIV3_L_REV_13262 CAATCCCAGAACCTCTTGAATACT 
PIV3_L_FOR_13632 TTAATTAAATCGTTCCCATCAACTG 
PIV3_L_REV_13687 GACTAATACCGCGAATCCTTAGAT 
PIV3_L_FOR_13939 AAGGAGGGAATTATCTATCGCATC 
PIV3_L_REV_14150 TCTCGTTGACCAATTACATCTGTT 
PIV3_L_FOR_14220 GGAAATGTGACACAGATTCTTAACAG 
PIV3_L_REV_14422 TCATCCCCAATCAAGTATGTAATTC 
PIV3_L_REV_14617 TGATAAAACAATTTCACTAGGTTCCA 
PIV3_L_FOR_14700 TCAAAGAAGAGGAATAATGAATGG 
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PIV3_L_REV_14936 CCGCCTAATTTATGTCTCTTATCA 
PIV3_L_FOR_15004 TGCTATCGAGAAGACTAGTATTAAGTTG 
PIV3_L_REV_15086 CCAGTCTGTGCTCTATGTTCAAAT 
PIV3_L_REV_15293 TTGTAGTTTTCTAATAACTGGTCTTCG 
PIV3_L_REV_15377 TGTCTATTCCTAGGCTTAAAGATAAAGG 
PIV3_5UTR_REV_15433 AAACAAGAGAAGAACTCTGTTTGGTAT 
PIV3_5UTR_REV_15436 ACCAAACAAGAGAAGAACTCTGTTTGG 
 
6.3.5. wt EBOV GP sequencing primers 
Name Sequence (5'-3') 
wtEBOV-GP_For_1 AGGAATATTGCAGTTACCTCGTGAT 
wtEBOV-GP_For_2 TCCACAATAGCACATTACAGGTTAG 
wtEBOV-GP_For_3 GTATGTGCACAAAGTATCAGGAACG 
wtEBOV-GP_For_4 ACCCGTCTAGTGGCTACTATTCTAC 
wtEBOV-GP_For_5 GGAAAACTAATTTGGAAGGTCAAC 
wtEBOV-GP_For_6 TTGTCTTTCACAGTTGTATCAAACG 
wtEBOV-GP_For_7 TACACCCGTGTATAAACTTGACATCT 
wtEBOV-GP_For_8 AACAACAACACTCATCACCAAGATA 
wtEBOV-GP_For_9 GAATTTACATAGAGGGGCTAATGC 
wtEBOV-GP_For_10 CACATGATTGGACCAAGAACATAAC 
wtEBOV-GP_For_11 CATGATTTTGTTGATAAAACCCTTC 
wtEBOV-GP_Rev_1 GGAAAAGGATAATTACCCAAAGAAAG 
wtEBOV-GP_Rev_2 CTGAAGCCCCATCTTTTAGTTG 
wtEBOV-GP_Rev_3 TACAGGAAGAAAGCACCCTCTTTAT 
wtEBOV-GP_Rev_4 TACTCTGTCTCATTGGTTCCAAAAC 
wtEBOV-GP_Rev_5 CGAATTTTTCTAGTGAGGTTCTTCTT 
wtEBOV-GP_Rev_6 TTTTCTGAAGCCATGATTTTGTG 
wtEBOV-GP_Rev_7 GTGTTGGTGTTCTCTGCTTTTG 
wtEBOV-GP_Rev_8 AATTGCTTCTCTTCGAGTTCTTCTC 
wtEBOV-GP_Rev_9 AGGAACAGTTGAAGAGCTTGAGTC 
wtEBOV-GP_Rev_10 GGTTTTATCAACAAAATCATGAATAA 
 
6.3.6. GenScript-optimized EBOV GP sequencing primers 
Name Sequence (5'-3') 
optEBOV-GP_For_1 CTTAGGATTAAAGAAGCCGCC 
optEBOV-GP_For_2 GACGTCGATAAGCTGGTGTGTC 
optEBOV-GP_For_3 GGCTGAGAATTGCTATAACCTGG 
optEBOV-GP_For_4 TCTTTCTGTACGATAGACTGGCATC 
optEBOV-GP_For_5 TGAGACAGAATACCTGTTTGAAGTG 
optEBOV-GP_For_6 GAGTTTCACCGTGGTCTCTAATG 
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optEBOV-GP_For_7 ACTACCCTGGCCACAATCTCTAC 
optEBOV-GP_For_8 GCTGAGAATACTAACACCTCAAAAAG 
optEBOV-GP_For_9 ACTATTGGACTACCCAGGACGA 
optEBOV-GP_For_10 CTACCACAGAGCTGCGGACC 
optEBOV-GP_For_11 GATCAGGGAGACAATGATAACTGG 
optEBOV-GP_Rev_1 CTGGAACAGAATGATGACCCAC 
optEBOV-GP_Rev_2 GCCTCGTAATTGACCACTTTAGGT 
optEBOV-GP_Rev_3 CCAGAGACCTTGTGCACGTATC 
optEBOV-GP_Rev_4 GCAGTGGATGACTAGAAAAGAAGTC 
optEBOV-GP_Rev_5 ATCAGCTTTCCAGTTGTATTGGAG 
optEBOV-GP_Rev_6 ATGATCTTGTGATCTTCTGTGGTAGTA 
optEBOV-GP_Rev_7 ACTGGTGTGTTATGGGTACTATTGTC 
optEBOV-GP_Rev_8 GGTGCTTTTTGAGGTGTTAGTATTC 
optEBOV-GP_Rev_9 GTTTGGATTGCATTTAGGCTGTG 
optEBOV-GP_Rev_10 AGATCAGCCCATCCTGATTATG 
optEBOV-GP_Rev_11 CCAGTTATCATTGTCTCCCTGATC 
 
6.3.7. Mutagenesis primer pairs used to introduce NotI restriction sites flanking the F and HN 
genes in the wt HPIV3 JS full-length anti-genome plasmid  
Name Sequence (5'-3') [underlined: NotI restriction site] 
HPIV3_NotI_4818_F CTA ATA TTA TTG CAA AAG GAG TTG GGA AAA TCA AAC AAT GGA ACT 
AGT AAG CGG CCG CTT AGT CCG GAC GTA TCT ATT AAG CCG A 
HPIV3_NotI_4818_R TCG GCT TAA TAG ATA CGT CCG GAC TAA GCG GCC GCT TAC TAG TTC 
CA TTG TTT GAT TTT CCC AAC TCC TTT TGC AAT AAT ATT AG 
HPIV3_NotI_8582_F CAT CAA TCT ATC TAT AAT ACA AGT ATA TGA TAA GTA ATC AGG CGG 
CCG CCA ATA GAC AAA AGG GAA ATA TAA AAA ACT TAG GAG CAA AGC 
HPIV3_NotI_8582_R GCT TTG CTC CTA AGT TTT TTA TAT TTC CCT TTT GTC TAT TGG CGG 
CCG CCT GAT TAC TTA TCA TAT ACT TGT ATT ATA GAT AGA TTG ATG 
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6.4. Design of rHPIV3/NotI ∆F-HN/EboGP 
The full-length antigenomic plasmid pFlc HPIV3wt BsiWI (P-M) of wt HPIV3 strain JS (GenBank 
ID: Z11575.1), containing a unique BsiWI restriction site at the P-M position [generated by 
Matthias Lingemann (2013), Master’s thesis: “Regulation of HPIV3 F-protein expression and its 
consequences for virus fitness and immunogenicity” and published in (Lingemann et al. 2015)] 
was used for generating the rHPIV3/NotI ∆F-HN/EboGP construct, shown in Figure 48. 
Two NotI restriction sites, flanking the F and HN genes (Figure 48), were inserted into the 
pFlc HPIV3wt BsiWI (P-M) plasmid by site directed mutagenesis with the QuikChange Lightning 
Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA), as described by the 
manufacturer’s protocol. Primers used for introducing the NotI site at the M-F site were: 
HPIV3_NotI_4818_F and HPIV3_NotI_4818_R and for the second NotI site, downstream of the 
HN ORF: HPIV3_NotI_8582_F and HPIV3_NotI_8582_R. (for primer sequences see 6.3.7) 
After insertion of the EBOV GP gene at the BsiWI site (Figure 48), the F-HN genes were 
removed by a NotI restriction digest and re-ligation of the remaining pFlc plasmid, resulting in the 
pFlc HPIV3/NotI ∆F-HN/EboGP (Figure 48). The virus was recovered by reverse genetics as 
previously described (Durbin et al. 1997), sequenced and used for the EBOV GP neutralization 
assay (2.2.20.2.4). 
 
Figure 48: Design of the rHPIV3/NotI ∆F-HN/EboGP construct used for the EBOV GP neutralization 
assay. 
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